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ABSTRACT 
The long-term stability and brittle nature of ceramic bone replacements in 
physiological conditions makes them prone to mechanical failure. These problems 
have led to the development of bioresorbable bone replacement materials. 
Bioresorbable biomaterials are expected to degrade at a rate which is proportional to 
the rate of formation of new bone tissue. In the majority of cases, however, 
resorption is driven by simple dissolution and so it is difficult to ensure an 
appropriate degradation rate for all patients.  This thesis seeks to develop a material 
that can degrade in response to the bone formation process, thus linking implant 
resorption to tissue formation.  We have shown that this can be achieved by linking 
implant resorption to a biological stimulus, such as the enzyme alkaline phosphatase 
(ALP), which is found on the surface of bone forming cells (osteoblasts). ALP causes 
bone mineralisation by removing the pyrophosphate (P2O7
4-) ion, a known inhibitor 
to calcium phosphate formation. By removing the P2O7
4- ions from solution the 
dissolution of calcium pyrophosphate (Ca2P2O7) crystals were accelerated in 
accordance with Le Chetalier's principle.  We demonstrated that for this accelerated 
dissolution to occur, the ALP did not require access to the crystal surface.  This is 
contrary to previous work which suggested that CPPD dissolution occurred as a 
result of ALP cleaving the crystal surface. Bulk Ca2P2O7 ceramics were successfully 
produced by sintering brushite cement at temperatures ≥ 400°C, the dissolution of 
which could accelerated in the presence of ALP but was heavily dependent on 
material specific surface area.  The process of sintering limits the possibility of 
producing biomaterials of complex morphology; therefore the final part of this thesis 
involved the fabrication of Ca2P2O7 ceramic using stereolithography.   
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1. INTRODUCTION 
There is increased demand for bone replacement materials worldwide due to an 
ageing population (Hing, 2004). Annually around 2.2 million bone grafting 
procedures are carried worldwide with most of them using autograft tissue (Malak 
and Anderson, 2008). Other biological bone grafting options include allograft and 
xenograft. The disadvantages associated with these biological bone grafts such as 
immune rejection and disease transmission outweigh their advantages driving 
research into alternative bone replacement materials (Precheur, 2007). Synthetic 
materials such as metals, glass ceramics, polymers, hydrogels, cements and ceramics 
have been studied for use as bone replacements (Frame, 1975; Levine, 2008). A 
suitable bone replacement material is expected to be osteoconductive, non-cytotoxic 
and bioresorbable.  
 
Hydroxyapatite (HA) is a calcium phosphate material which forms a strong bond 
with hard tissue and as such it has found extensive use in the repair of bone defects 
(Bucholz et al., 1987; Jarcho, 1981). HA is the most thermodynamically stable 
calcium phosphate in physiological conditions (Ishikawa et al., 2003) meaning that 
the implant will remain in situ for an extended period of time and present a 
significant chance of failure during the lifetime of the patient (Uemura et al., 2003). 
Brushite cement is another calcium phosphate which is more soluble than HA in 
physiological conditions and so can be more rapidly replaced with bone. As brushite 
cement degrades and the local environment becomes supersaturated with HA, HA is 
formed within the cement. This prevents resorption of the material and can lead to 
implant failure. One way to avoid this long term implant stability is to develop a 
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bioresorbable material. The degradation of such a material would be linked to a 
biological stimulus associated with the process of bone mineralisation. 
 
Alkaline phosphatase (ALP) is an enzyme associated with bone mineralisation and 
found on the surface of osteoblasts. It is thought to aid bone mineralisation by 
removing pyrophosphate (P2O7
4-) ions from solution (Balcerzak et al., 2003; Johnson 
et al., 2000). The P2O7
4- ion inhibits bone mineralisation by suppressing HA 
crystallisation; it adsorbs to the surface of the crystals, blocking further crystal 
growth (Addison et al., 2007; Hessle et al., 2002). ALP hydrolyses P2O7
4- ion into 
orthophosphate (PO4
3-) ions which initiate mineralisation. The hydrolysis of P2O7
4- 
by ALP has been exploited by Xu et al. (Xu et al., 1991b) as a means for dissolving 
calcium pyrophosphate dihydrate (CPPD) crystals in arthritic joints. The dissolution 
of CPPD crystals was found to be faster in the presence of ALP (Xu et al., 1991b). 
This suggested that it would be possible to develop a calcium pyrophosphate based 
ceramic whose degradation can be linked to the bone mineralisation process. The 
ability to link both processes makes it possible to overcome variations in bone repair 
which occurs due to differences in age, health and gender of patients (Fahrleitner-
Pammer et al., 2005; Havill, 2004). 
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This thesis begins with the precipitation of phase pure CPPD and brushite crystals 
which were characterised using X-ray diffraction, fourier transform infrared and 
scanning electron microscopy. The dissolution of these crystals in the presence and 
absence of ALP was investigated and quantified using a colourimetric phosphate 
assay. The mechanism by which ALP accelerated dissolution was investigated by 
ageing the crystals in the same solution as the ALP, but isolated from the surface of 
the crystals by visking tubing. 
 
Following this, calcium pyrophosphate ceramics were formed by sintering brushite 
cements at temperatures ≥ 400°C.  The influence of process parameters on the 
composition and mechanical properties of the ceramic were investigated and selected 
formulations were aged in the presence of ALP to determine whether bulk ceramic 
dissolution could be accelerated by the enzyme. Finally, stereolithography was 
evaluated as a means to produce complex calcium pyrophosphate structures. 
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2. BONE 
Bone is a mineralised connective tissue: it protects the internal organs and provides 
structural support in vertebrates and in conjunction with the muscles facilitates 
movement (Dorozhkin, 2007; Hing, 2004). The main constituents of bone are: 
calcium phosphate crystals (65 wt%) (mainly HA); an organic phase consisting of 
type I collagen; cells and other macromolecules (25 wt%) and water (10 wt%) 
(Kuhn, 2001; Currey, 2001; Olszta et al., 2007). The high toughness of bone is as a 
result of the presence of collagen (Wang and Puram, 2004). The organic component 
of bone is responsible for giving bone its form and its ability to resist tension 
(Hedberg and Mikos, 2001). The inorganic component is important for the stiffness 
and compressive strength of bone (Hedberg and Mikos, 2001; Wang and Puram, 
2004). Bone is an important reservoir and regulator of mineral ions; it contains 99% 
of the body‟s calcium and about 88% of the phosphates (Ng et al., 1997; Hedberg 
and Mikos, 2001). Bone is heterogeneous and anisotropic with a hierarchal structure 
which can be divided into four parts: macrostructure, microstructure, nanostructure 
and sub-nanostructure (Figure 2.1) (Rho et al., 1998).  
 
2.1. BONE STRUCTURE  
2.1.1. Macrostructure  
Mature bone is composed of two types of tissue: the cortical (compact) bone found 
on the outer surface of most bones and cancellous (spongy or trabecular) bone found 
near the ends of long bones (e.g. tibia) and at the centre of flat bones (e.g. the skull 
and ribs) (Rho et al., 1998; Hing, 2004; Hedberg and Mikos, 2001; Dorozhkin, 
2007).  Cortical bone is denser than cancellous bone with a porosity of 5% - 10% 
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(Martin et al., 1998) (Table 2.1). It consists of regular cylindrical lamellae. 
Cancellous bone is composed of trabecular struts and marrow filled cavities which 
give it a relatively high surface area (Rho et al., 1998); its porosity is 75% - 95% 
(Martin et al., 1998). Cancellous bone can be categorised as either coarse or fine 
(Hing, 2004). The coarse cancellous bone is found in the body of healthy adult while 
fine cancellous bone is characteristic of a foetal skeleton (Hing, 2004).  Generally 
cancellous bone is more metabolically active and it is therefore remodelled more 
often than cortical bone (Rho et al., 1998). As shown in table 2.1 cortical bone has a 
higher compressive, tensile and flexural strength than cancellous bone. 
 
Table 2.1: Mechanical properties exhibited by cortical and cancellous bone (Hedberg 
and Mikos, 2001; Lawson and Czernuszka, 1998). 
Property Cortical bone Cancellous bone 
Compressive strength (MPa) 106 - 215 0.5 - 50 
Tensile strength (MPa) 55 - 146 10 - 20 
Flexural strength (MPa) 130 - 180 2 - 25 
Young‟s modulus (GPa) 10 - 22 0.05 - 1.0 
Density (gcm-3) 1.8 0.1 - 1.0 
 
 
2.1.2. Microstructure  
The bone microstructure consists of the lamellae, haversian canals and osteons which 
are then arranged to form either compact or cancellous bone (Olszta et al., 2007; Rho 
et al., 1998). Osteons are large hollow fibres with a diameter of 200 μm (Lakes, 
1993); they consist of concentric lamellae (3 - 7 µm wide; (Rho et al., 1998)) and 
pores containing osteocytes cells (Lakes, 1993). The lamellae consist of fibrils which 
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on a sub-microstructural level consist of calcium phosphates and collagen (Lakes, 
1993). As shown in figure 2.1b, osteons are made up of haversian canals which 
contain blood vessels carrying the necessary nutrients to the surrounding tissue 
(Lakes, 1993).  
 
Figure 2.1: a) The hierarchal structure of the human bone (Kuhn, 2001; Rho et al., 
1998) and b) microstructural division of bone (Lakes, 1993). 
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2.1.3. Nanostructure and sub-nanostructure 
Collagen fibres and apatite make up 95% of the dry weight of bone and the 
remainder of the bone matrix consists of other organic molecules (known as non-
collagenous protein), which are outlined in the following section.  
2.1.3.1. Collagen 
Collagen is the most abundant protein found in the body; it occurs in both calcified 
and non-calcified tissues and accounts for 70-90% of non-mineralised component of 
bone (Hing, 2004). Bone consists mostly of type-I with some type-V collagen. Type-
I accounts for 90% of the body‟s total collagen (Hing, 2004) and is characterised by 
its fibrous nature (Weiner and Wagner, 1998). It consists of carefully arranged arrays 
of tropocollagen molecules which are long rigid molecules (300 nm in length, 1.5 nm 
wide), consisting of three polypeptides chains about 1000 amino acids in length; 
these are wound together in a triple helix (Weiner and Wagner, 1998; Hing, 2004). 
The flexibility and tensile strength of bone arises from its collagen structure (Martin 
et al., 1998). 
2.1.3.2. Mineral 
Since 1926, bone mineral has been known to be a calcium phosphate with an apatite-
like structure (de Jong, 1926); it has a similar crystallographic structure to HA and 
calcium to phosphate ratio (Ca:P = 1.67). Apatite is often described by the formula 
A4B6(MO4)6X2; in bone A and B are mostly calcium ion (Ca
2+), MO4 is a PO4 group 
and X is mostly hydroxyl ion (OH-) with some fluoride ions (F-) (Brown and Chow, 
1976). In this thesis apatite has been used to mean a calcium phosphate with the 
same chemical formula of HA (Ca10(PO4)6(OH)2). The crystals of bone are plate or 
needle shaped with an average length between 40 – 60 nm, 20 nm wide and 1.5 – 5 
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nm thick (Suchanek and Yoshimura, 1998). The apatitic calcium phosphates crystals 
are deposited in discrete spaces of the collagen fibril (Figure 2.2). It is described as 
poorly crystalline (amorphous) because of the presence of impurities such as acid 
phosphates (HPO4), sodium (Na), magnesium (Mg) and carbonates (Rho et al., 1998; 
Olszta et al., 2007; Fratzl et al., 2004). 
 
 
Figure 2.2: Schematic diagram illustrating the assembly of collagen fibrils and 
apatitic calcium phosphate in bone.  
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2.1.3.3. Non-collagenous proteins 
Non-collagenous proteins (NCP) in bone include glycoproteins, proteoglycans and 
phosphoproteins such as osteocalcin, osteopontin, osteonectin and bone sialoprotein. 
These phosphoproteins are produced by bone cells and are responsible for regulating 
bone mineralisation and remodelling (Hing, 2004; Rho et al., 1998). Of these 
proteins bone sialoprotein and osteocalcin are specific to mineralised tissue (Hunter 
et al., 1996). 
 
Osteocalcin 
Osteocalcin, also known as bone Gla protein and it is one of the most abundant NCPs 
comprising up to 20% of the total NCP in bone (Hing, 2004). Osteocalcin is thought 
to inhibit HA formation by delaying crystal nucleation (Hunter et al., 1996).  
 
Osteonectin  
Osteonectin is expressed by osteoblast cells and is present in high concentrations in 
bone (Hunter et al., 1996; Hing, 2004). Osteonectin is believed to lack all inhibitory 
effect on HA crystal growth at concentrations ≤10 µg/ml (Hunter et al., 1996) and it 
is thought to be involved in cell-matrix interactions (Hing, 2004).  
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Bone sialoprotein  
Bone sialoprotein and osteopontin are phosphorylated sialoproteins containing an 
arginine-glycine-aspartate (RGD) sequence required for cell adhesion (Hing, 2004; 
Hunter et al., 1996; Mckee and Nanci, 1996). Bone sialoprotein makes up 15% of the 
total NCP in bone (Hing, 2004; Wuttke et al., 2001). It does not inhibit HA formation 
at concentrations below 10 μg/ml; it is also thought to be involved in the nucleation 
of HA thereby promoting bone mineralisation (Hunter et al., 1996; Hunter and 
Goldberg, 1993).  
 
Osteopontin 
Osteopontin is a multifunctional protein involved in various physiological and 
pathological processes including: cell migration, adhesion and signalling, and 
regulation of osseous and ectopic calcification (Pampena et al., 2004).  Osteopontin 
has been shown to inhibit calcification in vitro, studies also show osteopontin is a 
potent inhibitor of the de novo formation and seeded growth of HA (Pampena et al., 
2004; Hunter et al., 1994; Boskey et al., 1993).  
 
2.2. BONE CELLS 
2.2.1. Osteoclasts 
Osteoclasts originate from haematopoietic stem cell lineage and maintain mineral 
homeostasis by resorbing the surface of bone (Zaidi, 2007). Osteoclasts are large and 
multinuclear because they are formed from the fusion of monocytes (20 - 100 μm in 
diameter) (Kuhn, 2001; Martin et al., 1998).   
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2.2.2. Osteoblasts 
Osteoblasts are mononuclear, cubodial cells that produce osteoid (Martin et al., 1998; 
Kuhn, 2001; Ng et al., 1997). They are derived from bone marrow mesenchymal 
stem cells (Martin et al., 1998; Hing, 2004). Differentiation of mesenchymal stem 
cells into osteoblasts occurs within 2-3 days. The osteoblasts lay down osteoid at a 
rate of 1 μm/day, mature osteoblasts become embedded in the matrix and 
differentiates to become osteocytes (Martin et al., 1998).  
2.2.2.1. Role of osteoblast cells in bone mineralisation 
Osteoprogenitor cells differentiate to become osteoblasts which express alkaline 
phosphatase and secrete type 1 collagen and NCPs (Johnson et al., 2000; Zaidi, 
2007). The collagen formed is arranged in fibrillar structures, the spaces between the 
end of the collagen fibres are known as hole zones as shown in figure 2.2. Apatite 
crystals are formed in the interior of matrix vesicles (MVs) (Johnson et al., 2000; 
Hessle et al., 2002; Anderson et al., 2005; Tomatsu et al., 2006). MVs are sub-
microscopic, extracellular membranes located on osteoblasts and enriched in ALP, 
Ca2+ and PO4
3- ions (Anderson et al., 2005; Johnson et al., 2000; Tomatsu et al., 
2006; Hessle et al., 2002; Balcerzak et al., 2003; Hsu and Anderson, 1978). The 
formation of apatite is followed by its extrusion into the hole zones. Besides the 
presence of Ca2+ and PO4
3- ions, apatite formation is also aided by the removal of 
P2O7
4- ion a known inhibitor to bone mineralisation by alkaline phosphatase as 
shown in figure 2.3 (Anderson et al., 2005; Hessle et al., 2002). P2O7
4- ion suppresses 
the formation and growth of hydroxyapatite (Hessle et al., 2002) and at high 
concentrations of P2O7
4- osteopontin is expressed (Addison et al., 2007; Moochhala 
et al., 2008). Osteopontin is a known inhibitor of HA formation (Pampena et al., 
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2004; Hunter et al., 1994; Boskey et al., 1993). ALP hydrolyses the P2O7
4- ion into 
PO4
3- ion which is then used to form bone mineral (hydroxyapatite). Further 
mineralisation of the collagen occurs by the nucleation of crystals already formed 
within the hole zone. Once the available space within the hole zone is filled the 
crystals grow and extend beyond the hole zones and into pore spaces between the 
collagen fibrils (Kuhn, 2001). 
 
 
Figure 2.3: a) Effect of pyrophosphate ion on the mineralisation of bone and b) 
alkaline phosphatase aids bone mineralisation by hydrolysing pyrophosphate ion into 
phosphate ion which is then precipitated as hydroxyapatite. 
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2.2.3. Osteocytes  
Osteocytes are the most common cell type in bone; they are responsible for its 
maintenance (Hing, 2004; Nijiweide et al., 2002). Osteocytes are spaced throughout 
the mineralized matrix confined within cavities called lacunae (Nijiweide et al., 
2002). Osteocytes maintain a link with osteoblasts through small canals within the 
bone matrix known as canuliculi (Nijiweide et al., 2002; Martin et al., 1998). 
Osteocytes receive stimuli that enable response to ionic concentrations of calcium 
and phosphate and mechanical strain through this network of canuliculi (Kuhn, 
2001). 
 
2.3. BONE FORMATION AND REMODELLING 
This section discusses the formation of bone in humans from childhood to adulthood, 
the roles of the various bone cells and proteins and the process by which bone 
remodels and repairs itself.  
 
2.3.1. Bone formation  
Bone formation occurs by the intramembranous ossification or endochondral 
ossification process (Kuhn, 2001). The intramembranous ossification forms flat 
bones such as the skull and pelvis while endochondral ossificat ion produces long 
bones such as the femur that bear weight and are linked to joints (Kuhn, 2001; 
Martin et al., 1998; Marks and Odgren, 2002).  
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Endochondral ossification  
Endochondral ossification occurs during embryonic development when the 
chondroprogenitor cells become chondrocytes which then forms a cartilaginous 
model of bone (Kuhn, 2001). Other undifferentiated cells in the surrounding areas 
form osteoblasts which forms a bony collar in centre of the cartilaginous long bones 
(Kuhn, 2001). The bony collar starves the cells which lead to the degradation of the 
cartilage. As the cartilage degrades the product of the degradation is transported via 
blood vessels leaving empty canals. This is then filled with bone forming cells which 
deposit osteoid forming a network of spongy bone (Kuhn, 2001; Schoenau et al., 
2004). 
 
Intramembranous ossification 
Intramembranous ossification occurs during embryonic development (Marks and 
Odgren, 2002). It involves the formation of fibrous connective tissue which is used 
as a scaffold (Kuhn, 2001). The fibrous connective tissue is formed by mesenchymal 
progenitor cells (Kuhn, 2001). Unmineralised osteoid matrix is secreted around the 
fibrils of the connective tissue membranes by osteoblasts. The osteoid matrix is then 
mineralised to become a network of porous cancellous bone (Kuhn, 2001). A 
periosteum is a multilayered connective tissue which encloses the cancellous bone. 
Over time new bone fills the spaces beneath the periosteum and at the outer portion 
of the cancellous bone thereby forming a compact bone shell (Kuhn, 2001). This 
encloses the cancellous bone in a sandwich structure.  
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Bone modelling  
Bone modelling involves the growth and reshaping of bone in childhood and 
adolescence (Ng et al., 1997). Longitudinal growth of long bones depends on the 
proliferation and differentiation of cartilage cells at growth plates which are then 
transformed to bone tissue in the metaphysis (Ng et al., 1997; Schoenau et al., 2004). 
The growth of bone in width occurs by the formation of bone at the periosteal surface 
with resorption at the endosteum (Schoenau et al., 2004; Ng et al., 1997).  In adults, 
bone growth in length and endochondral bone formation ceases once the epiphyses 
close but the process of bone remodelling continues throughout life (Ng et al., 1997). 
 
2.3.2. Bone remodelling  
Bone remodelling refers to the process whereby old bone is replaced by new bone 
(Ng et al., 1997). This occurs throughout adult life in both cancellous and cortical 
bone. It is estimated that 25% of cancellous bone and 3% of cortical bone is resorbed 
and replaced annually (Parfitt, 1994). The process of remodelling is initiated by 
osteoclasts which bind to the bone surface using cell attachment proteins called 
integrins (Ng et al., 1997; Kuhn, 2001). Osteoclasts release H+ lowering the pH of 
the local environment this causes the dissolution of bone crystals and other organic 
components thereby producing “resorption pits” (Ng et al., 1997; Kuhn, 2001). After 
the resorption process, osteoblasts deposit osteoid which is later mineralised (Ng et 
al., 1997).  The newly deposited osteoid has a new (lamellae) microstructure (Kuhn, 
2001; Ng et al., 1997). The remodelling process involves the removal and 
replacement of bone in this particular order and on the same site (Martin et al., 
1998). The group of cells which partake in these processes are called the basic 
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multicellular unit (BMU). The link between osteoblast and osteoclasts activity is 
called coupling (Ng et al., 1997; Schoenau et al., 2004). 
 
2.4. ALKALINE PHOSPHATASE  
Alkaline phosphatase (ALP) is a plasma bound enzyme which occurs widely in many 
organisms (McComb et al., 1979; Millan, 2006; Muginova et al., 2007). ALP is a 
metalloenzyme that forms an isologous dimer with two reactive centres in which 
magnesium and zinc are present (Balcerzak et al., 2003; Mornet et al., 2001; 
McComb et al., 1979). It is known to catalyse the hydrolysis of phosphomonoesters 
(Schwartz and Lipmann, 1961) and has inorganic pyrophosphatase activity (Cox et 
al., 1967) and can therefore hydrolyse pyrophosphates and polyphosphates ions, 
releasing inorganic phosphate (Anderson et al., 2005; Hessle et al., 2002; Omelon et 
al., 2009). P2O7
4- ions are produced by the nucleoside triphosphate 
pyrophosphohydrolase (NTPs) activity of a family of enzyme which includes plasma 
cell membrane glycoprotein-1 (PC-1). In conjunction with PC-1 ALP seeks to 
control bone mineralisation by regulating the concentration of pyrophosphate ions 
present within the MVs as seen in figure 2.4 (Hessle et al., 2002). The process of 
regulating the concentrations of P2O7
4- and PO4
3- is important in order to avoid 
abnormalities in bone mineralisation (Hessle et al., 2002).  
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2.4.1. Forms of alkaline phosphatase 
Alkaline phosphatase is divided into four isozymes. Three forms of the enzyme are 
tissue specific - intestinal, placental and germ cells (Moss, 1982; Muginova et al., 
2007). The tissue specific ALP is 90 – 98% homologous and their genes are located 
on chromosome 2 (Mornet et al., 2001). The fourth isozyme, which is 50% identical 
to the other three is tissue non-specific as it is widely distributed in the liver, bone 
and kidney (Mornet et al., 2001; Llinas et al., 2006). The genes of the tissue non-
specific ALP can be found on chromosome 1 (Mornet et al., 2001). 
 
Figure 2.4: Schematic diagram showing the role of ALP and PC-1 activity in 
regulating bone mineralisation by controlling inorganic phosphate and 
pyrophosphate ion concentrations (Balcerzak et al., 2003; Hessle et al., 2002). 
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3. BONE REPLACEMENT MATERIALS 
One of the earliest modern applications of a biomaterial as a bone replacement was 
in the early 1900‟s when bone plates conventionally made from stainless steel, 
chromium-cobalt, titanium alloys were used to successfully stabilise fractures and 
accelerate its healing (Ben-Nissan and Pezzotti, 2004). Although bone can regenerate 
to a certain extent following injury, beyond a critical size defect it is impossible for 
bone tissue to regenerate and fibrous in growth will occur. The advancement in 
technology and an ageing population has increased the focus on finding various 
means and methods by which bone can be replaced. Key properties of bone 
replacement materials include: non-toxicity, availability, osteoconductivity and 
wherever possible bioresorbability.  Osteoconductivity refers to the ability of the 
material to act as a scaffold on which new bone tissue can grow across (Ilan and 
Ladd, 2002). Osteoinductivity is the ability of a bone replacement material to induce 
the formation of new bone tissue (Ilan and Ladd, 2002). Bone replacement materials 
can be classified as either biological or synthetic. This chapter discusses the relative 
merits and drawbacks of synthetic and biological bone graft replacements.  
 
3.1. BIOLOGICAL BONE REPLACEMENT 
3.1.1. Autograft  
It has been estimated that approximately 500,000 bone grafting procedures are 
carried out annually in the USA and about 2.2 million procedures worldwide in the 
orthopaedics and dental industry (Lewandrowski et al., 2000; Giannoudis et al., 
2005; Ilan and Ladd, 2002). Autograft tissue is the „gold standard‟ for bone graft 
procedures; the bone graft is transferred from one site to another within the same 
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individual (Precheur, 2007). The tissue can be harvested from either cortical or 
cancellous bone (e.g. iliac, femur and tibia); a mixture of both types of bone tissue 
can also be used (Precheur, 2007; Ludwig et al., 2000). Autologous tissue provides 
osteogenic, osteoinductive and osteoconductive properties (Giannoudis et al., 2005). 
The problems associated with the autografting procedure include: donor site 
morbidity, increased surgery and patient recovery time (Giannoudis et al., 2005; 
Ludwig et al., 2000).  
 
3.1.2. Allograft 
Allograft tissue is taken from another individual of the same species and it is the 
most frequently chosen bone graft where autograft is not available. Allograft tissue is 
available as either dowels, strips or chips (Giannoudis et al., 2005; Sandhu et al., 
1999). It is prepared fresh but it‟s rarely used in this state as it ignites an immune 
response or can transmit disease (Friedlander et al., 1999). Allograft tissue is 
persevered by freezing or freeze drying, these processes could result in the 
destruction of osteoprogenitor cells leading to some loss in osteoinductive properties, 
but the osteoconductive property is retained (Giannoudis et al., 2005; Ludwig et al., 
2000; Ilan and Ladd, 2002). The problems associated with allograft tissue include: 
antigenicity and disease transmission (Precheur, 2007). As allograft tissue is 
cadaveric in origin (Precheur, 2007), it is sometimes difficult to obtain reproducible 
bone tissue for grafting (Giannoudis et al., 2005; Vaccaro, 2002).   
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3.1.3. Xenograft 
Xenograft tissue involves the transplantation of bone tissue from one species to 
another, it is often bovine in origin (Precheur, 2007). Bovine bone is non-toxic to 
human osteoblasts (Blom, 2007; Doherty et al., 1994). The main disadvantages of 
xenograft is the theoretical risk of transmission of bovine spongiform 
encephalopathy although there is no firm evidence that it can be transmitted to 
humans (Precheur, 2007). It has also been documented that xenografts could cause 
an intense inflammatory response (Begley et al., 1995). The source of xenograft bone 
tissue could also raise strong ethical issues.  
 
3.2. SYNTHETIC BONE REPLACEMENT 
The use of synthetic materials in humans dates as far back as ancient Phoenicia 
where gold wires were used to bind artificial teeth with the neighbouring ones (Ben-
Nissan and Pezzotti, 2004). Developments in technology have led the research into 
synthetic bone replacement materials; the aim is to overcome the disadvantages 
associated with biological bone tissue replacement. Synthetic bone replacement 
materials include: metals, polymers, hydrogels, cements, ceramics and glasses. The 
basic properties required of a suitable bone replacement materials include non-
toxicity, reproducibility and osteoconductivity (Ben-Nissan and Pezzotti, 2004; 
Vaccaro, 2002; Giannoudis et al., 2005). Any material placed into the body elicits a 
response from the surrounding tissue (Table 3.1) (Ben-Nissan and Pezzotti, 2004; 
Hulbert et al., 1982; Hench, 1998). As a result of this interaction materials may be 
described as nearly inert, bioactive or bioresorbable (Hench, 1991). 
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Bioinert (nearly inert) 
Bioinert materials have little or no interaction with the surrounding tissues (Hench, 
1991). They do not bond chemically or biologically with the bone tissue, this results 
in the formation of a fibrous tissue layer at the bone-tissue interface (Hench, 1991). 
Any movement at this interface can cause implant failure (Hench, 1991). To resolve 
this, biomaterials with pore sizes between 100 – 150 μm have been developed, 
enabling biological fixation to the host tissue through the growth of healthy and 
viable bone tissue (Hench, 1991). Table 3.1 gives some examples of nearly inert 
biomaterials. 
 
Bioactive (surface reactive) 
Bioactive biomaterials were discovered in 1969 when Hench reported the first in vivo 
results and in vitro tests from the use of Bioglass® (Hench et al., 1972). The glass 
material was found to form a stable bond with bone due to the kinetic modification of 
the surface in a time dependent manner when implanted (Hench, 1991). Although the 
implant is strongly attached there is a possibility that the bone or implant (bulk) 
could fail (Hench, 1991). Bioactive materials are also known to enhance bone tissue 
formation (Precheur, 2007). Due to these properties HA has been used as coatings for 
various bioinert materials especially in hip replacement (Hench and Wilson, 1984; 
Nagano et al., 1996; Geesink et al., 1988; Ducheyne et al., 1980).  
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Bioresorbable  
Resorbable materials are designed to degrade slowly in the body before they are 
replaced by the host tissue (e.g. bone) (Hench, 1991; Hench, 1998). Due to the 
resorbable nature of these materials there is little interface layer formed (Hench, 
1991). A suitable resorbable material should be made up of ions which are tolerated 
in the body and easily removed from circulation therefore limiting the risk of 
toxicity. The limitations of designing suitable resorbable biomaterial include: (1) 
maintaining the strength of the implant and the stability of the interface throughout 
degradation and new tissue formation and (2) matching the rate of material 
degradation to new tissue formation (Hench, 1991). 
 
Table 3.1: Interaction between the biomaterial and host tissue (Hench, 1991; Hulbert 
et al., 1982; Ben-Nissan and Pezzotti, 2004; Dubok, 2000). 
Biomaterial type Tissue reaction Example  
Nearly inert  Undergoes little or no chemical 
change, formation of a fibrous 
tissue layer  
Al2O3, ZrO2, titanium 
and stainless steel. 
Bioactive Chemical bond between the 
tissue and implant surface 
Hydroxyapatite, 
Bioglass® and glass 
ceramic. 
Resorbable  Gradual dissolution in the body 
while it is replaced by the new 
bone tissue 
Calcium phosphate salts 
and polylactic-
polyglycolic acid 
copolymers.  
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3.2.1. Metals   
Metals were first used in orthopaedic procedures by the ancient Greeks to treat bone 
fractures (Sumita and Teoh, 2004). In 1991 over half of the total market for implants 
and instrumentation in orthopaedics was for joint prostheses made of metallic 
materials (Brunski JB, 1996). Metallic implants take the form of nails, screws, bone 
plates and staples amongst others (Sumita and Teoh, 2004).  The main advantage of 
using metallic implant is their high mechanical strength and fracture toughness 
making them suitable for use in load bearing applications (Brar et al., 2009; Staiger 
et al., 2006). Unfortunately their usually low corrosion resistance means they release 
potentially toxic ions that could lead to tissue inflammation (Staiger et al., 2006; 
Sumita and Teoh, 2004; Jacobs et al., 1998). The material does not form a significant 
bond with bone and the patient would require a secondary surgery to remove the 
implant (Staiger et al., 2006). There is also a problem with implant failure due to 
fracture arising from corrosion or fretting fatigue (Sumita and Teoh, 2004). 
Examples of metallic implants currently available on the market are: stainless steel, 
titanium, cobalt-chromium based alloys and magnesium.  
3.2.1.1. Magnesium  
Magnesium‟s properties make it suitable for use in bone tissue repair. It is 
lightweight, non-toxic and biodegradable; it has a similar density to that of bone 
(Staiger et al., 2006; Tan et al., 2009). Magnesium is essential for human metabolism 
with work showing that magnesium enhances cell adhesion on alumina and has no 
inhibitory effect on cell growth (Li et al., 2004; Pietak et al., 2008; Brar et al., 2009; 
Zreiqat et al., 2002). Magnesium was first used in 1907 by Lambotte (Lambotte, 
1932) to secure a fractured leg bone (Brar et al., 2009; Staiger et al., 2006). This 
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biomaterial failed to provide sufficient mechanical support to the surrounding tissue 
as it corroded and degraded too rapidly (Staiger et al., 2006; Lambotte, 1932). 
Furthermore, as magnesium undergoes corrosion hydrogen gas is released and this 
was found to have been accumulated underneath the skin were the implant was 
placed (Staiger et al., 2006; Lambotte, 1932). The low corrosion resistance of 
magnesium has led to the development of various magnesium alloys which have a 
higher resistance at physiological pH.  
3.2.1.2. Stainless steel 
Stainless steel is made from iron alloyed with various other elements such as silicon, 
molybdenum, carbon, and chromium (Sumita and Teoh, 2004). The addition of 12 
wt% or more of chromium to steel increases corrosion resistance due to the 
formation of a chemically stable oxide layer (Sumita and Teoh, 2004). The most 
common grade of stainless steel used for tissue transplantation is 316L as it contains 
less than 0.03 wt% carbon because this reduces the possibility of corrosion in vivo 
(Brunski JB, 1996).  Nickel is sometimes added to stainless steel to promote the 
higher corrosive resistance austenitic phase (Sumita and Teoh, 2004). The 
disadvantage of using nickel is its toxicity to the surrounding tissue therefore the 
material is used in temporary devices (Sumita and Teoh, 2004).  
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3.2.2. Ceramics, Bioglass and Glass Ceramics 
3.2.2.1. Alumina 
α-Alumina is the form of alumina used in bioceramics; it is the most stable form 
when free from impurities (Ishikawa et al., 2003). In 1963 alumina ceramic (Al2O3) 
was mixed with epoxy resin before implantation into rabbits (Smith, 1963). After 40 
days implantation the biomaterial was found to have been kept in place by cancellous 
bone and fibrous tissue (Hulbert et al., 1982; Hulbert et al., 1972). High purity, 
polycrystalline alumina was developed and used for total hip prostheses and tooth 
implants as a replacement to surgical metal alloys (Ben-Nissan and Pezzotti, 2004; 
Boutin et al., 1988; Hench, 1991). The advantage of using alumina in articulating 
areas is its low wear rate due to its high hardness, low friction coefficient and high 
corrosion resistance (Ben-Nissan and Pezzotti, 2004; Hench, 1991).  
3.2.2.2. Zirconia 
Zirconia is of interest in the orthopaedics field due to its mechanical strength, high 
fracture toughness and relatively low Young‟s modulus (Ishikawa et al., 2003); about 
600,000 zirconia femoral heads have been implanted worldwide (Chevalier, 2006). 
These properties enable the production of smaller femoral heads for total hip 
prostheses than alumina (Hench, 1998). Zirconia occurs in three forms: monoclinic, 
cubic and tetragonal (Ishikawa et al., 2003; Piconi, 2001). From room temperature up 
to 1170°C zirconia exists in the monoclinic form, above this temperature it changes 
to the tetragonal phase (Ishikawa et al., 2003; Piconi, 2001). Biomedical grade 
zirconia has been shown to exhibit the best mechanical strengths of the oxide 
ceramics due to phase transformation toughening (Chevalier, 2006).  Phase 
transformation involves the application of stress, inducing the transformation from 
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the metastable tetragonal to monoclinic phase. Zirconia is prone to ageing in the 
presence of water due to this metastability (Chevalier, 2006; Ben-Nissan and 
Pezzotti, 2004).  The addition of calcium oxide (CaO), magnesium oxide (MgO), 
cerium oxide (CeO2) or Yttrium oxide (Y2O3) has been shown to prevent phase 
transformation in the material (Ishikawa et al., 2003; Piconi, 2001). The products of 
the degradation of zirconia leads to osteolysis which is thought to be the major cause 
of long term failure of total hip replacements (Ben-Nissan and Pezzotti, 2004; 
Ishikawa et al., 2003).  
3.2.2.3. Bioglass and glass-ceramics  
Bioglass and glass ceramics are used in spinal surgery, maxillofacial reconstruction, 
coatings for inert biomaterials, and as bone and dental implants (Hench, 2001; 
Hench, 1998; Rezwan et al., 2006). Hench (Hench et al., 1972) discovered that 
bioactive glasses containing Na2O, CaO, P2O5 and SiO2 bonded to femoral bone in 
rats 10 days after implantation. Bioglass®, PerioGlas®, BioGran®, 45S5® and S53P4® 
are types of bioglass and glass ceramics currently in use in clinics (Hench, 2001). 
The 45S5 (45% SiO2, 24.5% CaO, 24.5% Na2O and 6% P2O5 by weight) bioglass is 
commonly used. The products of its degradation are found to upregulate the 
expression of genes that control osteogenesis and the production of growth factors 
thereby enhancing osteoblast proliferation (Rezwan et al., 2006). The extent of bone 
bonding is thought to be affected by the silica content of the biomaterial; the upper 
limit is 60% (Hench, 2001). It has also been suggested that 45S5 bioglass enhances 
the growth of osteoblast on its surface than hydroxyapatite due to the rapid exchange 
of ions at the surface (Rezwan et al., 2006; Ben-Nissan and Pezzotti, 2004). CaO-
SiO2-B2O3 glass ceramic was investigated as a possible bone replacement material 
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but the tensile strength was lower than that of HA and when implanted into New 
Zealand white male rabbits (Lee et al., 2006). CaO-SiO2-B2O3 glass ceramic was also 
found to show a higher biodegradation than β-TCP and HA in vivo (Lee et al., 2006).  
 
3.2.3. Polymers 
Biodegradable polymers can be classified as either natural polymers e.g. 
polysaccharides, collagen or synthetic polymers e.g. poly(glycolide), poly(ε-
caprolactone), poly(lactic-coglycolide). The success in the late 1960s of a poly(-
glycolic acid) based wound suture has led to the design and development of a variety 
of polymer biomaterials (Gilding and Reed, 1979; Middleton and Tipton, 2000). 
Since then there has been considerable interest in polymers as dental materials 
(Kulkarni et al., 1971; Miller et al., 1977), coatings for orthopaedic implants 
(Gollwitzer et al., 2005; Seal et al., 2001; Ignjatovic et al., 2007), orthopaedic 
biomaterials (Middleton and Tipton, 2000; Nair and Laurencin, 2007; Rezwan et al., 
2006; Athanasiou et al., 1998) and as drug delivery matrices (Rezwan et al., 2006; 
Seal et al., 2001; Ramchandani and Robinson, 1998).   Due to the versatility of 
polymers in 2003, the sale of polymeric biomaterials was in excess of $7 billion 
(Nair and Laurencin, 2007).  
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3.2.4. Hydrogels 
Hydrogels are a network of macromolecular hydrophilic polymers forming a gel, 
which have the ability to hold water many times their weight (Patel and Mequanint, 
2007; Ulijn et al., 2007; Li, 2004; Griesser and Kambouris, 2001). The first hydrogel 
to be used in the 1950‟s was poly(hydroxyethyl methacrylate) (poly-HEMA); it was 
found to be well tolerated in the body (Griesser and Kambouris, 2001; Wichterle and 
Lim, 1960). Poly-HEMA resists protein adsorption and lubricity making it an ideal 
material for contact lenses (Batich and Leamy, 2003). Hydrogels can be classified as 
either chemical or physical based on the bonding of the crosslinks present and also as 
either natural, synthetic or a combination of both based on the source (Li, 2004). 
Chemical hydrogels are also known as permanent hydrogels as they cannot be 
dissolved using water or other solvents (Li, 2004). The polymer network of a 
chemical hydrogel is formed by covalent bonding (Li, 2004). The polymer networks 
for physical hydrogels are formed by cohesion forces such as ionic bond, hydrogen 
bond and van der Waals forces  (Li, 2004). Hydrogels are employed in a variety of 
applications including: wound dressing (Rosiak et al., 1989), coatings for 
orthopaedic materials (Zdrahala, 1996; Griesser and Kambouris, 2001), drug delivery 
(Schmaljohann et al., 2003; Ulijn et al., 2007; Peppas et al., 2006) and in tissue 
engineering (Ulijn et al., 2007; Peppas et al., 2006). The mechanical properties of 
hydrogels have been vastly improved (Gong et al., 2003) although it is still 
comparatively lower than that of metals, metallic alloys, cements and ceramics 
(Grimm, 2003).    
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4. CALCIUM PHOSPHATES 
Calcium phosphate materials have been in use in medicine (Friedman et al., 1998; 
Jarcho, 1981; de Groot K., 1984; de Groot, 1980) and dentistry (Brown and Chow, 
1985; LeGeros, 1988) for over 30 years (Hench, 1998). The applications include: 
coatings for orthopaedic implants (Geesink, 1990; Geesink et al., 1988; Stephenson 
et al., 1991), maxillofacial surgery (Hench, 1998), scaffolds for bone growth (Hench, 
1998), materials in total hip and knee surgery (Hench, 1998; Gatti et al., 1990; van 
Hemert et al., 2004) and as a drug release matrices (Ginebra et al., 2006; Paul and 
Sharma, 1999; Itokazu et al., 1998; Hamanishi et al., 1996). Calcium phosphates are 
widely available and are of interest to  a variety of fields including geology, 
chemistry, biology  and medicine (Dorozhkin, 2007). As the name suggests they 
comprise calcium (Ca), phosphorus (P) and oxygen (O) atoms but could also consist 
of hydrogen (H+) ions either as an acidic phosphate e.g. HPO4 or as water (H2O). 
Calcium phosphates are all soluble in acids and insoluble in alkaline solution while 
the vast majority are sparingly soluble in water (Dorozhkin, 2007). The chemical 
similarity of bone with calcium phosphate materials (Kuhn, 2001; Currey, 2001; 
Olszta et al., 2007) and their osteoconductive nature makes them suitable materials 
for bone replacement (Gatti et al., 1990; Kitsugi et al., 1993). A benefit of using 
calcium phosphates is the non-toxicity of its degradation products which are easily 
cleared from the body (del Valle et al., 2007; Constantz et al., 1995; Suchanek and 
Yoshimura, 1998; Anee et al., 2003; Ng et al., 2008).  A brief description of some of 
the calcium phosphates used in the production of bone replacement materials are 
provided below.  
 
30 
 
4.1. CALCIUM ORTHOPHOSPHATES  
4.1.1. β – Tricalcium phosphate (β-TCP) 
There are three polymorphs of TCP: β-TCP, α-TCP and α‟-TCP (Choi and Kumta, 
2007). α‟-TCP is the high temperature phase and exists above 1470°C (Ryu et al., 
2002; Elliot J.C., 1994). Due to its unstable nature it has not found any use as bone 
replacement. β-TCP is the most stable form at temperatures below 1180°C (Elliot 
J.C., 1994). A combination of β-TCP, HA and their derivatives form the basis of 
most calcium phosphate bone cements used in bone replacement (Navarro et al., 
2008) as it is considered to be non-toxic and resorbable (Peters and Reif, 2004). The 
powder and highly porous blocks of β-TCP degrade too rapidly resulting in no bone 
formation at the implant site of the implant (Lin et al., 1995b; Uemura et al., 2003). 
Pure β-TCP (Ca3(PO4)2) does not occur in biological calcifications and cannot be 
precipitated in aqueous solution (Dorozhkin, 2007). It can be produced only through 
thermal decomposition at temperatures above 800°C (Dorozhkin, 2007).  β-TCP is 
also used as a coating for orthopaedic appliances (Hulbert et al., 1982; Peters and 
Reif, 2004) and is added to some brands of toothpaste as a gentle polishing agent and 
in multivitamin complexes (Dorozhkin, 2007). 
 
4.1.2. α – Tricalcium phosphate (α-TCP) 
α-TCP is stable at temperatures between 1180 -1400ºC and is formed by the phase 
transformation of β-TCP at temperatures above 1125ºC (Choi and Kumta, 2007; 
Dorozhkin, 2007). α-TCP has the same chemical composition as β-TCP but a 
different crystallographic structure (Table 4.1) (Dorozhkin, 2007). This is thought to 
be responsible for the higher solubility of α-TCP when compared to β-TCP (Bohner, 
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2000). Compared to β-TCP, α-TCP is less stable and more reactive in aqueous 
systems (Peters and Reif, 2004). It hydrolyses and reprecipitates as apatitic products 
(Peters and Reif, 2004). α-TCP was shown to degrade faster in vivo than β-TCP and 
was surrounded by new bone (Yamada et al., 2007). α-TCP does not occur in 
biological calcification and in its pure form it is occasionally used in bone cement 
(Dorozhkin, 2008; Dorozhkin and Epple, 2002; Bermudez et al., 1994; Driessens et 
al., 1994; Kurashina et al., 1997; Constantz et al., 1995).   
 
4.1.3. Tetracalcium phosphate (TTCP) 
TTCP (Ca4(PO4)2O) is also known as hilgenstockite and is the most basic calcium 
orthophosphate (Dorozhkin and Epple, 2002; Dorozhkin, 2007). TTCP has a higher 
solubility than HA in water (Table 4.2) and cannot be precipitated from aqueous 
solution (Kalita et al., 2007). TTCP is not stable in aqueous conditions and it 
hydrolyses slowly to HA and calcium hydroxide (Kalita et al., 2007; Elliot J.C., 
1994). It can be prepared by solid state reactions at temperatures above 1300°C in a 
dry atmosphere, in vacuum or with rapid cooling to prevent water uptake and HA 
formation (Elliot J.C., 1994; Dorozhkin, 2007). TTCP is never found in biological 
calcification (Kalita et al., 2007). It is widely used for the preparation of various self 
setting calcium phosphate cements such as HA (Elliot J.C., 1994).  
32 
 
 
 
  
U
n
it
 c
e
ll
 
 
γ 
 (
°)
 
1
2
0
 
 1
0
8
.6
5
(1
) 
8
3
.3
4
4
(6
) 
  1
2
0
 
1
2
0
 
β
  
(°
) 
 1
2
6
.2
0
(1
) 
9
2
.5
4
(2
) 
1
1
8
.2
6
2
(6
) 
1
1
6
.4
2
(3
) 
9
0
.9
0
(1
) 
  
α
  
(°
) 
   9
0
.1
5
(2
) 
9
8
.6
3
3
(6
) 
    
c 
(Å
) 
 3
7
.3
7
5
(6
) 
1
5
.2
1
9
(2
) 
6
.8
3
5
(2
) 
6
.4
7
3
1
(8
) 
6
.2
3
9
(2
) 
9
.4
7
3
(2
) 
6
.8
8
1
4
(7
) 
6
.8
9
1
1
(2
) 
b
 (
Å
) 
 1
0
.4
1
8
3
(5
) 
2
7
.2
8
0
(4
) 
9
.5
2
3
(2
) 
1
1
.8
8
9
(2
) 
 1
5
.1
8
0
(3
) 
1
1
.9
8
6
(4
) 
2
a 
9
.4
3
0
2
(5
) 
a 
(Å
) 
1
0
.4
1
8
3
(5
) 
1
2
.8
8
7
(2
) 
1
9
.6
9
2
(4
) 
5
.6
2
6
1
(5
) 
5
.8
1
2
(2
) 
7
.0
2
3
(1
) 
9
.8
4
2
1
4
(8
) 
9
.4
3
0
2
(5
) 
S
p
a
c
e
 
g
ro
u
p
 
R
h
o
m
b
o
h
ed
ra
l 
R
3
C
h
 
M
o
n
o
cl
in
ic
 
P
2
1
/a
 
T
ri
cl
in
ic
 
P
1
 
 T
ri
cl
in
ic
 
P
1
 
M
o
n
o
cl
in
ic
 
Ia
 
M
o
n
o
cl
in
ic
 
P
2
1
 
M
o
n
o
cl
in
ic
 
P
2
1
/b
 
 H
ex
ag
o
n
al
 
P
6
3
/m
 
  
C
o
m
p
o
u
n
d
 
β
-T
C
P
 
α
-T
C
P
 
O
C
P
 
M
C
P
M
 
D
C
P
D
 
T
T
C
P
 
H
A
 
H
A
 
33 
 
4.1.4. Amorphous calcium phosphate (ACP)  
ACP [((Ca3(PO4)2). nH2O; n = 3 - 4.5; 15-20% H2O) (Bohner, 2000; Dorozhkin, 
2007)] was previously reported to be a component of bone the concentration of 
which decreases with age (Termine and Posner, 1966). Further investigations carried 
out by Grynpas et al. (Grynpas et al., 1984) indicated that ACP was not present in 
bone. ACP often occurs as a transient phase in the formation of calcium phosphates 
in aqueous solutions (Dorozhkin and Epple, 2002; Elliot J.C., 1994). ACP is used to 
produce calcium phosphate cements (Takagi et al., 1998; Bohner, 2000). The 
chemical composition of ACP, in the final mixing solutions, is dependent on the pH, 
calcium and phosphate ion concentrations (Dorozhkin and Epple, 2002; Dorozhkin, 
2007). Electron microscopy has shown that ACP consists of spherical particles with 
diameters in the range of 20 – 200 nm without distinct morphology (Dorozhkin and 
Epple, 2002; Dorozhkin, 2007). It is also thought to have apatitic structure but with a 
crystal size that is X-ray amorphous (Dorozhkin and Epple, 2002; Dorozhkin, 2007). 
It has also been proposed that ACP has a basic structural unit 9.5 Å diameter, 
roughly spherical, cluster of ions comprising Ca9(PO4)6 (Betts and Posner, 1974).  
 
4.1.5. Monocalcium phosphate monohydrate (MCPM) 
MCPM (Ca(H2PO4)2.H2O) is the most acidic and soluble of all the calcium 
phosphates (Elliot J.C., 1994), at temperatures above 100°C it loses its water of 
crystallisation and becomes anhydrous (Dorozhkin, 2007). Due to its high acidity and 
solubility MCPM is not found in biological calcifications and is not cytotoxic with 
bone in its pure form (Koster et al., 1977). Mirtchi et al (Mirtchi et al., 1989) used 
MCPM in conjunction with β-TCP to form self hardening cement (DCPD; brushite) 
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for use as bone replacement material. This cement has been reported to be non-toxic 
and osteoconductive (Ohura et al., 1996). MCPM is used in food, beverages and as 
mineral supplement in dry baking powders in addition it is used in agriculture as a 
fertilizer (Dorozhkin, 2007). According to the European Union classification MCPM 
is a food additive marked as E34 (Dorozhkin, 2007). 
 
Table 4.2: Properties of some calcium orthophosphates (Dorozhkin, 2007; 
Dorozhkin, 2008; Fernandez et al., 1999). 
Compound Ca/P 
molar 
ratio 
Density 
(gcm-3) 
Solubility at 
25ºC 
–Log(Ksp) 
Solubility at 
37ºC 
-Log(Ksp) 
MCPM 0.5 2.23 1.14 - 
DCPD 1.0 2.32 6.59 6.59 
OCP 1.33 2.61 96.6 95.9 
TTCP 2.0 3.05 38 – 44 37 – 42 
β-TCP 1.5 3.08 28.9 29.5 
α-TCP 1.5 2.86 25.5 25.5 
HA 1.67 3.16 58.4 58.6 
 
 
4.1.6. Octacalcium phosphate (OCP) 
OCP (Ca8(HPO4)2(PO4)4.5H2O) is found biologically in dental and urinary calculi 
(Dorozhkin, 2007). It often occurs as an intermediate phase during the precipitation 
of more stable calcium orthophosphate from aqueous solution (Dorozhkin and Epple, 
2002). It has been proposed that OCP is an intermediate phase in the mineralisation 
of bone and teeth (Brown et al., 1987; Tomazic et al., 1994; Nancollas and Wu, 
2000; Suzuki et al., 1991; Bohner, 2000; Brown, 1962; Brown et al., 1962). 
35 
 
Therefore OCP has been investigated for use as an implant coating as well as 
promoting bone formation in vivo and in vitro due to its bioactive and 
osteoconductive properties (Barrere et al., 2003; Kamakura et al., 1999; Shelton et 
al., 2006). OCP consists of apatitic layers separated alternately by hydrated layers 
(Elliot J.C., 1994; Dorozhkin and Epple, 2002; Suzuki et al., 2006). The presence of 
apatitic layers explains the structural similarities with HA (Brown et al., 1962) and 
the transition of OCP to HA is thermodynamically favoured (Suzuki et al., 2006). 
This transition in physiological conditions is thought to be responsible for the low 
detection of OCP in vascular calcification (Suzuki et al., 2006).  
 
4.1.7. Hydroxyapatite (HA) 
HA (Ca10(PO4)6(OH2)) is the most stable and the least soluble of all the calcium 
orthophosphates in physiological conditions (Table 4.2) (Ben-Nissan and Pezzotti, 
2004; Dorozhkin and Epple, 2002). It has a chemical composition similar to the 
mineral content of bone (Vallet-Regi and Gonzalez-Calbet, 2004; Kalita et al., 2007; 
Bow et al., 2004).  It is osteoconductive and bioactive therefore bonds well with bone 
(Ng et al., 2008; Vallet-Regi and Gonzalez-Calbet, 2004; Ben-Nissan and Pezzotti, 
2004) and soft tissue (Hench, 1991; Suchanek and Yoshimura, 1998). HA has been 
widely used in orthopaedic (Dorozhkin and Epple, 2002) and dental applications 
(Denissen and Degroot, 1979; LeGeros, 1988) either in powder or bulk form. It is 
used as a coating for metallic prostheses due to its bioactive properties (Ben-Nissan 
and Pezzotti, 2004; Liu et al., 2001; Suchanek and Yoshimura, 1998; Willmann, 
1999). HA is also used as a matrix for drug release (Paul and Sharma, 1999; Liu et 
al., 2005; Palazzo et al., 2005; Lin et al., 1996). A composite of HA and poly(vinyl 
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alcohol) gel have also been investigated for use as a biomaterial in articular cartilage 
repair (Pan et al., 2007).  
 
4.1.8. Dicalcium phosphate dihydrate (DCPD) 
DCPD is commonly known as brushite and can be easily crystallized from aqueous 
solutions (Dorozhkin, 2007). It is often found in pathological calcifications dental 
calculi, chondrocalcinosis (LeGeros, 2001) and urinary stones (Hesse and Heimbach, 
1999). It has been proposed as an intermediate in the formation of bones and teeth 
i.e. bone mineralization and dissolution of enamel in acids (dental erosions) (Sainz-
Diaz et al., 2004). Brushite cement can be produced by a mixture of phosphoric acid 
and β–TCP (Bohner et al., 1996), which is transformed into its anhydrous form 
(dicalcium phosphate anhydrous; DCPA) at temperatures above 55°C (Grover et al., 
2005). Brushite cement has been developed as a bone replacement material in place 
of HA due to its higher solubility at pH 7.4 in physiological conditions. Other uses of 
brushite are as a texturizer in the food industry and as a water retention additive 
(Dorozhkin, 2007).  
 
4.2. CALCIUM PHOSPHATE CEMENT  
Calcium phosphate cements were discovered in the 1980‟s by Brown and Chow 
(Brown and Chow, 1985) and are widely used as bone substitutes due to their 
osteoconductive properties (Bucholz, 2002). Calcium phosphate cements are 
produced by the reaction of one or more calcium phosphate powders in an aqueous 
solution (Bohner et al., 2005). The calcium phosphate cement dissolves depending 
on the chemical composition and pH of the solution before the final product is 
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precipitated (Dorozhkin, 2008). During precipitation the newly formed crystals form 
a web as they grow providing mechanical rigidity to the calcium phosphate cement 
(Bohner, 2000). Calcium phosphate cements can also be implanted into patients as a 
workable paste to fit various shape defects (Alkhraisat et al., 2008) leading to the 
development of a wide variety of commercially available calcium phosphate cements 
(Table 4.3) (Bohner et al., 2005). Depending on the end product of the cement setting 
reaction calcium phosphate cement can be classified as apatite or brushite cement 
(Bohner, 2000). 
 
Table 4.3: Examples of commercially available calcium phosphate cements and their 
compositions (Bohner et al., 2005; Dorozhkin, 2008; Ishikawa et al., 2003). 
Brand 
Name 
Cement 
type 
Powder 
component 
Liquid 
component 
Company 
BoneSource® Apatite TTCP + DCPA H2O, mixture of 
Na2HPO4 and 
NaH2PO4 
Stryker-
Leibinger 
Corp. 
Norian SRS® Apatite α-TCP + MCPM 
+ CaCO3 
H2O, Na2HPO4 Synthes-
Norian 
MimixTM Apatite TTCP + α-TCP Citric acid Biomet 
Biopex® Apatite α-TCP + TTCP 
+ DCPD + HA 
Succinic acid 
and chonroitin 
sulphate  
Mitsubishi 
materials  
Eurobone® Brushite  β-TCP + 
Na4P2O7 
H2O, H3PO4 
and H2SO4  
Kasios 
chronOSTM 
Inject 
Brushite  β-TCP,  MCPM, 
MgHPO4.3H2O,  
MgSO4 and  
Na2H2P2O7 
H2O, sodium 
hyaluronate 
Synthes-
Norian 
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4.2.1. Apatite cements  
The formation of calcium deficient apatite (CDHA) cement by the hydrolysis of α-
TCP between 60 - 100°C was first reported by Monma and Kanazawa (Monma and 
Kanazawa, 2000). The presence of calcium phosphate crystals which are closely 
similar to CDHA and carbonated apatite in bone and teeth is thought to be 
responsible for its osteoconductive nature and non-cytotoxic properties in vivo 
(Dorozhkin, 2008). Brown and Chow (Brown and Chow, 1985) reported on the 
formation of apatite from the combination of TTCP and DCPA or DCPD powders in 
an aqueous medium. The setting period for this apatite cement (Brown and Chow, 
1985) was shorter at physiological temperature than that of CDHA (Monma and 
Kanazawa, 2000) but could be further reduced by adding MCPM, orthophosphoric 
ions and phosphoric acid which lower the pH of the mixture (Dorozhkin, 2008). 
Apatite cements are formed at near physiological pH (> 4.2) (Xia et al., 2006). As 
DCPA and TTCP powders in aqueous solution dissolve and calcium and phosphate 
ions are released these results in the supersaturation of the solution with respect to 
apatite. Apatite, crystals are then precipitated to form the hardened apatite cement 
mass (equation 4.1). This process is known as “dissolution-precipitation mechanism” 
(Ishikawa et al., 2003). Due to the thermodynamic stability of apatite cement at 
neutral pH most calcium phosphates are hydrated to form apatite (Ishikawa et al., 
2003).  
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4.2.2. Brushite cements 
Brushite cement was first introduced in 1987 by (Lemaitre et al., 1987) and can only 
be produced by an acid base reaction (Bohner, 2000). It has a faster setting time than 
apatite cement and citric acid and sodium citrate delay the hardening reaction. 
Brushite cement is formed when the pH of the setting cement past is acidic i.e. pH ≤ 
4.2 (Bohner et al., 1997). Brushite cement can be produced from a mixture of β-TCP, 
MCPM and water (equation 4.2) (Mirtchi et al., 1989). When MCPM is replaced 
with orthophosphoric acid (equation 4.3) it is easier to control the physico–chemical 
properties of the cement such as longer setting times and larger tensile strengths due 
to a higher homogeneity as well as the chemical composition and reactivity of the 
cement (Dorozhkin, 2008). 
                                                  
                                         
 
Brushite cements are osteoconductive and also more soluble than apatite cements 
(Dorozhkin, 2008). They are metastable and more soluble at physiological pH than 
apatite cement (Vereecke and Lemaitre, 1990) making them more resorbable in vivo 
(Apelt et al., 2004). The linear degradation rate of brushite cement is calculated as 
0.25 mm/week (Ohura et al., 1996) which is thought to be too fast as not to allow the 
formation of mature bone. The release of orthophosphoric acid when large amounts 
of brushite cement are implanted in vivo is thought to be responsible for the 
inflammation of the surrounding tissue (Bohner, 2000). The inflammation is thought 
to occur by the transformation of DCPD into CDHA which increases the resorption 
time leading to cement implant failure (Dorozhkin, 2008; Grover et al., 2003). P2O7
4- 
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ions or magnesium salts of low solubility can be incorporated into the brushite 
cement to inhibit apatite formation (Grover et al., 2006; Apelt et al., 2004; Bohner 
and Matter, 2004). 
4.2.2.1. Pyrophosphate modified brushite cement   
Pyrophosphate ions prevent the seeding of calcium phosphate crystals by binding 
onto the crystal surface therefore stopping it from reaching its critical size (Caswell 
et al., 1991). This property has been exploited in reducing setting times for brushite 
cement. Grover et al. reported the formation of a new type of brushite cement 
containing calcium pyrophosphate (Grover et al., 2003). This cement was found to 
degrade faster than brushite cement in phosphate buffered saline solution (Figure 
4.1) (Grover et al., 2006). This is due to pyrophosphate ion inhibiting the formation 
of apatite within the brushite cement (Grover et al., 2006). This property of P2O7
4- 
ion as well as its interaction with ALP has ensured the possibility of developing a 
pyrophosphate based bone replacement material (Whited et al., 2006).   
 
Figure 4.1: Degradation of brushite and pyrophosphate modified brushite cement in 
phosphate buffered saline solution (Grover et al., 2006).   
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5. CONDENSED PHOSPHATES 
Condensed phosphates were discovered in 1827 (Vanwazer and Holst, 1950). They 
can be formed either by an enzymatic reaction using polyphosphatase kinases 
(Kornberg et al., 1999) or a condensation reaction. The condensation reaction 
involves the elimination of the water component of orthophosphoric acids and other 
phosphate species (Greenfield and Clift, 1975). Condensed phosphates have a wide 
variety of applications such as in drug delivery matrices (Dion et al., 2005) and as a 
multivalent electrolyte in aqueous solutions (Van Wazer, 1974). They can be 
classified as: polyphosphates, cyclophosphates and ultraphosphates. Linear and ultra 
(branched) - phosphates are formed by the condensation of phosphoric acids with the 
empirical formula: 
                                     
While cyclophosphates are salts of cyclic acids with an empirical formula of:  
                         
Where n is the number of phosphates in the linear or cyclic chain. 
 
Biological occurrence of condensed phosphate salts  
McCarty (Mccarty et al., 1962) first discovered the presence of CPPD crystals in 
articular cartilage and synovial fluid of humans. The presence of these crystals leads 
to the clinical disease known as calcium pyrophosphate deposition disease, with 
patients exhibiting arthritic symptoms (Song et al., 2002). High concentrations of 
P2O7
4- ions were also found in fluid collected from the joints of patients suffering 
with osteoarthritis (Hearn and Russell, 1980). Polyphosphates have also been 
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identified in a wide variety of microorganisms such as bacteria, fungi and algae 
(Kornberg et al., 1999) and in higher plants and animals (Harold, 1966).  
 
5.1. TYPES OF CONDENSED PHOSPHATES 
5.1.1. Pyrophosphates  
PO4
3- ion consists of a central phosphorous atom surrounded by four oxygen atoms at 
the corners of a tetrahedron (Vanwazer and Holst, 1950). Pyrophosphate, the 
simplest form of condensed phosphates is formed by linking two phosphate ions 
together by a central oxygen atom as illustrated in figure 5.1b. Pyrophosphates are 
usually non-linear and the P-O-P (phosphoanhydride) bond angle is rarely 180° 
(Greenfield and Clift, 1975).  
 
Figure 5.1: A diagram representing the structure of a) orthophosphoric ion and b) 
pyrophosphate ion. 
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5.1.2. Linear polyphosphates 
Linear polyphosphates are represented by the general formula M(n+2)PnO3n+1, where n 
is the number of phosphorous atoms in the chain. In the polyphosphate chain, the 
phosphorous atoms are linked another by an oxygen atom as shown in figure 5.2. 
The degree of polymerisation n, varies from 2 (pyrophosphate) to106 (Kualev et al., 
2004). Polyphosphates chains between 2 and 5 can be obtained in a pure and 
crystalline phase while polyphosphates of higher chain length are obtained in 
mixtures with each other (Kualev et al., 2004; Vanwazer and Callis, 1958). 
Polyphosphates are stable at neutral pH, room temperature (Kualev et al., 2004) and 
alkali solution but reactive in acids (Harold, 1966).  
 
Figure 5.2: Structure of linear condensed phosphate, where M is a hydrogen ion or a 
monovalent metal cation. 
 
Linear polyphosphates contains terminal hydroxyl groups which are weakly acidic 
and intermediate hydroxyl groups that are strongly acidic (Kualev et al., 2004). This 
property makes it possible to determine the type of condensed phosphate and the 
length of the polymer chain.  The alkali metal salts are more soluble in water with the 
exception of Kurrol‟s (large macromolecular potassium polyphosphate) and 
Maddrell‟s (high molecular weight sodium polyphosphate) salt (Kualev et al., 2004). 
Polyphosphates salts produced from divalent metals are either completely insoluble 
or sparingly soluble in aqueous solution (Kualev et al., 2004). 
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5.1.3. Cyclophosphates  
Cyclophosphates also known as “metaphosphates” have the general formula 
MnPnO3n. Most common compounds in this group of condensed phosphates are the 
tri- and tetra-methaphosphates (Figure 5.3). Cyclophosphates are weak BrØnsted 
bases due to the absence of terminal hydroxyl groups, however, they hydrolyse faster 
in strongly acidic and basic solutions (Kualev et al., 2004; Kura, 1987a). They are 
also very stable in neutral aqueous solutions (Kura, 1987a).  
 
 
Figure 5.3: Structure of cyclophosphates: a) tri-metaphosphate and b) tetra-
metaphosphate.  
 
 
5.1.4. Ultraphosphates 
Ultraphosphates contain branched phosphates i.e. phosphorous atom shares three 
oxygen atoms with the neighbouring phosphorous atom (Harold, 1966). The 
branching points on the chain are easily hydrolysed in aqueous solution irrespective 
of pH or temperature therefore ultraphosphate salts are difficult to detect in living 
organisms (Harold, 1966; Kualev et al., 2004).  
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5.2. STABILITY OF CONDENSED PHOSPHATES 
5.2.1. Hydrolytic degradation of condensed phosphates  
Linear polyphosphates and cyclophosphates hydrolyse very slowly at neutral pH and 
room temperature. The hydrolysis of these condensed phosphate salts is increased in 
the presence of complex ion, by reducing pH and increasing temperature (Greenfield 
and Clift, 1975; Kura and Tsukuda, 1993). The hydrolysis of linear polyphosphates 
occurs faster in acidic solution through the nucleophilic attack of water on the 
phosphorous atoms in the P-O-P bonds (Kura, 1991). This is initiated by the reaction 
of the linear polyphosphates a strong BrØnsted base with hydrogen ion (H+) in the 
acidic solution (Kura, 1991).  
 
The degradation of cyclophosphates occurs in two stages: (i) it is converted into 
linear polyphosphate of the same chain length in strong alkali solution and (ii) the 
linear polyphosphate is degraded in acidic solution in a manner similar to that 
described above (Kura, 1987b). Pyrophosphates breakdown into PO4
3- ions which are 
the end product of hydrolytic degradation of all condensed phosphates (Kura et al., 
1998), polyphosphates do not degrade directly and completely into only phosphate 
ions (Greenfield and Clift, 1975). For example the degradation of tetrapolyphosphate 
into orthophosphate ions occurs in three stages as shown below: 
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5.2.2. Enzymatic degradation of condensed phosphates 
Karl-Kroupa (1950) found that polyphosphates are degraded in the presence of 
various living organisms (Karlkroupa et al., 1957). Polyphosphatase enzymes 
degrade polyphosphates by cleaving orthophosphate ion from the end of the chain 
(exopolyphosphatase) or by breaking the chain in the middle to produce two shorter 
polyphosphate chains (endopolyphosphatase) (Omelon and Grynpas, 2008). The 
phosphorlaytion of glucose is catalysed by the polyphosphate glucose 
phosphotransferase enzyme which uses adenosine triphosphate (ATP) or 
polyphosphate as its source of orthophosphate (Omelon and Grynpas, 2008; Harold, 
1966). ALP can hydrolyse both pyrophosphate and polyphosphate  to produce 
orthophosphate thereby contributing to the overall pool of orthophosphate ion which 
is then used in bone mineralisation (Omelon et al., 2009; Hessle et al., 2002). 
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5.2.3. Degradation of CPPD by polyphosphates 
Polyphosphate materials with at least three PO3 units were found to be effective in 
dissolving CPPD crystals (Cini et al., 2001). There was no significant effect on 
CPPD dissolution when the PO3 units were increased further (Cini et al., 2001). 
These crystals were removed from female patients suffering from degenerative 
meniscal lesions. Linear polyphosphates (sodium tripolyphosphate; 
Na5O(PO3)3.6H2O) are found to be more effective in increasing CPPD crystal 
dissolution than cyclic trisodium metaphosphate (Na3(PO3)3) (Cini et al., 2001). It is 
thought that the higher negative charge and complexing ability of linear 
Na5O(PO3)3.6H2O enables it to remove and bind effectively and more tightly to 
calcium ion on the crystal surface than cyclic  Na3(PO3)3 (Cini et al., 2001).  
 
5.3. APPLICATION OF CONDENSED PHOSPHATES 
5.3.1. Enhanced biological phosphorous removal; EBPR 
Polyphosphate accumulating organisms are used in wastewater treatment (Kualev et 
al., 2004). Wastewater contains orthophosphate ions from the run off of fertilizers, 
detergents and other industrial discharges (Kualev et al., 2004). The presence of 
PO4
3- ions in wastewater encourages the growth of destructive blue algae blooms in 
natural waters (Kualev et al., 2004). These microorganisms consume large amount of 
phosphates than that needed for their growth by storing and accumulating it within 
their cells as polyphosphates (Kualev et al., 2004; Seviour et al., 2003).  
 
  
48 
 
5.3.2. Food and agriculture  
Calcium ammonium pyrophosphate and ammonium polyphosphates are some of the 
condensed phosphates widely used in fertilizers (Kualev et al., 2004; Brown et al., 
1963). Polyphosphates are added to food to maintain its pH at optimal level 
prolonging the lifetime of the food as well as preventing changes in colour and fat 
decomposition during storage (Kualev et al., 2004).  
      
5.3.3. Biological applications  
Polyphosphates have been identified as a phosphate storage in many microorganisms 
such as Saccharomyces cerevisiae (Urech et al., 1978) and it was proposed that the 
microorganisms obtain orthophosphates from the polyphosphates during periods of 
starvation (Harold, 1966). It has also been proposed that the storage of phosphates as 
polyphosphate is favoured due to the efficiency of the system and it produces little 
effect on the osmotic pressure (Harold, 1966). As explained previously 
pyrophosphates and polyphosphates perform an important role in bone mineralisation 
as they are known inhibitors to the growth of apatite crystals (Johnson et al., 2000; 
Omelon et al., 2009). Excess orthophosphate is also polymerised to form 
polyphosphates (Omelon et al., 2009). 
 
5.3.4. Orthopaedic biomaterials 
Calcium pyrophosphate ceramics are non-toxic and osteoconductive (Kitsugi et al., 
1993; Lin et al., 1995b). It also forms very good bond with bone (Kitsugi et al., 
1993). Calcium pyrophosphate is also thought to be an intermediate product in bone 
mineralisation. Its calcium to phosphorus ratio (Ca/P = 1.0) is lower than that of 
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tricalcium phosphate (Ca/P = 1.5) and therefore more soluble (Lin et al., 1995a). 
These properties have made it favourable to be evaluated as a possible bone 
replacement material. Some calcium pyrophosphate and calcium polyphosphate 
ceramic materials have been discussed below.  
5.3.4.1. Sintered calcium pyrophosphate  
Kitsugi et al. produced and implanted bulk dicalcium pyrophosphate ceramic into 
mature male rabbits and found the ceramic to be non-toxic and osteoconductive 
(Kitsugi et al., 1993). It was reported that no fibrous tissue layer was formed at the 
bone and ceramic interface (Kitsugi et al., 1993). The mechanical strength of sintered 
Ca2P2O7 ceramic was found to improve when a liquid additive, sodium 
pyrophosphate (Na4P2O7.10H2O) up to 5 wt% was added (Lin et al., 1995b). The 
porous β-Ca2P2O7 with 5 wt% Na4P2O7.10H2O ceramic was implanted into New 
Zealand white rabbits where it was found to form a strong bond with the bone tissue 
without the formation of a fibrous tissue layer (Lin et al., 1995b). The bone tissue 
grew into the macropores of the ceramic and gradually dissolved over time to be 
replaced by a bony structure (Lin et al., 1995a). Sintered calcium pyrophosphate 
particles were also found to have no inhibitory effect on the growth of osteoblast 
cells (Sun et al., 1997). Sun et al. evaluated the use of Ca2P2O7 as a possible 
treatment for osteoporosis (Sun et al., 2002). Postmenopausal osteoporosis is a 
disorder which affects elderly women and is characterised by increase bone 
resorption relative to bone formation. This occurs generally with an increase bone 
turnover. In ovariectomized rats the increased bone turnover and increased bone 
porosity was treated with sintered dicalcium pyrophosphate (Ca2P2O7) (Sun et al., 
2002). The increase in bone mineral content in long bones was higher in rats which 
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ingested Ca2P2O7 than those which ingested alendronate (Sun et al., 2002). The 
porosity of the trabecular bone was decreased when Ca2P2O7 was ingested (Sun et al., 
2002).  
5.3.4.2. Pyrophosphate glass ceramic 
Phosphate based glass ceramics are easily machinable using conventional tools 
(Kasuga, 2007). It is possible to incorporate a wide range of compositions in glass 
ceramics which in conjunction with heat treatment makes it easy to control chemical 
and physical properties of glass ceramics (Kasuga, 2007). Phosphate based glass 
ceramics are degradable and non-toxic (Ahmed et al., 2004). Osteoblasts and 
fibroblasts cells were successfully seeded onto phosphate based glass ceramics with 
no adverse cell reactions (Bitar et al., 2004). Calcium pyrophosphate glass ceramics 
consisting of β-Ca3(PO4)2 and β-Ca2P2O7 crystals was made by sintering a powder 
consisting of 60 mol% CaO, 30 mol% P2O5, 7 mol% Na2O and 3 mol% TiO2 at 
850°C (Kasuga and Abe, 1998). This glass ceramic was found to be bioactive due to 
the formation of a calcium phosphate phase on the surface of the ceramic when 
soaked in simulated body fluid (Kasuga et al., 1999). Dias et al. developed two glass 
ceramics; MK5B consisting of KCa(PO3)3, β-Ca(PO3)2, β-Ca2P2O7 and Ca4P6O19 and 
MT13B consisting of CaTi4(PO4)6, TiP2O7, α- and β-Ca2P2O7 phases (Dias et al., 
2006).  When implanted into the tibiae of Japanese white rabbits both glass ceramics 
were found to be osteoconductive and allowed the formation of new bone tissue 
(Dias et al., 2006). The MK5B ceramic was found to have been almost completely 
surrounded by bone whereas some spaces where found surrounding the MT13B glass 
ceramic (Dias et al., 2006). 
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5.3.4.3. Calcium polyphosphate ceramic  
Calcium polyphosphate biomaterials have been synthesised for use in tissue 
engineering (Nelson et al., 1993) and in cartilaginous tissue repair (Waldman et al., 
2002). Lagow et al. used a calcium polyphosphate material to repair mandibular bone 
defects in vivo (Lagow et al., 1991).  Pilliar et al. have manufactured a highly porous 
calcium polyphosphate ceramic through the process of sintering (Pilliar et al., 2001). 
This was then implanted in New Zealand white rabbits where it was shown to 
encourage bone growth (Grynpas et al., 2002). Calcium polyphosphate biomaterials 
can also be manufactured by the solid freeform fabrication process (Porter et al., 
2001). This process would then be used to design a „tailor made‟ bone replacement. 
Calcium polyphosphate fibres have been synthesised (Griffith, 1982) with 
application in the repair of tendon tissue (Sun and Zhao, 2002).   
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6. MATERIAL CHARACTERISATION 
This thesis investigates the possibility of forming Ca2P2O7 ceramic which is to be 
used as a bioresponsive bone replacement material.  It is therefore important to 
thoroughly characterise the ceramic material with regards to the sintering process, 
porosity and mechanical strength. To further develop the ceramic material for 
clinical application it is important to study the in vitro degradation of the Ca2P2O7 
ceramic. Other characterisation techniques used in this thesis involved the 
characterisation of precipitated crystals and colorimetric testing procedures. This 
chapter briefly outlines the characterisation techniques carried out in this thesis.  
 
6.1. COMPOSITION CHARACTERISATION 
6.1.1. X-ray diffraction (XRD) 
X-ray diffraction enables the determination of the crystal structure of unknown 
materials. XRD is also used to measure the spacings between the layers of atoms and 
the structural properties e.g. preferred orientation, phase composition and grain size 
of the crystals. X-rays are electromagnetic radiation generated from two metal 
electrodes enclosed in a vacuum chamber. The electrons are produced by heating a 
tungsten filament cathode. The highly negative potential cathode produces high 
accelerating electron which hit the water cooled anode (usually at ground potential) 
to produce X-rays (loss of energy upon impact). In 1912 Laue found that crystals 
diffracted X-rays (Figure 6.1) (Bragg, 1975). Bragg‟s law (equation 6.1) is an 
alternative way of expressing Laue‟s equation which fulfils the three conditions 
which need to occur before the X-rays are diffracted by crystals.   
           ... (6.1) 
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Where d is the distance between atomic layers in a crystal, θ (theta) is the angle of 
incidence, λ (lambda) is the wavelength of the incident X-ray beam and n is an 
integer.  
 
Figure 6.1: Schematic diagram showing the diffraction of X-rays by the crystal 
lattice. 
  
6.1.2. Rietveld refinement phase analysis 
Rietveld refinement phase analysis can be used to determine the composition of a 
multiphase ceramic. The Rietveld refinement phase analysis compares a calculated 
pattern to the measured diffraction pattern ensuring it fits as best as possible. The 
difference between the measured and calculated pattern is minimized by using the 
least-square method to adjust structural parameters such as unit cell dimensions, 
atomic coordinates and scale factors, displacement parameters, lattice parameters and 
parameters associated with the instrument or experiment. The X-ray diffraction peaks 
are assumed to be Gaussian in shape and the calculated intensity at each point (e.g. 
0.2° at 2θ) is a sum of the constituent Gaussian peaks representing that individual 
reflections. The profile refinement using the least square method is minimised by the 
function M, where wi is the weighting factor, c is an overall scale factor, y i (obs) is 
the observed profile and yi (calc) is the calculated profile.  
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... (6.2) 
The goodness of fit is measured by x2 comparing the agreement of the weighted 
pattern (Rwp) to the agreement of the expected pattern (Rexp). 
     
   
    
 
  ... (6.3) 
     
                      
 
  
              
 
 
 
 ... (6.4) 
      
     
   
 
            
 
 
 
 
... (6.5) 
N is the number of observations and P is the number of parameters. 
 
6.1.3. Fourier transform infrared spectroscopy (FTIR) 
FTIR is used to identify unknown chemicals by identifying the chemical bonds 
present within the material. Infrared radiation is absorbed by the material causing the 
chemical bonds present to vibrate (Smith, 1996). The functional groups present 
absorb the infrared radiation at the same wavenumber range irrespective of the rest of 
the molecule in which it was present (Smith, 1996). Therefore based on the 
functional group present the structure of the unknown molecule could be identified. 
It is also possible to derive quantitative information such as the concentration of the 
molecule from the FTIR spectrum. The relationship between absorbance and 
concentration is given by Beer‟s law (equation 6.6). 
       ... 6.6 
Where: A – Absorbance, ε – Absorptive, l – Pathlength and c – Concentration.   
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Infrared spectroscopy is the study of the interaction of infrared light with matter 
(Smith, 1996). The interferometer takes a beam of light, splits it into two and makes 
one of the light beam travel a different distance than the other.  The difference in the 
distance travelled by the two light beams is referred to as the optical path difference. 
The Michelson was the first interferometer to be used in FTIR instruments and is still 
in use in commercially available machines. A Michelson interferometer (Figure 6.2) 
consists of a source for infrared light, a stationary mirror and a moving mirror. The 
Beamsplitter which is present between the stationary and moving mirror and it is 
designed to transmit half of the radiation that falls to the movable mirror and reflect 
the other half onto the fixed mirror.  The lights then recombine at the beamsplitter 
before leaving to interact with the sample and the detector.  The variations in the 
light intensity as it move from the detector to the source as a function of the optical 
path difference generates the spectrum which is obtained from the FTIR machine 
(Smith, 1996; Griffiths and de Haseth, 2007).  
 
Figure 6.2: An optical diagram of a Michelson interferometer (adapted from Smith, 
B.C (Smith, 1996)). 
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6.1.4. Differential scanning calorimetry (DSC) 
DSC is a technique for measuring the energy necessary to obtain a near zero 
temperature difference between a sample and the reference material, when both 
materials are subjected to identical temperature regimes. The materials are heated 
and cooled at a constant rate. DSC is used in a wide variety of applications including: 
characterisation of materials, investigating stability of materials, evaluation of phase 
diagrams, relative comparison measurements, determining the purity and safety of 
material. There are two types of DSC‟s: 
Heat-flux DSC 
In heat-flux DSC the exchange of heat (temperature difference) between the sample 
and the reference material is measured via a thermal resistance. Both samples are 
placed in the same furnace. The heat capacity changes in the sample causes a 
temperature difference between the reference material and the sample.   
Power-compensation DSC 
In the power-compensation DSC the temperature of the material and reference 
material are controlled independently by using identical but separate furnaces. To 
maintain both materials at the same temperatures the power input into both furnaces 
was varied. The energy required to maintain similar temperatures is a measure of the 
capacity changes in the sample relative to the reference material.  
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6.2. PARTICLE SIZE MEASUREMENT  
6.2.1. Scanning electron microscopy (SEM) 
The sintering of calcium pyrophosphate ceramic results in the changes to the 
topography and composition of the material. The surface morphology of calcium 
pyrophosphate dihydrate crystals could also be changed by the presence of 
dissolution products therefore it is essential to observe the effect of these processes 
using a scanning electron microscope. The electron column consists of an electron 
gun and two or more magnetic lenses as shown in figure 6.3.  The electron gun 
generates electrons which accelerate to energy in the range of 1 – 40 keV.  The 
condensed (projective and objective) lenses reduce the diameter of the electron beam 
to about 5-100 nm (Sarkar et al., 2001) making it small and focused on the specimen. 
The electrons then interact with the atoms at or near the surface of the material 
resulting in the release of signals which are formed as images. Secondary electrons, 
backscattered electrons, Auger electrons, X-rays and transmitted electrons are some 
of the signals which can be produced from an SEM and collected if the appropriate 
detector. The deflection system is used to control the magnification of the image. It 
operates by generating a raster which is controlled by the scanning coils on both the 
specimen and the screen (Goldstein et al., 1992). The two pairs of scanning coils are 
used to control the raster of the beam. The magnification of the sample image is the 
ratio of the linear size of the cathode ray tube (CRT) to the linear size of the raster on 
the sample. Therefore the magnification can be increased by exciting the scanning 
coils less strongly thereby deflecting the beam a smaller distance onto the specimen.  
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Figure 6.3: A diagrammatic representation for the setting of a scanning electron 
microscope.   
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6.3. SPECIFIC SURFACE AREA (SSA) MEASUREMENT  
Along with other properties the chemical and physiochemical reactivity of a 
biomaterial could be controlled by the size and quality of the surface of the solid 
biomaterial (Skalny and Hearn, 2001).  The degree of control can be linked to the 
SSA which is defined as the surface area per unit mass and expressed in centimetre 
squared per gram (cm2/g) or metre squared per kilogram (m2/kg). The SSA of a 
biomaterial depends on the shape and size of the particle and also the size and shape 
of flaws present at the surface of the material (Skalny and Hearn, 2001). Sintering 
process leads to the presence/absence of flaws and changes to the particle size and 
shape of the ceramics. Therefore SSA measurement enables the effect of changes in 
temperature to be monitored on the change in particle size which can also be related 
to the porosity (pore fraction). The SSA is determined by applying Brunauer-
Emmett-Teller (BET) equation to sorption isotherm data. Sorption is the interaction 
between a gas (adsorbate) which can be nitrogen or octane gas and the solid ceramic 
surface.  The adsorption experiment works on the assumption that gas molecules are 
strongly attracted to the surface of the ceramic and that the adsorbate is small enough 
to reach all the pores on the ceramic surface. By increasing the pressure of the gas 
the amount of gas adsorbed to the ceramic surface can be increased and another layer 
of gas can be formed onto the initial one.  
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The BET equation is given below: 
  
      
              
 
  
 
 ... (6.7) 
Where: V – is the volume of gas adsorbed (cm3), Vm is the monolayer capacity (cm
3), 
c is a constant related to the average heat of adsorption of the monolayer, P is the 
vapour pressure (kPa) and Po is the saturation vapour pressure (kPa). 
 
6.4. MECHANICAL STRENGTH 
Compressive strength 
It is important to understand the mechanical behaviour of a newly fabricated 
biomaterial when placed under stresses that it may experience in vivo. The 
biomaterial which is developed as a bone replacement should be able to withstand 
such stresses as failure would lead to trauma and implant site morbidity. The 
mechanical failure of such a material would culminate in the patient undergoing 
further surgical procedure to retrieve and replace the biomaterial.  The material 
studied in this thesis was produced by sintering; this process introduces microscopic 
defect into the ceramic. Unlike tensile fracture which occurs as the result of a single 
severe flaw, compression failure occurs when the accumulation of numerous flaws 
within the ceramic results in structural collapse. Therefore the sintered ceramic 
studied in this thesis was subjected to compressive testing. The cylindrical sintered 
ceramic with an aspect ratio of 2 was loaded perpendicularly along its long axis until 
the ceramic fails. The compression test consists of two load blocks exerting a 
compressive force on the cylindrical ceramic material (Figure 6.4). The compressive 
stress of the sintered ceramic (σc) can be calculated in accordance with equation 6.8: 
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Where F is the load at failure (N) and d is the diameter of the ceramic sample (mm). 
 
Figure 6.4: The stresses and causes of failure in a cylindrical ceramic loaded along its 
long axis.   
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6.5. POROSITY  
The porosity of the sintered ceramic was determined by using either a helium 
pycnometer or an Archimedes balance. Using an Archimedes balance the specific 
gravity of the sintered ceramic was calculated from the weight of the ceramic 
measured in air and in water according to equation 6.9.  
                   
             
                             
... (6.9)  
The true density of the ceramic was calculated by multiplying the specific gravity by 
1000 Kg/m3 (density of water at 25°C).  Relative density was calculated by dividing 
the apparent density by the true density (equation 6.10a) and the apparent density 
was calculated by dividing the mass of the ceramic by its volume (equation 6.10b).  
                  
                
            
         
                                        
The porosity of the ceramic was then calculated by subtracting the relative density 
from 1.  
                                             
 
Helium pycnometry is used to obtain an accurate measurement of the volume of the 
ceramic which in turn gives the true density of the material. The helium atom is 
small and able to penetrate very small pores within the ceramic to the limit of 0.1 nm 
(Asthana et al., 2006; Ayral et al., 1992; Petropoulos et al., 1983). Helium 
pycnometer measures the total porosity by calculating the volume of the sample from 
the changes in pressure between the two chambers in the machine when the porous 
sample is introduced into one of the chambers (Figure 6.5). The chamber with 
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volume VI is filled with helium at a pressure P1, the gas is then allowed to flow into 
the second chamber (when there is no sample present) (Figure 6.5).   
The pressure in the whole system is P1
* and the cell volume is given by VC (equation 
6.12).  
       
  
  
      ... 6.12 
When the sample is present in the chamber the volume of the sample (VS) is given by 
equation 6.13:  
         
  
  
       ... 6.13 
Where P2 and P2
* is the pressure in the chamber and the whole system when the 
sample is present.  
 
Figure 6.5: Schematic diagram of apparatus which allows helium density 
measurements (redrawn from (Ayral et al., 1992)). 
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7. ALP MEDIATED DEGRADATION OF CALCIUM 
PYROPHOSPHATE DIHYDRATE CRYSTALS 
Alkaline phosphatase (ALP) is an enzyme associated with bone mineralisation 
(Hessle et al., 2002; Johnson et al., 2000). It acts by removing the P2O7
4- ion, an 
inhibitor to bone mineralisation (Anderson et al., 2004). ALP hydrolyses P2O7
4- ion 
to produce the PO4
3- ion which is then added to the pool of PO4
3- ion resulting in 
localised supersaturation with respect to apatite and therefore precipitation of bone 
mineral. The ability of ALP to break down P2O7
4- ion has been exploited by Xu et al. 
(Xu et al., 1991b) in removing CPPD crystals which are deposited in the joints of 
patients suffering from calcium pyrophosphate deposition disease (Mccarty et al., 
1962; Pritzker, 1980; Song et al., 2002). Xu et al. found that CPPD degraded faster in 
the presence of yeast inorganic pyrophosphatase and ALP (Xu et al., 1991a; Xu et 
al., 1991b). This chapter describes the precipitation of phase pure CPPD and brushite 
crystals as well as investigating the mechanism by which crystal dissolution occurs 
in the presence of ALP, this has previously been reported to be enzyme attachment 
mediated (Shinozaki et al., 1995).  The dissolution of CPPD and brushite crystals in 
control Tris HCl solution was also investigated as well as the changes to the surface 
morphology of both crystals once exposed to the ALP and control solutions. The 
effect of saturation on the rate of crystal dissolution and the adhesion of ALP onto 
the crystal surface was also investigated.  
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7.1. MATERIALS AND METHODS 
7.1.1. Precipitation of CPPD, brushite and OCP crystals   
7.1.1.1. CPPD 
CPPD crystals were precipitated according to the method of Shinozaki et al. 
(Shinozaki et al., 1995) from a mixture of 500 mL calcium chloride (CaCl2) and 
1300 mL sodium pyrophosphate (Na4P2O7) solution at 37°C and pH 5.5 for 21 days. 
The 40 mM Na4P2O7 solution (Sigma Aldrich, Dorset, UK) and 3.6 mM CaCl2 
solution (Sigma Aldrich, Dorset, UK) at pH of 5.5 were mixed and the pH of the 
resulting solution was adjusted to pH 5.5 using either hydrochloric acid (HCl) 
(Fluka, Dorset, UK) or sodium hydroxide (NaOH) (Fluka, Dorset, UK). The solution, 
which was in a 2 L beaker, was placed in the 37°C incubator and its pH was adjusted 
daily using HCl and/or NaOH. After 21 days the crystals were filtered using a 
Buchner funnel. The crystals were then washed using double distilled water to 
remove excess NaCl and NaOH before drying overnight at room temperature.  
7.1.1.2. Brushite 
Brushite crystals were precipitated by the method outlined below. Calcium chloride 
dihydrate solution (CaCl2.2H2O) (Sigma Aldrich, Dorset, UK) 0.50 M and 500 mL 
was poured into a burette; 500 mL solutions of 0.50 M sodium acid phosphate 
(Na2HPO4) (Sigma Aldrich, Dorset, UK) and 0.04 M potassium dihydrogen 
phosphate (KH2PO4) (Sigma Aldrich, Dorset, UK) was poured into another burette. 
The 0.15 M 250 mL solution of KH2PO4 which was placed in the 2.5 L beaker was 
continuously stirred using a magnetic stirrer. The solutions from both burettes were 
allowed to flow into the beaker in a drop wise manner over the period of 2.5 – 3 h at 
25˚C (room temperature). The solution was continuously stirred and the pH was 
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maintained between 4 and 5 by adjusting the flow of either of the reactants from the 
burettes.  
7.1.1.3. OCP  
OCP crystals were precipitated at a temperature of 60°C in a 250 mL jacketed vessel.  
20 mM 100 mL Na2HPO4 was placed into the jacketed vessel and allowed to attain 
the set temperature. The pH was also adjusted to 5 using HCl.  To this solution 20 
mM 100 mL calcium acetate Ca(CH3COO)2 (Sigma Aldrich, Dorset, UK) was added 
in a drop wise manner from the burette. The solution in the jacketed vessel was 
constantly stirred throughout the experiment. After 3 – 4 h the solution was filtered 
and the crystals were washed with distilled water before drying at room temperature.  
 
7.1.2. Characterisation of brushite and CPPD crystals using XRD,  
FTIR and SEM  
The chemical composition of all the precipitated crystals were determined using an 
X-ray diffractometer (D5000 Brucker, Siemens, Germany) with CuKα1 radiation (λ 
= 1.5406 Å). The precipitated crystals were scanned over a 2θ range of 3 - 50° at 
25°C using a step size of 0.020° and a step time of 0.3 s. Further chemical analysis 
was conducted by using FTIR (NICOLET 380, Thermo Scientific). The absorption 
mode scanning was from 400 to 4000 cm-1. The shape of the precipitated brushite 
and CPPD crystals were observed under the light microscope (OLYMPUS BX50, 
Japan).The surface morphology of the crystals which were precipitated and used in 
the experiments was observed using the SEM (Philips XL 30).  
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7.1.3. Measuring dissolution in the presence and absence of ALP 
The interaction between CPPD crystals and ALP enzyme (calf intestinal mucosa; 
Fluka, Dorset) was investigated by incubating 10 mg of the crystals with 10 U ALP 
in 5 mL Tris HCL solution. The Tris HCl solution used in these experiments had a 
concentration of 100 mM and pH 7.4, it contained 1 mM MgCl2 and 0.01% sodium 
azide (NaN3, Sigma Aldrich, Dorset). The solutions were placed on a rack and into a 
37C rotating incubator (Mk X Incubator Shaker, LH Engineering, UK) at 150 rpm. 
The amount of PO4
3- ion released into solution was determined by modifying the 
method of Chen et al. and Xu et al. (Xu et al., 1991b; Chen et al., 1956). For the first 
hour at intervals of 15 min and 30 min subsequently, the mixture was removed from 
the incubator and centrifuged separating the crystals from the medium before 300 μL 
aliquot was removed. To the aliquot, 3.7 mL of distilled water was added to make the 
solution up to 4 mL. 1600 µL of distilled water, 800 µL 3 M sulphuric acid (H2SO4) 
(Fisher Scientific, Loughborough UK), 800 µL of ammonium molybdate 
((NH4)6Mo7O24.4H2O) (Riedel – de Haen, Germany) and 800 µL ascorbic acid 
(C6H8O6, Sigma Aldrich, Dorset UK) was added and the resulting solution was 
thoroughly mixed before placing into a 37C incubator for 1.5 h. The mixture was 
allowed to cool to room temperature and the absorbance was measured at 620 nm in 
Uvikon 922 spectrophotometer (Kontron Instruments). A control experiment was 
carried out by following the same procedure as above without the ALP enzyme. The 
interaction of brushite crystals with ALP was also investigated. A standard 
calibration curve was plotted using a phosphate standard (KH2PO4) with known 
orthophosphate ion concentration (Figure 7.1). Using this calibration curve unknown 
orthophosphate ion concentrations were determined.  
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Figure 7.1: Calibration curve for orthophosphate ion determination.  
7.1.3.1. Effect of saturation on the dissolution of CPPD crystals  
As CPPD crystals dissolve in solution the ageing medium becomes saturated with 
respect to either PO4
3- or P2O7
4- ion. This could reduce the amount of crystals which 
are then dissolved in solution.  To overcome this problem the same experiment 
described in section 7.1.3 was carried out but 4 mL aliquot was removed instead of 
300 μL. The 4 mL aliquot removed was replaced with fresh ageing media of the 
same volume.  
 
7.1.4. Protein attachment on CPPD crystals  
7.1.4.1. Crystals surface staining  
The method Shinozaki et al. (Shinozaki et al., 1995) used to determine enzyme 
attachment was employed in this research to understand the adhesion behaviour of 
ALP to CPPD and brushite crystals surface. 2.5 mg of CPPD crystals were placed 
into a 2 mL eppendorf with 75 U of ALP before adding 750 µL of the Tris HCl 
69 
 
buffer (without sodium azide). The solution was then placed in a shaker at 1000 rpm 
for 60 min at room temperature after which the crystals were washed several times 
with 750 µL of the Tris HCl solution. The crystals were then placed in another 
eppendorf and the staining solution of 0.025% naphthol AS-MX phosphate (Sigma 
Aldrich, Dorset) at pH 7.4 containing 1 mg/ml of fast red TR salt (5-chloro-2-
toluenediazonium chloride hemi [zinc chloride]) (Sigma Aldrich, Dorset) was added. 
The mixture stood at room temperature for 1 h before the crystals were washed with 
double distilled water to remove non-specific products. To determine enzyme 
attachment the washed crystals were then observed using the light microscope 
(OLYMPUS BX50, Japan). The control experiment was carried out by following a 
similar procedure as above in the absence of ALP. The attachment of ALP to the 
surface of the crystal is expected to decrease if the experiment is carried out at higher 
temperatures (this was not measured here).   
7.1.4.2. Bichinchoninic Assay (BCA) 
To quantify ALP attachment to CPPD crystal surface in solution, the BCA protein 
assay procedure was used. 10 mg of CPPD crystals were incubated with 10 U of 
ALP (calf intestinal mucosa, Fluka) in 1.5 mL Tris HCl solution (without sodium 
azide). The mixture was placed in an eppendorf that was shaken at room temperature 
on a shaker operating at 1250 rpm. At intervals of 30 s for the first 5 min and every 
five minutes afterwards 100 µL of aliquot was taken from the mixture; to this 2 mL 
of the BCA working reagent was added. The mixture was gently shaken before it was 
placed in the 37ºC incubator for 30 min. The absorbance of the solution was 
measured using the Uvikon 922 spectrophotometer at 562 nm. The interaction of 
brushite crystals with ALP was studied using the same procedure as above.  To 
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determine the concentration of enzyme (from which the amount on the crystal can be 
determined) in solution a calibration curve was drawn based on known concentration 
of bovine serum albumin (BSA) as shown in figure 7.2. 
 
Figure 7.2: Calibration curve of BCA using known concentrations of bovine serum 
albumin (BSA) at ambient conditions. The calibration curve was obtained from three 
separate calibration experiments.  
 
7.1.5. Dissolution of CPPD crystals in visking tubing 
To fully understand the mechanism of CPPD crystal dissolution in ALP solution, the 
crystals were placed in a SnakeSkin® pleated dialysis tubing (visking tube) (Thermo 
Scientific, Rockford, USA) with a molecular weight cut of (MWCO) of 3500. This 
was used to separate the ALP enzyme in solution from the crystals. The enzyme is 
not expected to pass through the visking tube as it has a very high molecular weight 
of 160 kDa. 10 mg of CPPD crystals were placed in the visking tube this was then 
placed in a Tris HCl solution containing ALP; the control experiment had no ALP 
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present. Every 30 min aliquots were removed from the solution to test for the 
presence of PO4
3- ion using a CECIL CE7500 spectrophotometer as described in 
section 7.1.3.  
 
7.1.6. Protein interaction with pyrophosphate ion 
ALP activity in solution was measured by studying the rate of P2O7
4- ion  breakdown 
in ALP containing solution using the method of Xu et al. and Woltgens et al. 
(Woltgens and Ahsmann, 1970; Xu et al., 1991b). Na4P2O7 was dissolved in 100 mM 
Tris HCl solution. This solution was then diluted using the Tris HCl buffer into 
concentrations of 0.04, 0.05, 0.06, 0.07 and 0.08 mM. To carry out the experiment 
ten samples at the same concentration each 1 mL in volume was used. To each 
volume placed in a 5 mL Bijou bottle 1 mL 2 U ALP (Bovine intestinal mucosa, 
Sigma Aldrich, Dorset) was added and then mixed for 10 seconds using a test tube 
shaker. The first of the ten samples stood at room temperature for 1 min, the second 
sample for 2 min and so on until the tenth sample stood at room temperature for 10 
min. After the experimental time has elapsed the reaction was stopped by adding 2 
mL of solution A (10% TCA and 5 mM CuSO4) and 3 mL of solution B (5% FeSO4, 
1% (NH4)6Mo7O24.5H2O and 0.5 M H2SO4). The colour of the solution was allowed 
to develop for 5 min at room temperature before measuring the absorbance at 690 nm 
in Uvikon 922 spectrophotometer. Using a calibration curve it was therefore possible 
to plot a graph of PO4
3- concentration against time for each of the P2O7
4- ion 
solutions.  From these graphs the initial rates were determined from the gradient of 
the curve and documented in table 7.1.   
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7.2. RESULTS 
7.2.1. Characterisation of CPPD crystals 
Crystals were precipitated from the reaction mixture and over 21 days of ageing 
exhibited a blade-like morphology typical of CPPD (Figure 7.3a).  
 
 
Figure 7.3: a) Image of the precipitated triclinic CPPD crystals taken with the light 
microscopy and b) XRD pattern for calcium pyrophosphate dihydrate crystals 
precipitated at 37°C and pH 5.5 for 21 days. 
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The crystals precipitated at pH 5.5 and a temperature of 37°C were shown to be 
CPPD and were phase pure (Figure 7.3b). The peaks identified on figure 7.3b are 
indicative of triclinic CPPD as opposed to the monoclinic isoform. The precipitated 
CPPD crystals were shown to vary in length from 10 - 40 μm and width from 2 - 4 
μm (Figure 7.3a and 7.4a).  
 
 
Figure 7.4: a) SEM micrograph of CPPD crystals precipitated at pH 5.5 and 
temperature 37°C and b) the FTIR spectrum of the precipitated CPPD crystals. 
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An FTIR spectrum of CPPD on figure 7.4b shows peaks associated with 
phosphoanhydride (P-O-P) bonds at 748, 987 and 1122 cm-1. The peak at 1076 cm-1 
indicates the presence of hydroxyl bond (P-OH) which is associated with water of 
crystallisation and is present in CPPD. The presence of the phosphate and oxygen 
bond (P-O) is identified at 527, 1025.8, 1180 cm-1 (Figure 7.4b). The uniform shape 
and size of the precipitated triclinic CPPD crystals can be clearly observed on the 
SEM micrograph in figure 7.4a.  
 
7.2.2. Characterisation of brushite crystals  
Crystals of plate like morphology, similar to that reported for brushite were 
precipitated from a solution of KH2PO4, Na2HPO4 and CaCl2 at room temperature as 
shown in figure 7.5a. The crystalline composition of the precipitate was confirmed 
using XRD, the peaks which are clearly marked is indicative of the monoclinic 
brushite crystal (Figure 7.5b).   
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Figure 7.5: a) Image of the precipitated brushite crystals taken with the light 
microscopy and b) XRD pattern for brushite crystals precipitated at room 
temperature and pH between 4 and 5. 
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The SEM micrograph shows that the precipitated monoclinic brushite crystals were 
plate like in shape (Figure 7.6a). Acid phosphate bonds (HPO4
2-) present in brushite 
crystals were clearly identified in figure 7.6b at 517, 575 and 866 cm-1. The FTIR 
spectrum also shows the peaks which indicate the presence of phosphate bonds (P-O) 
at 771, 982 and 1050 cm-1 and of water molecule at 1641 cm-1. 
 
 
Figure 7.6: a) SEM micrograph of precipitated brushite crystals at pH 4-5 and room 
temperature and b) FTIR spectrum for the precipitated brushite crystals.  
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7.2.3. Characterisation of OCP crystals  
Crystals of needle like morphology were precipitated from a reaction mixture of 
calcium acetate and sodium phosphate (Figure 7.7). The crystals were precipitated at 
pH 5 and temperature of 60°C.  
 
Figure 7.7: Light microscopy image of needle like precipitated OCP at 60°C. 
 
The characteristic primary (100) peak of OCP at 2θ° = 4.7 was clearly identified on 
XRD patterns collected from the sample (Figure 7.8a). The precipitated triclinic OCP 
was phase pure and all the peaks which identify it are clearly identified on figure 
7.8a. The peaks identified on the FTIR spectrum in figure 7.8b are indicative of that 
reported for OCP (Suzuki et al., 2006). Although it has been shown that it is possible 
to precipitate phase pure OCP crystals, there was no corresponding experiment 
carried out using the crystals in this thesis. Since brushite and CPPD crystals have 
similar Ca/P brushite crystals were used as the negative control in the dissolution 
experiments rather than OCP.   
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Figure 7.8: a) XRD pattern of precipitated triclinic OCP crystals and b) FTIR 
spectrum of OCP crystals precipitated at 60°C. 
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7.2.4. Dissolution of CPPD crystals 
The rate of CPPD crystal dissolution in the ageing medium was determined by 
measuring the concentration of PO4
3- ion in solution with time. Figure 7.9a shows 
that the concentration of PO4
3- ion detected in the ALP solution was greater than that 
in the control. After ageing CPPD crystals in ALP containing solution for 6 h the 
concentration of PO4
3- ion was four times greater than that in the control Tris HCl 
solution (Figure 7.9a). There was a gradual increase in PO4
3- ion concentration from 
15 min to 1 h, a slight reduction between 1 – 4 h and then an increase until the end of 
the experiment (Figure 7.9a). Once the aliquot was taken it was replaced with a fresh 
ageing solution of the same volume and this change was accounted for when 
calculating the concentration of PO4
3- ion released into solution. Using the molecular 
mass of CPPD crystals the concentration of PO4
3- ion detected at each time point was 
converted to the mass of CPPD crystals dissolved as shown in figure 7.9b. The shape 
of the graph on figure 7.9b is the same as that in figure 7.9a in that there was a 
gradual increase in the mass of CPPD crystals which dissolved from 15 min to 1 h 
before a period where there was little increase in the mass of crystals dissolving. 
After ageing for 6 h 6.9 wt% of CPPD was found to have dissolved in the presence 
of ALP, four times that which dissolved in the control solution (1.7 wt%) (Figure 
7.9b). The error bars on figure 7.9 were obtained by calculating the standard 
deviation of three PO4
3- ion concentration at each time point and three mass loss data 
at each time point.  
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Figure 7.9: a) Cumulative concentration of orthophosphate ions detected in solution 
from the dissolution of CPPD crystals at 37°C and pH 7.4 and b) percentage mass of 
CPPD crystals dissolved in ALP and control solution over 6 h at pH 7.4 and 
temperature 37°C. 
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7.2.5. Dissolution of brushite crystals 
The dissolution of brushite crystals in the presence and absence of ALP was carried 
out at pH 7.4 and 37°C. Figure 7.10 shows that ALP had no effect on the rate or 
amount of brushite dissolved in solution. The concentration of PO4
3- ion detected 
when brushite was aged in ALP solution was six times that detected when CPPD 
crystals of the same weight were aged in similar solution. This is due to the higher 
solubility of brushite crystals as compared to triclinic CPPD crystals. Over the 6 h 
experimental period there was little increase in the total concentration of PO4
3- ion 
detected in solution (Figure 7.10a). This could be due to the saturation of the solution 
with respect to PO4
3- ion which causes the reprecipitation of apatite in the sample. 
22.0 wt% of brushite crystals were dissolved in both the ALP and control solutions 
(Figure 7.10b).   
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Figure 7.10: Cumulative concentration of orthophosphate ion detected in solution 
from the dissolution of brushite crystals and b) percentage mass of brushite crystals 
dissolved in ALP and control solution over 6 h at pH 7.4 and temperature 37°C. 
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7.2.6. Effect of ageing on the chemical composition and surface 
morphology of CPPD and brushite crystals 
Figure 7.9 shows that there was very little increase in PO4
3- concentration after the 
initial burst of PO4
3- ion in solution. SEM was used to observe what was happening 
on the crystal surface during ageing. Figure 7.11a shows the surface morphology of 
typical triclinic CPPD crystals after precipitation. After the crystals were exposed to 
an ageing medium the surface morphology was found to change as shown in figures 
7.11b and 7.11c. Figure 7.11c shows signs of CPPD crystals dissolution as well as 
the presence of reprecipitated crystals on the surface which could have been apatite. 
These were not identified on the XRD pattern (Figure 7.12) and this could be 
attributed to the small size of the reprecipitated crystal and the low sensitivity of 
XRD which can detect masses of a minimum of 2 mg. The micrograph of the crystals 
aged in Tris HCl (control) solution (Figure 7.11b) also show the presence of 
reprecipitated crystals although it was of a smaller quantity to that observed on figure 
7.11c. There was no sign of cleaving on crystal surface when aged in either the 
control or ALP solution as has previously reported (Figure 7.11) (Shinozaki et al., 
1995). After the dissolution experiment the remaining crystals were dried and the 
chemical composition determined using XRD (Figure 7.12).  
 
84 
 
 
 
 
Figure 7.11: Surface morphology of a) precipitated CPPD crystals, b) CPPD crystals 
aged in Tris HCl solution and c) CPPD crystals aged in ALP containing Tris HCl 
solution. 
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Figure 7.12: Chemical composition of CPPD crystals after ageing in Tris HCl 
solution and ALP containing Tris HCl solution at 37°C.   
 
The peaks in figure 7.12 are clearly identified as that of CPPD crystals. There was 
little change in diffraction pattern suggesting no change in crystalline composition 
(Figure 7.12). Figure 7.13 shows the surface morphology of brushite crystals when 
precipitated and after ageing in Tris HCl and ALP containing solution. The 
micrographs in figure 7.13b and 7.13c show signs of crystal dissolution as well as the 
presence of smaller crystals. These smaller crystals are thought to be reprecipitated 
crystals although this could not verified by XRD.  There was no significant 
difference in the SEM micrographs of the brushite crystals incubated in the control 
solution (Figure 7.13b) and those incubated in the ALP solution (Figure 7.13c).  
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Figure 7.13: Surface morphology of a) precipitated brushite crystals, b) brushite 
crystals aged in Tris HCl solution and c) brushite crystals aged in ALP containing 
Tris HCl solution.  
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7.2.7. Effect of saturation on crystal dissolution 
The results shown previously suggest that the rate of crystal dissolution was severely 
affected by the saturation of the ageing solutions with PO4
3- ions. This problem was 
overcome by increasing the volume of the aliquot which was taken at each time point 
from 6% (300 μL) to 80% (4 mL). The concentration of PO4
3- ion released into 
solution was found to increase significantly in both CPPD and brushite experiment 
(Figure 7.14).  In the ALP solutions the concentration of PO4
3- ion released from 
both CPPD and brushite crystals when 80% of the aliquot was removed was four 
times greater than that detected when only 6% aliquot was removed (Figure 7.9a, 
7.10a and 7.14). Figure 7.14a shows that the concentration of PO4
3- ion released into 
ALP solution from CPPD crystals was greater than that detected in the control 
solution; this follows a similar trend to that observed in figure 7.9a when only 6% of 
the solution was removed as aliquot. Figure 7.14b shows a slight difference in the 
mass of brushite which degraded in ALP solution as compared to the control 
solution. The difference in mass in both solutions was of no statistical significance 
(i.e. P>0.05). Figure 7.15a shows that 24.8 wt% of CPPD was dissolved in the ALP 
solution an increase from 6.9 wt% when only 6% aliquot was removed. There was 
also an increase in the percentage of CPPD crystals which dissolved in the control 
solution from 1.7 wt% to 2.2 wt%. Refreshing 80% of the ageing solution also 
produced a marked increase in the mass of brushite which was dissolved in solution 
(Figure 7.15b). In the ALP solution the increase was from 22.0 wt% to 91.2 wt% of 
brushite crystals dissolved (Figure 7.15b).  The error bars i.e. standard deviation of 
the three concentration or mass data on figures 7.14 and 7.15 are very small therefore 
not visible.  
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Figure 7.14: Cumulative concentration of orthophosphate ion released when 80% of 
the solution was replaced at each time point from a) CPPD and b) brushite crystals.  
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Figure 7.15: Percentage mass of a) CPPD and b) brushite crystals dissolved in the 
ageing solutions when 80% of the solution was replaced at each time point.    
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7.2.8. ALP activity in pyrophosphate solution 
Mathematical evaluation of enzyme kinetics is used to understand the rate and 
mechanism of enzyme catalysed reactions. It helps to understand and determine the 
affinity with which the ALP binds to P2O7
4- ion in a single substrate reaction as well 
as the turnover rate of the enzyme. The activity of ALP on the P2O7
4- ion was 
investigated to understand the rate at which CPPD crystals would be dissolved when 
ALP enzyme is present. Michaelis-Menten is the equation which describes an 
enzyme catalysed reaction and is given by equation 7.1.  
        
   
      
        
Lineweaver – Burk equation (equation 7.2) is the linear form of the Michaelis-
Menten equation.  
 
 
  
  
    
  
 
   
  
 
    
       
Where V = rate of enzyme activity, Km = Michaelis-Menten constant, Vmax = 
maximum rate of the enzyme and [S] = substrate concentration in mM. Km relates to 
the affinity of the enzyme to the substrate and Vmax is the maximum rate it takes the 
enzyme to breakdown the substrate. The Vmax and Km values are determined from 
the initial rates; the initial rate in table 7.1 was calculated from the gradient of a 
graph of concentration with time. 
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Table 7.1: Initial rate values for ALP activity experiments carried out at varying 
concentrations and ambient conditions.  
Concentration of 
P2O7
4- ion (mM) 
1/[S] (mM-1) Initial rate 
(mM/min) 
1/rate (min/mM) 
0.04 25.0 0.0068 147.1 
0.05 20.0 0.0086 116.3 
0.06 16.7 0.0102 98.0 
0.07 14.3 0.0119 84.0 
0.08 12.5 0.0127 78.7 
 
Using the initial rate values a Lineweaver-Burk graph was plotted on figure 7.16. 
The Vmax was calculated from the intercept of the graph on the y-axis graph while 
the Km was calculated from the gradient of figure 7.16. Therefore Vmax = 161.2 
μM/min and Km = 898.9 μM. 
 
Figure 7.16: Lineweaver-Burk graph for ALP activity in pyrophosphate solution 
under ambient condition. 
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7.2.9. Enzyme mineral interaction  
Since it has been established that CPPD crystals dissolve faster in the presence of 
ALP the mechanisms by which this occurs was investigated. The BCA assay was 
used to observe the attachment of ALP to the surface of both brushite and CPPD 
crystals. CPPD and brushite crystals were aged in Tris HCl buffer containing known 
concentrations of ALP. The mass of ALP in the buffer solution was determined using 
the BCA assay. To determine the mass of ALP which adhered to the surface of the 
crystals at each time point, the mass of ALP in solution was subtracted from that in 
the original buffer solution (Figure 7.17). Figure 7.17 shows that there was a 
continuous process of adsorption and desorption of ALP enzyme on both CPPD and 
brushite crystals over the duration of the experiment, no particular relationship was 
evident between protein adsorption and dissolution. Since the pattern observed in 
figure 7.17 was not observed in figures 7.9 and 7.10 it can be understood that the 
adsorption of ALP onto the crystal surface is not solely responsible for crystal 
dissolution. Figure 7.17b also shows that a larger quantity of enzyme is adhered to 
the surface of brushite crystals as compared with CPPD crystals this could be due to 
the larger surface area of the brushite crystals. As the crystals dissolve the amount in 
solution decreases resulting in the decrease in the amount enzyme which adheres to 
the crystal (Figure 7.17b). The adhesion of ALP onto CPPD crystal was confirmed 
by staining as shown in figure 7.18. ALP was present on the crystal surface as well 
as the surrounding areas. In the control experiment (Figure 7.18a) there was no red 
stain as no ALP enzyme was present in solution.  
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Figure 7.17: a) mass of ALP adhered to CPPD and brushite crystal surface over 5 
min and b) mass of ALP enzyme adhered to the surface of CPPD and brushite 
crystals over 160 min. 
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Figure 7.18: a) CPPD surface staining in the absence of ALP and b) CPPD staining 
in the presence of ALP using naphthol phosphate. 
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7.2.10. CPPD dissolution mechanism 
The final experiment in understanding CPPD dissolution in the presence of ALP was 
to repeat the dissolution experiment but placing the crystals in a visking tube to 
separate it from the ALP enzyme. CPPD crystals were placed in a visking tube 
before placing in the ALP and control solutions. The MWCO of the visking tube was 
low (3500) so as to prevent the enzyme from passing through to interact directly with 
the crystals. The crystals are also too large to pass through the visking tube into the 
ageing solution. The control experiment was carried out in a similar manner without 
the ALP enzyme. Figure 7.19 show that the mass of CPPD crystal which degraded in 
the visking tube and ALP solution was greater than that when the ALP was not 
present. This follows the same trend observed in figure 7.9 when the crystals were 
exposed directly to the ALP enzyme.  
 
Figure 7.19: Dissolution of CPPD crystal in a visking tube ALP and control solution. 
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There was a gradual increase in the mass of CPPD crystals which dissolved in 
solution although between 1 - 4 h the solution appeared saturated with PO4
3- and 
P2O7
4- ion resulting in reprecipitation.  Figure 7.19 shows that CPPD crystals 
dissolve in solution (equation 7.3) to produce calcium and pyrophosphate ion. ALP 
enzyme then hydrolyses the pyrophosphate ion to produce orthophosphate ion. This 
shows that the accelerated dissolution was not solely mediated by surface attachment 
as has previously been reported Shinozaki et al. (Shinozaki et al., 1995). 
                
        
         
  
97 
 
7.3. DISCUSSION 
7.3.1. Crystal precipitation and dissolution in the presence and 
absence of ALP 
The rate of bone turnover is known to vary with the age and health of a patient, 
making it difficult to link the rate of implant degradation to the formation of new 
bone tissue (Fahrleitner-Pammer et al., 2005; Havill, 2004). A suitable biomaterial 
would be one that degrades at a rate proportional to the formation of new bone tissue. 
One way to achieve this is to link the degradation of a biomaterial to the presence of 
a suitable biological stimulus. In bone ALP is an enzyme present on osteoblast cells 
and it aids bone mineralisation by removing P2O7
4- ion an inhibitor to bone 
mineralisation (Anderson et al., 2004; Hessle et al., 2002). The ability of ALP to 
remove the P2O7
4- ion has been exploited by Xu et al. (Xu et al., 1991b) with the aim 
of removing CPPD crystals present in the joints of patients suffering from calcium 
pyrophosphate dihydrate disease. This chapter further investigates the possibility of 
enhancing CPPD dissolution in the presence of ALP as well as the mechanism by 
which the process occurs. Initial investigation involved the precipitation of phase 
pure CPPD, brushite and OCP crystals (Figures 7.3b, 7.5b and 7.8b). Triclinic CPPD 
crystals were precipitated using the method of Shinozaki et al. (Shinozaki et al., 
1995) according to equation 7.4. The crystals which were produced at pH 5.5 and 
temperature 37°C contained were phase pure and confirmed to be CPPD (Figure 
7.3b).  
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The peaks on the FTIR spectrum in figure 7.4a indicate the presence of 
pyrophosphate bonds, phosphate and phosphorous hydroxyl (P-OH) bonds which are 
present in CPPD crystals. Monoclinic brushite crystals were also successfully 
precipitated as verified using XRD (Figure 7.5b). The FTIR spectrum of brushite 
crystals shows the presence of PO4
3-, HPO4
2- and H2O (Figure 7.6b). The triclinic 
and monoclinic shape of CPPD and brushite crystals respectively can be clearly 
observed figures 7.4a and 7.6a. Phase pure triclinic OCP crystals were successfully 
precipitated as verified by the presence of the characteristic primary (100) peak of 
OCP at 2θ° = 4.7 (Figure 7.8a). OCP was not used as the negative control to CPPD 
as it is less stable than brushite and it converts easily to HA (Arellano-Jimenez et al., 
2009; Lu and Leng, 2005).  
 
The trend observed by Xu et al. (Xu et al., 1991b) was confirmed on figure 7.9 where 
the mass of CPPD dissolved in ALP solution was four times that which dissolved in 
the control solution (ALP absent). The percentage mass of CPPD crystals dissolved 
was derived from the concentration of PO4
3- ions released into solution at each time 
point as shown in figure 7.9b. ALP had no effect on the degradation of brushite 
crystals in solution due to the absence of pyrophosphate bonds (Figure 7.10). The 
percentage mass of brushite crystals (22.0 wt%) which dissolved in solution was 
higher than that of CPPD crystals (6.9 wt%) due to its lower solubility product 
(Table 7.2) i.e. brushite is more soluble than CPPD crystals. The dissolution of 
CPPD crystals in both ALP and control solution shows that after the initia l increase 
in PO4
3- ions there was a period between 1 - 4 h where very little increase in PO4
3- 
ions concentration was observed (Figure 7.9). Figure 7.10a shows that the dissolution 
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of brushite crystals resulted in very little increase in the concentration of PO4
3- ions 
over the 6 h experimental period (0.655 mM). The reduction in the concentration of 
PO4
3- ions over the experimental time is thought to be due to the reprecipitation of 
apatite crystals. The presence of reprecipitated crystals was confirmed on SEM 
micrographs in figures 7.11c and 7.13c. The amount of reprecipitated crystals 
observed on the surface of CPPD crystals was higher on crystals aged in ALP 
solution than on that aged in control solution (Figure 7.11). The small quantities of 
reprecipitated crystals and low sensitivity of XRD made it difficult for the chemical 
composition of the reprecipitated crystals to be determined on figure 7.12. Solubility 
products was used to determine the concentration of PO4
3- and P2O7
4- ion required in 
solution for apatite and CPPD reprecipitation to occur.  
 
Table 7.2: Properties of calcium pyrophosphate dihydrate, brushite and HA crystals 
precipitated at 37°C (Christoffersen and Christoffersen, 2003; Elliot J.C., 1994; 
Fernandez et al., 1999). 
 CPPD; 
Ca2P2O7.2H2O 
Brushite; 
CaHPO4.2H2O 
HA; Ca5(PO4)3OH 
Crystal system Triclinic Monoclinic Monoclinic 
Cell data a = 6.70, b = 7.38, c 
= 8.31 Å and β = 
102.48° 
a = 6.361(3), b = 
15.191(4), c = 
5.814(2) Å and β = 
118.45(4)° 
a = 9.84214(8), b = 
2a, c = 6.8814(7) Å  
and γ = 120° 
Density 
(g/cm3) 
2.46 2.32 3.15 
Solubility 
product 
18.35 6.63 58.6 
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7.3.2. Determining the concentration at which HA reprecipitation 
was likely to occur  
Solubility product (Ksp) of HA and CPPD crystals (Table 7.2) was used to calculate 
the minimum concentration of PO4
3- and P2O7
4- ion required for the precipitation of 
HA and CPPD crystals in solution at 37°C. The dissolution of HA crystal is given by 
equation 7.5: 
                 
        
               
     
           
   
 
     
               
 
                          
   
 
      
            [  ] 
                           
                     
Therefore the concentration of PO4
3- required for apatite to be reprecipitated in 
solution is 0.260 μM (i.e. 3 x 86.8 E -09 M). Equation 7.6 represents the mechanism 
by which CPPD crystal is dissolved in solution. At 37°C the concentration of P2O7
4- 
ion is given by: 
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Therefore the concentration of P2O7
4- ion required for the reprecipitation of CPPD 
crystal in solution is 0.482 μM. From figure 7.9a and 7.10a it can be noted that the 
concentration of PO4
3- ion at 15 min is much greater than 0.260 μM (the minimum 
concentration required for apatite precipitation) strongly supporting the hypothesis 
that the reprecipitated crystals are apatite (equation 7.7b). The excess PO4
3- ion in 
solution can also be condensed to form P2O7
4- which is then reprecipitated as CPPD 
(equation 7.7a).  
    
       
                       
                 
       
             
   
                      
To increase the amount of crystals dissolved in solution by reducing the effect of 
saturation of the ageing solution the volume of aliquot removed at each time point 
was increased from 300 μL to 4 mL. By removing 80% (4 mL) of the ageing medium 
there was an increase of 75% in the mass of CPPD which dissolved in ALP solution 
(Figure 7.15a) and 76% increase in the mass of brushite crystal which dissolved in a 
similar solution (Figure 7.15b). There was also a significant increase in the mass of 
crystals which dissolved in the control solution 23% for CPPD crystals and 79% for 
brushite crystals. The increase in concentration of PO4
3- ion can be explained by Le 
Chatelier‟s principle (Figure 7.14). By increasing the volume of aliquot the 
concentration of PO4
3- ion in solution is reduced i.e. the concentration of CPPD and 
brushite crystals is higher than PO4
3- therefore the equilibrium position moves to the 
right (equation 7.8a and 7.8b). This means that the dissolution of CPPD and brushite 
crystals is favoured i.e. the mass of CPPD and brushite crystals dissolved in solution 
increases (Figure 7.14 and 7.15).  
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In reactions containing ALP it was important to understand the rate at which the 
enzyme breaks down P2O7
4- into PO4
3- ions. Km value for ALP determined from 
Michealis – Menten kinetics was 898.9 μM showing that the enzyme has a high 
affinity for P2O7
4- ion. The Ksp value for CPPD crystals reveal that the maximum 
concentration of P2O7
4- ion which leads to the formation of the crystals in solution is 
0.482 μm. The maximum rate at which ALP hydrolyses P2O7
4- ion to produce PO4
3- 
ion is 161.2 μM/min. This shows that ALP will breakdown the P2O7
4- ion released 
into solution producing PO4
3- ion with a concentration greater than 0.260 μm. 
Therefore the solution becomes saturated with respect to PO4
3- ion resulting in the 
reprecipitation of apatite crystals as illustrated by equation 7.8a (Figure 7.11c). If 
most of the PO4
3- ion is converted to apatite the amount detected in solution would be 
reduced, this explains what was observed in solution between 1 – 4 h (Figure 7.8).  
 
7.3.3. Surface interaction of CPPD and brushite crystals with ALP 
The adhesion of ALP onto the surface of CPPD and brushite crystals was 
investigated to further understand if crystal dissolution was surface mediated. The 
adhesion of ALP onto the surface of CPPD and brushite crystals was shown to 
increase and decrease throughout the experiment (Figure 7.17b). The adhesion of 
ALP onto CPPD crystal was confirmed using light microscopy (Figure 7.18b). 
Shinozaki et al. suggested that the dissolution of CPPD crystals occurs through 
surface mediation i.e. the ALP that adheres to CPPD crystal stereo selectively 
cleaves it surface therefore results in crystal dissolution (Shinozaki et al., 1995). 
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Figure 7.17b suggests that there is continuous adsorption and desorption of ALP 
from the surface of the crystals. In figure 7.9a and 7.10a the concentration of PO4
3- 
ion in solution was found to increase gradually and not as suggested by the BCA 
assay to increase and decrease. In conjunction with figures 7.11c and 7.13c which 
shows no evidence that ALP cleaved the surface of both CPPD and brushite crystals 
it can be concluded that crystal dissolution was not surface mediated. The visking 
experiment in figure 7.19 provides conclusive evidence that CPPD dissolution was 
not surface mediated. Figure 7.19 shows that the crystals (in visking tube) in the ALP 
solution degraded faster than that which was aged in the control solution. This result 
confirms the mechanism of CPPD crystal dissolution to be (1) dissolution of CPPD 
into calcium and pyrophosphate ions and then (2) the hydrolysis of the P2O7
4- ion by 
ALP (equation 7.8a).  
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7.4. CONCLUSION 
Phase pure CPPD, brushite and OCP crystals were successfully precipitated and this 
was confirmed using XRD, FTIR and SEM. CPPD crystals dissolved faster in the 
presence of ALP but brushite crystals were not affected by the enzyme. A higher 
percentage of brushite crystals were dissolved in solution than CPPD as it is more 
soluble in physiological conditions. SEM micrographs of CPPD crystals aged in the 
control and ALP solution show the presence of reprecipitated crystals which is due to 
the saturation of the ageing solution with respect to PO4
3- ion. The Michaelis-Menten 
kinetics showed the high affinity ALP had for P2O7
4- ion and therefore releasing 
orthophosphate ion at very high concentrations that result in reprecipitation. The 
mass of CPPD and brushite crystals which were dissolved in the ageing solutions 
increased significantly with increase in the volume of aliquot removed. This 
confirms that the solubility of the precipitated crystals is inhibited by the 
reprecipitation of apatite and CPPD crystals. Although ALP was shown to adsorb to 
the surface of CPPD crystals the adhesion experiment (BCA assay) does not support 
the hypothesis that CPPD dissolution occurs when ALP cleaves to the surface of the 
crystal on which it was attached. CPPD crystal dissolution was found to increase in 
ALP solution than the control even though the crystals were placed in a visking tube 
which would prevent direct interaction with the enzyme. It can be concluded that the 
dissolution of CPPD in the presence of ALP occurs in two stages: (1) hydrolytic 
degradation of the crystals and (2) enzymatic degradation of the pyrophosphate 
bonds resulting in the release of phosphate ions.   
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8. FORMULATING AND PROCESSING A BULK CALCIUM 
PYROPHOSPHATE CERAMIC 
The human body is limited in its ability to regenerate bone defects caused by 
infection and trauma. Therefore various materials have been investigated as a 
possible bone replacement material. ALP which is found on the surface of 
osteoblasts cells plays an important role in bone mineralization by hydrolyzing the 
P2O7
4- ion to PO4
3- ion which causes supersaturation and apatite formation 
(Balcerzak et al., 2003). Although CPPD crystals were shown to dissolve faster in 
the presence of ALP (chapter 7), CPPD crystals are not suitable biomaterials as they 
cannot be produced phase pure in large quantities. The presence of CPPD crystals in 
the body is also associated with calcium pyrophosphate dihydrate deposition disease 
and pseudogout (Mccarty, 1976; Mccarty et al., 1971). Therefore this chapter seeks 
to investigate the formulation and processing of a bulk calcium pyrophosphate 
ceramic which is reproducible and can be produced in large quantities. The ceramic 
is also expected to degrade in the presence of ALP therefore acting as a 
bioresponsive bone replacement. A ceramic is an inorganic, non-mettalic solid 
prepared by the action of heat and subsequent cooling (Dorozhkin, 2010). Ceramics 
can be crystalline, partly crystalline or amorphous (Dorozhkin, 2010). Sintered 
dicalcium pyrophosphate (SDCP) and β-dicalcium pyrophosphate (β-DCP) particles 
have been shown to encourage osteoblast cell growth (Sun et al., 1997). Calcium 
pyrophosphate ceramic is also osteoconductive and well tolerated in vivo (Lin et al., 
1995b). When Lin et al. implanted β-DCP doped with sodium pyrophosphate 
(Na4P2O7.10H2O)  into the femur of New Zealand white male rabbit the ceramic was 
found to be degradable in vivo and new bone tissue was formed within the 
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macropores of the compacted ceramic (Lin et al., 1995b). Another experiment 
showed that bone mineral was increased and porosity of trabeculae bone was 
decreased in the long bone of ovariectomized rats when the Wistar rats ingested 
SDCP (Sun et al., 2002), suggesting that the material could play a broader 
therapeutic role. The presence of a glass phase within the SDCP ceramic could result 
in a low SSA, a factor known to influence the biological reaction to the material (Lin 
et al., 1995b; Barralet et al., 2002). In this chapter the process of producing calcium 
pyrophosphate ceramic from brushite based cement was investigated. The effect of 
varying process conditions and cement compositions on the microstructure, porosity 
and compressive strength of the ceramic was also investigated. The mass loss and 
volumetric shrinkage of the ceramic was also investigated with respect to varying 
powder liquid (P:L) ratio and sintering temperature.  Finally the degradation of the 
sintered ceramic in ALP containing solution and in serum was investigated. The 
effect of SSA, sintering temperature and P:L ratio on ceramic degradation was also 
determined.   
107 
 
8.1. MATERIALS AND METHODS  
8.1.1. Synthesis of calcium pyrophosphate ceramics 
The brushite cement for thermal treatment was synthesized by combining β-TCP 
with 3.5 M H3PO4 (Fisher Scientific, Dorset, UK) containing citric acid at a 
concentration of 50 mM (Fluka, Dorset, UK) (equation 8.1).  The β-TCP was mixed 
with H3PO4 solution at powder to liquid ratio (P:L)  of 1.25 g/mL.  The resulting 
paste was cast into a polytetrafluroethylene (PTFE) split mould to form cylindrical 
samples of diameter 6 mm and height 12 mm.  The cylinders were allowed to harden 
at 37°C for 24 h prior to testing or further heat treatment. The hardened cement 
cylinders were subsequently sintered at temperatures between 400 and 1200°C for 5 
h using a muffle furnace (CWF 1300; Carbolite, UK), the heating and cooling rate of 
the furnace was set at 10°C/min converting the brushite cement into monetite and 
then calcium pyrophosphate ceramic (Ca2P2O7) in accordance with equation 8.2 and 
8.3.  
                                     … (8.1) 
                          … (8.2) 
                   … (8.3) 
 
8.1.2. Monitoring phase transitions  
Dried brushite cement (P:L = 1.25 g/mL) was ground and then placed in a 
temperature controlled X-ray diffractometer. The X-ray diffractometer (D5005 
Brucker, Siemens, Germany) with CuKα1 radiation λ = 1.5406 Å and CuKα2 
radiation λ = 1.5444 Å was used in determining the crystal composition of the 
powder as it was heated from 27 to 1000°C over a 2θ range of 5 - 70° using a step 
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size of 0.036° and a step time of 0.5 s. Thermogravimetric analysis (TGA) and 
differential thermal analysis (DTA) was carried out on brushite cement powder over 
a temperature range of 25 – 1200°C with a flow rate of 50 mL/min and at a heating 
rate of 20°C/min using a simultaneous thermal analysis machine (STA 1500, Stanton 
Redcroft).  
 
8.1.3. Effect of varying cement composition  
The concentration of H3PO4 acid determines the amount of β-TCP that reacts to form 
brushite (equation 8.1) and hence subsequent amount of pyrophosphate within the 
ceramic. The acid concentration was varied from 1.5 – 4.5 M and the effect on the 
porosity and mechanical strength of the ceramic was investigated. The effect of 
mixing incremental amounts of β-TCP with H3PO4 acid at P: L between 1.25 and 3.0 
g/mL was studied. The effect of increasing the P:L on the porosity and mechanical 
strength of the ceramic was investigated as increasing P:L should result in increased 
amount of unreacted β-TCP. The changes to surface morphology, mass and volume 
loss with increasing P:L was also observed.  
 
8.1.4. Effect of varying process conditions 
Sintering time and temperature are driving forces in the process of sintering and 
therefore affect the microstructure and composition of the resulting ceramic. The 
sintering time was varied over 3 – 10 h and the effect on the porosity and mechanical 
strength of calcium pyrophosphate ceramic was investigated.  The effect of varying 
sintering temperature from 400 – 1200°C on microstructure, porosity, mass and 
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volume loss and mechanical strength while keeping the sintering rate and time 
constant was also investigated.  
 
8.1.5. Characterisation of calcium pyrophosphate ceramic 
8.1.5.1. Mass and volume change 
At each operating condition geometrical and mass measurements of each sample 
(n=9) were made and from these data, volumetric shrinkage and mass loss were 
calculated. The mass loss is given by: 
      
     
  
            
Where Ms is the mass loss from the ceramic upon sintering, Mi is the mass of 
brushite cement and Mf is the mass of the sintered Ca2P2O7 ceramic. The volumetric 
shrinkage of Ca2P2O7 ceramic is given by: 
      
     
  
            
Where Vs is the volumetric shrinkage, Vi is the volume of brushite cement and Vf is 
the volume of the sintered Ca2P2O7 ceramic. 
8.1.5.2. Ceramic microstructure  
The new microstructure formed within the ceramic was observed using SEM. The 
changes to the cement and ceramic microstructure with varying P:L and sintering 
temperature was observed using SEM (Philips XL 30 and Joel 6060).  The fracture 
surface of the cement and ceramic was gold plated (depth of 1 mm) to make them 
conductive and potentials of 10 kV were applied to obtain clear pictures. 
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8.1.5.3. Porosity 
The conversion of brushite to Ca2P2O7 results in density changes within the material. 
There are also additional density changes when phase change occurs between the 
different isoforms of Ca2P2O7 at temperatures above 400°C.  The changes to density 
as well as composition would affect the porosity and therefore the compressive 
strength of the ceramic according to equation 8.5:  
                    
Where σc is compressive strength at porosity P, σo is compressive strength at zero 
porosity, K is a constant and P is the porosity of the ceramic. Using Archimedes 
principle, the porosity of the ceramic was determined from apparent and true density 
measurements.  True density was calculated from the mass of the ceramic in air (dry) 
and in water (wet) while the apparent density was calculated from the mass and 
volume (measured using the outer dimensions of the ceramic) of the ceramic.  
              
           
                        
             
                   
                
                      
         
             
                
                             
                                     
8.1.5.4. Compressive strength 
Prior to testing in compression, ceramic samples were immersed in double distilled 
water for a period of 2 h and stored at 37ºC.  The wet ceramic samples were mounted 
on the testing machine (Dartec HCIO, UK) so that the long axes of the ceramic 
cylinders were perpendicular to the lower anvil.  A compressive force was then 
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applied to the upper surface of the ceramic samples at a constant crosshead 
displacement rate of 1 mm/min until failure occurred.  Mean strength was determined 
from the average of nine measurements. The applied load was measured using a 1 kN 
load cell (Dartec HCIO, UK). Compressive strength was determined in accordance 
with equation 8.7: 
    
  
   
         
Where σc is compressive strength (MPa), F is load at failure (N) and d is the diameter 
of the cylindrical sample (mm). 
8.1.5.5. Specific surface area  
The changes to SSA of Ca2P2O7 ceramic with sintering temperature was measured 
and calculated according to Brunauer Emmet Teller (BET) method by a Tristar II 
3020 apparatus (Tristar Gemini, Micrometrics) with the nitrogen liquid at 77 K.  
SSA measurements for the ceramics degraded in ALP, Tris HCl, serum and PBS 
solutions was calculated by applying BET equation to the data collected from a DVS 
Advantage II (Surface Measurement Systems, UK). Octane was used as the probe 
molecule. 35 – 50 mg ± 1mg of sample was loaded onto one side of the twin pan 
balance,  before running the software-controlled sequence that held the sample at 0% 
relative humidity (dry nitrogen) for 12 h to remove any surface moisture followed by 
humidity steps from 0% relative humidity up to 90% relative humidity in 3% 
increments.  This procedure was repeated three consecutive times on each sample 
except were stated. The temperature throughout was 25°C ± 0.1°C. The sample was 
allowed to reach a near equilibrium state (% dm/dt = 0.002%/min) at each humidity 
stage before progressing to the next. 
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8.1.5.6. Statistical analysis 
One-way analysis of variance (ANOVA) was employed to determine the statistical 
significance of differences between mass loss, volumetric loss, porosity and 
compressive strengths of the ceramics. Comparison of these raw data was performed 
using the post-hoc Tukey test. Differences between sample groups was deemed 
significant when p ≤ 0.05. All statistical analysis was performed using Primer of 
Biostatistics for windows version 4. 
 
8.1.6. Degradation of calcium pyrophosphate ceramics 
Bulk Ca2P2O7 ceramics were aged in the presence of ALP; this is to determine if 
ALP accelerated the degradation of calcium pyrophosphate ceramic as was the case 
with CPPD crystals. To provide a more realistic simulation of body fluid, the ceramic 
was also aged in serum which should contain pyrophosphatase enzymes.  
8.1.6.1. Degradation in ALP solution 
Bulk Ca2P2O7 ceramics sintered at 1200ºC with varying P:L of 1.25 - 1.5 g/mL were 
aged in 20 mL Tris HCl solution containing ALP (10 – 75 U). The Tris HCl buffer 
was at a pH of 7.4 and it contained 0.01% sodium azide (NaN3, Sigma Aldrich, 
Dorset) and 1 mM magnesium chloride (MgCl2, Sigma Aldrich, Dorset). As a control 
experiment the bulk ceramics were aged in the Tris HCl buffer without ALP. The 
experiments were carried out in a rotating incubator at 37°C with the rotor speed of 
150 rpm. The ageing solution was changed daily and the mass of the ceramic was 
measured daily. 
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8.1.6.2. Degradation in Foetal Bovine Serum (Serum) 
Ca2P2O7 ceramic (n=3) was aged in 20 mL foetal bovine serum (PAA laboratories, 
Somerset, UK) containing 0.01% sodium azide  (NaN3, Sigma Aldrich, Dorset) in a 
rotating incubator at 37°C with the rotor speed set at 150 rpm. As a control 
experiment Ca2P2O7 ceramic (n=3) with the same composition and sintering 
conditions was degraded in 20 mL phosphate buffered saline (PBS). The ageing 
solutions were changed daily over the duration of the study, the ceramics were dried 
and the mass was measured daily. 
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8.2. RESULTS 
8.2.1. Synthesis of Ca2P2O7 ceramic 
The change in the microstructure of brushite cement (P:L = 1.25 g/mL) after 
sintering is illustrated by figure 8.1. Before heat treatment the cement consisted 
predominantly of rectangular shaped crystals of 10 – 30 μm in length (Figure 8.1a). 
Following heat treatment the microstructure of the ceramic consisted of very small 
pores which are formed when the crystals of the cement diffuse into one another 
(Figure 8.1b).  
 
Figure 8.1: Microstructure of a) brushite based cement prior to sintering and b) 
Ca2P2O7 ceramic sintered at 1000°C.   
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The particles of the sintered ceramic consist of irregularly shaped particles (5 – 50 
μm long) and coarsened (densified) crystals with interconnected pores associated 
with neck formation and crystal growth (Figure 8.1b). X-ray diffraction showed that 
prior to heat treatment, the cement consisted in the most part of brushite, with some 
residual unreacted β-TCP (Figure 8.2). Sintering brushite cement to 200°C resulted 
in the conversion of all the brushite crystals within the cement into calcium hydrogen 
phosphate anhydrous (monetite; CaHPO4) in accordance with equation 8.8a. Figure 
8.2 also shows that monetite was completely converted to Ca2P2O7 when sintered at 
temperatures ≥400°C in accordance with equation 8.8b.   
 
Figure 8.2: XRD patterns showing the phase evolution with temperature during the 
formation of Ca2P2O7. 
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γ-Ca2P2O7 was formed when monetite was heated between 400 – 700°C while there 
was a phase change to β-Ca2P2O7 a more stable phase at 1000°C.  
                           ... (8.8a) 
                     ... (8.8b) 
Further heating of the ceramic to 1200°C resulted in a final phase change to α-
Ca2P2O7 as shown in figure 8.3. It can be clearly seen that the unreacted β-TCP 
remained within the ceramic over the sintering regime. Beyond 1200°C, the 
formation of a glass phase was apparent and the cylindrical samples lost their 
cylindrical conformation.  
 
Figure 8.3: XRD pattern of α-Ca2P2O7 ceramic (P:L = 1.25 g/mL) when brushite 
cement was sintered at 1200°C for 5 h.    
 
In addition to the temperature controlled XRD the conversion of brushite to Ca2P2O7 
was also monitored using TGA and DTA analysis as shown in figure 8.4. The 
dehydration of the cement up to a temperature of 225°C was associated with a mass 
loss of 12% and an exothermic reaction that can be associated with the phase change 
117 
 
from brushite to monetite (equation 8.8a). Further heating of the ceramic to 400°C 
caused a smaller exotherm and the loss of an additional ~6 wt% of the ceramic mass 
that may be associated with the formation of γ-Ca2P2O7 (equation 8.8b) in the matrix 
of the ceramic (Figure 8.2 and 8.4).  
 
Figure 8.4: Thermal and gravimetric profile for the solid state reaction of the 
conversion of brushite cement to Ca2P2O7. 
 
An endothermic peak at approximately 600°C may indicate an additional phase 
change that was associated with little or no mass loss (Figure 8.4). Indeed, following 
heating beyond 700°C, the ceramic was shown to contain β-Ca2P2O7 (Figure 8.2). As 
sintering temperature was increased from 1000 - 1200°C β-Ca2P2O7 was converted to 
α-Ca2P2O7 as confirmed on the XRD pattern in figure 8.3.   
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8.2.2. Effect of varying process condition on Ca2P2O7 ceramic 
Sintering time and temperature are two of the process variables which determine the 
conversion of one material to another and the microstructure of the sintered material. 
This section investigated the effect of varying sintering time and temperature.   
8.2.2.1. Sintering time   
The pores within the particles of the powder compact are expected to decrease with 
increase in sintering time i.e. ceramic porosity is expected to decrease as the sintering 
time increases. β-TCP powder consisted of irregularly shaped particles and 
agglomerates of 2 – 50 μm in diameter (Figure 8.5a) while the brushite crystals 
formed were of a rectangular shape of 10 – 30 μm in diameter (Figure 8.5b). The 
difference in shape and size of component particles of the brushite cement made it 
difficult to obtain uniform elimination of the pores within the cement (Figure 8.5b). 
Indeed there was no statistically significant change in ceramic porosity when the 
sintering time was varied from 3 to 10 h except when sintered at 5 h (Table 8.1). The 
compressive strength of the ceramic was also not affected by increasing sintering 
time (Table 8.1). The change in porosity and compressive strength of Ca2P2O7 
ceramic with increased sintering time was of no statistical significance. The porosity 
(30%) and compressive strength (11.1 MPa) of Ca2P2O7 ceramic was highest when 
brushite cement was sintered in the muffle furnace for 5 h (Table 8.1).   
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Figure 8.5: Scanning electron micrograph of a) β-TCP particles, b) brushite based 
cement (P:L = 3.0 g/mL) and c) Ca2P2O7 ceramic (P:L = 3.0 g/mL) sintered at 
1200°C for 5 h.  
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Table 8.1: Effect of sintering time on the compressive strength porosity and 
volumetric change of Ca2P2O7 ceramic sintered at 1200°C and P:L 3.0 g/mL.  
Time (h) Compressive 
Strength 
(MPa) 
Standard 
Deviation 
Porosity (%) Standard 
Deviation 
3 9.6 1.9 22 3 
5 11.1 1.8 30 2 
8 9.9 2.8 21 3 
10 9.5 1.9 20 2 
 
8.2.2.2. Sintering temperature  
Effect of sintering temperature on the specific surface area of Ca2P2O7 ceramic  
In general, ceramic densification increases as the sintering temperature is increased 
(German, 2001). The SSA of a ceramic is affected by sintering temperature and it is 
an important factor in the degradation of the ceramic (Barralet et al., 2002). The 
particles of the brushite crystals are irregularly shaped and between 10 – 30 μm in 
diameter (Figure 8.6a). As the brushite cement is sintered, neck formation occurs by 
mass transfer via solid state diffusion between contacting particles (Figure 8.6b, 8.6c, 
8.6d and 8.6e). As the sintering temperature is increased more particles become 
diffused and the neck formed grows which results in crystallite growth (Figure 8.6b, 
8.6c, 8.6d and 8.6e). The pore spaces between the particles also decreased with 
increasing sintering temperature; ceramics sintered at 400°C (Figure 8.6b) were 
compared with those at 1200°C (Figure 8.6e). The reduction in pore space might not 
be obvious from the SEM in figure 8.6 but the porosity was reduced from 44 ± 2% 
(400°C) to 32 ± 6% (1200°C). The reduction in porosity was of statistical 
significance (P < 0.05). 
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Figure 8.6: Scanning electron micrograph of a) brushite cement (P:L = 1.5 g/mL) and 
Ca2P2O7 ceramic sintered at b) 400°C, c) 700°C, d) 1000°C and e) 1200°C. 
 
The decrease in pore size i.e. ceramic densification leads to increased compressive 
strength as seen in figure 8.7. Increasing the sintering temperature also led to a 
decrease in the SSA of the sintered ceramic (Figure 8.7). The SSA could also be 
affected by the surface roughness of the sintered ceramic although not measured 
here. The SSA at each sintering temperature is the average SSA data obtained from 
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three samples collected from nitrogen BET (Tristar Gemini, Micrometrics). Although 
not measured here the SSA of Ca2P2O7 ceramic is expected to decrease with 
increased sintering temperature irrespective of the P:L ratio.  
 
Figure 8.7: Effect of sintering temperature on the specific surface area (SSA) of and 
compressive strength (CS) of the sintered Ca2P2O7 ceramic (P:L = 1.5 g/mL). The 
error bars on the SSA graph is very small. It is the standard deviation of three data 
obtained at each sintering temperature.  
 
Although the experiments carried out so far involved ceramics at P:L 1.25 and 1.5 
g/mL, further experiments involved increasing the P:L ratio of the sintered ceramic 
so as to optimise the properties of the ceramic with respect to porosity and 
compressive strength. This would provide a wider range of clinical applications for 
the Ca2P2O7 ceramic.    
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Effect of sintering temperature on porosity and compressive strength  
Ca2P2O7 ceramic is studied for its possible application as a bone replacement 
material therefore its compressive strength is an important parameter in determining 
its suitability.  The compressive strength of cancellous bone has been reported over a 
wide range between 0.5 – 50 MPa (Lawson and Czernuszka, 1998). Therefore in 
other to provide a clinical application for the formulated Ca2P2O7 ceramic the 
compressive strength should also be within the range of the cancellous bone. As the 
P:L ratio was increased the compressive strengths increased (Figure 8.7, 8.8 and 
8.10). The compressive strength of Ca2P2O7 ceramic increased from 5.0 ± 0.7 MPa at 
400°C to 8.8 ± 2.1 MPa at 1000°C (Figure 8.8).  
 
 
Figure 8.8: Effect of sintering temperature on the porosity and compressive strength 
of Ca2P2O7 ceramic at P:L 2.0 g/mL.  
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This change was of statistical significance (P ≤ 0.05). The increase in sintering 
temperature results in increased particle densification (Figure 8.12). Further increase 
in sintering temperature to 1200°C resulted in the compressive strength reducing to 
7.9 ± 1.0 MPa (Figure 8.8). The decrease in compressive strength when the sintering 
temperature was increased from 1000°C to 1200°C was statistically insignificant (P 
= 0.251). This decrease in compressive strength from 8.8 ± 2.1 MPa to 7.9 ± 1.0 MPa 
is associated with the presence of microcracks at 1200°C possibly as a result of 
tetragonal to monoclinic phase transformation (Figure 8.9).   
 
 
Figure 8.9: Scanning electron micrograph showing the presence of microcracks in 
Ca2P2O7 ceramic when sintered at 1200°C (P:L = 2.0 g/mL).  
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The porosity of Ca2P2O7 ceramic was 45 ± 3% when sintered at 700°C and this 
reduced to 34 ± 1% when it was sintered at 1200°C (Figure 8.8).  The reduction in 
porosity was of statistical significance (P ≤ 0.05) and the increase in porosity from 42 
± 3% at 400°C to 45 ± 3% at 700°C was also statistically significant (P = 0.009) 
(Figure 8.8). Irrespective of the increase in P:L ratio the trend observed with 
compressive strength and porosity over the range of sintering temperature was the 
same (Figure 8.10). Porosity was found to decrease from 32 ± 2% at 400°C to 23 ± 
3% at 1200°C at P:L ratio of 2.5 g/mL (Figure 8.10a). The compressive strength was 
also increased from 6.9 ± 1.4 MPa to 9.5 ± 1.2 MPa over 400 – 1200°C (Figure 
8.10a). The decrease in porosity and increase in compressive strength for the ceramic 
at P:L of 2.5 g/mL was of statistical significance. Overall the compressive strength of 
Ca2P2O7 ceramic was highest at P:L ratio of 3.0 g/mL (Figure 8.10b). At P:L ratio of 
3.0 g/mL the porosity decreased from  33 ± 2% at 400°C to 30 ± 2% at 1200°C 
(Figure 8.10b). The compressive strength increased significantly from 8.3 ± 1.3 MPa 
to 11.1 from ± 1.3 MPa over the same temperature range (Figure 8.10b).  
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Figure 8.10: Effect of sintering temperature on the porosity and compressive strength 
of Ca2P2O7 ceramic at a) P:L 2.5 g/mL and b) P:L 3.0 g/mL.  
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Effect of sintering temperature on mass loss and volumetric shrinkage  
In the case of materials processed at high temperatures it is important to be able to 
predict the shrinkage to the Ca2P2O7 ceramic to produce graft replacement of a 
defined size. As sintering temperature is increased the crystals present within the 
ceramic matrix grow and the pores within the crystals decrease therefore the ceramic 
shrinks in volume. Figure 8.11a shows that the volumetric shrinkage of the ceramic 
increased significantly from 3 ± 1% (400°C) to 14 ± 1% (1200°C). At temperatures 
greater than 400°C brushite was converted to Ca2P2O7 and there was no other 
chemical change within the ceramic over the sintering regime except phase changes. 
Therefore the mass loss from the ceramic is expected to be unchanged with 
increasing sintering temperature. There was a little increase in mass loss as shown in 
figure 8.11b from 16.0 ± 0% at 400°C to 18.0 ± 1% when brushite cement was 
sintered at 1200°C. The volumetric shrinkage could also be linked to the ceramic 
densification which also could influence the compressive strength of the sintered 
ceramic (Figure 8.12).   
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Figure 8.11: The effect of varying sintering temperature on a) volumetric shrinkage 
and b) mass loss of Ca2P2O7 ceramic at P:L 2.0 g/mL. 
 
 
129 
 
Figure 8.12: SEM micrographs showing the change in ceramic densification with 
temperature. Ceramic at P:L 2.5 g/mL was sintered at a) 400°C, b) 700°C, c) 1000°C 
and 1200°C. 
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8.2.3. Effect of varying cement composition  
The relative quantities of brushite and β-TCP crystals varied depending on the H3PO4 
acid concentration and P:L ratio. This section describes the effect of varying cement 
composition on mass loss, volumetric shrinkage, compressive strength and porosity 
of the sintered ceramic.   
8.2.3.1. Increasing acid concentration  
As H3PO4 acid concentration is increased the proportion of brushite present within 
the cement is increased as shown in table 8.2.  
Table 8.2: Relative composition of brushite and β-TCP crystals present within 
brushite cement with increase in acid concentration. 
Acid 
Concentration (M) 
CaHPO4.2H2O 
(% wt) 
β- TCP  
(% wt) 
1.5 43 57 
2.5 64 36 
3.5 81 19 
4.5 96 4 
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Figure 8.13: Effect of acid concentration on a) volumetric shrinkage and mass loss 
and b) compressive strength of Ca2P2O7 sintered ceramic at 1200°C and P:L 1.5 
g/mL.  
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As the acid concentration was increased from 1.5 M to 4.5 M the amount of brushite 
also increased from 43% to 96% (Table 8.2). Therefore the amount of water of 
crystallisation removed from the brushite crystals was increased leading to an 
increase in mass loss from the cement (Figure 8.13a). The mass loss increased from 9 
± 4% (1.5 M) to 25% (4.5 M). The increase in the proportion of brushite led to an 
increased proportion of Ca2P2O7 so that crystal densification and growth increase 
with increasing acid concentration. This led to increase in volumetric shrinkage as 
seen in figure 8.13a. Compressive strength was found to be highest when brushite 
cement was prepared with 3.5 M H3PO4 acid (Figure 8.13b). As acid concentration is 
increased cement setting times reduce, this makes cement handling difficult. 
Therefore voids may form within the cement matrix at high acid concentrations 
leading to the reduction in compressive strength. The compressive strength reduced 
from 6.4 ± 1.5 MPa at 3.5 M to 4.6 ± 0.6 MPa at 4.5 M (Figure 8.13b). The reduction 
in compressive strength was of statistical significance (P≤0.05).   
8.2.3.2. Increasing P:L ratio  
The ratio of β-TCP to H3PO4 acid mixed was varied from 1.25 – 3.0 g/mL. At P:L 
ratio of 1.25 g/mL the phase composition of Ca2P2O7 ceramic sintered at 1200°C was 
determined by means of Rietveld refinement phase analysis. The Rietveld plot shown 
in figure 8.14 showed that the ceramic contained 79 wt% α-Ca2P2O7 and 21 wt% β-
TCP. The bottom line on the Rietveld plot (Figure 8.14) is termed the difference plot 
which shows the difference between the calculated and observed pattern. The bottom 
line deviates very little from -1.0x102 counts indicating that there was a good 
agreement between the calculated and observed pattern. The Rietveld plot confirmed 
133 
 
that β-TCP is present in excess and the reaction occurs in accordance with equation 
8.9.  
                                                   
 
 
Figure 8.14: Rietveld plot of Ca2P2O7 ceramic (P:L = 1.25 g/mL) sintered at 1200°C.   
 
Table 8.3 shows the calculated relative quantities of β-TCP and Ca2P2O7 after 
sintering at 1200°C. The β-TCP content of the ceramic increased from 16 wt% to 45 
wt% as the P:L ratio was increased from 1.5 g/mL to 3.0 g/mL (Table 8.3). 
Compressive strength of the sintered ceramic increased with increase in P:L ratio 
(Table 8.3). The increase in compressive strength from 6.7 ± 0.8 MPa at a P:L of 
1.25 g/mL to 11.4 ± 1.7 MPa at a P:L of 3.00 g/mL was of statistical significance (P 
= 0.000). The porosity was lowest at P:L ratio of 2.5 g/mL (24%) (Table 8.3). The 
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difference in porosity at P:L of 1.25, 1.5, 2.0 and 3.0 g/mL was not statistically 
significance (P = 0.137).  
 
Table 8.3: Effect of P:L ratio on the porosity and compressive strength of Ca2P2O7 
ceramic sintered at 1200°C. 
P:L 
Ratio 
Phase Composition Porosity Compressive 
Strength 
β-TCP 
(wt ± 2) % 
Ca2P2O7 
(wt ± 2) % 
(%) 
Standard 
Deviation 
(MPa) 
Standard 
Deviation 
1.25 7 93 33 4 6.7 0.8 
1.50 16 84 32 6 7.5 1.4 
2.00 25 75 33 1 8.2 0.5 
2.50 31 69 25 3 9.7 1.2 
3.00 45 55 30 2 11.4 1.7 
 
The volumetric shrinkage and mass loss from the sintered ceramic decreases with 
increase in P:L ratio (Figure 8.15). According to equation 8.9 water molecule is in 
excess and the amount present within the cement matrix reduces with increasing P:L 
ratio. Therefore the mass loss from the ceramic reduces from 24 ± 1% at P:L = 1.25 
g/mL to 12 ± 1% at P:L = 3.0 g/mL. As P:L ratio is increased the amount of β-TCP 
and brushite crystals present within the ceramic matrix is increased therefore the 
volumetric shrinkage that occurs with crystal growth is reduced. Volume shrinkage 
reduced from 27 ± 3% at P:L 1.25 g/mL to 10 ± 1% at P:L 3.0 g/mL (Figure 8.15).  
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Figure 8.15: Effect of P:L on the mass loss and volumetric shrinkage of Ca2P2O7 
ceramic at 1200°C.  
 
8.2.4. Degradation profile of Ca2P2O7 ceramic  
This section investigates the degradation of Ca2P2O7 ceramic in the presence of ALP 
and other proteins present in serum. The ceramics were aged over a period of time 
and the mass of the ceramic was measured daily from which the mass loss as a 
percentage of the original was calculated. In other to observe the effect of SSA on 
the degradation of the sintered ceramics the sintering temperature and P:L ratio were 
varied. Enzyme concentration was also varied to observe any effect it had on 
Ca2P2O7 ceramic degradation. The degradation of brushite and Ca2P2O7 ceramic was 
also compared in the same ageing solution.  
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8.2.4.1. Degradation in ALP solution 
Standard sized ceramics (height = 12 mm and diameter = 6 mm) were shown to 
degrade faster in ALP containing solution than in Tris HCl control solution (Figure 
8.16). Figure 8.16 shows that 41 wt% of the original ceramic degraded in 75 U of 
ALP and 48 wt% in 10 U ALP solution while 18 wt% of the original ceramic 
degraded in 20 mL Tris HCl solution and only 5 wt% in 40 mL Tris HCl solution 
over the same ageing period. The increase in ALP concentration from 10 U to 75 U 
did not produce an increase in the mass of Ca2P2O7 ceramic which degraded. 
 
Figure 8.16: Degradation of Ca2P2O7 ceramic of P:L of 1.25 g/mL and sintered at 
1200°C in 10 U, 75 U and control solution over 16 days. 
 
The degradation of ceramics at P:L ratio of 1.5 g/mL was studied due to the 
increased compressive strength (Table 8.3). Figure 8.17 shows that 8 wt% of the 
original Ca2P2O7 ceramic degraded in control solution but only 5 wt% of the original 
ceramic degraded in 15 U and 75 U ALP solutions. Increasing ALP concentration 
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did not produce an increase in the mass of ceramic which degraded in solution. As it 
was not possible to increase ALP concentration significantly the ceramics were then 
degraded in serum which is expected to contain pyrophosphatase that might enhance 
ceramic degradation. For the control experiment the brushite cement and Ca2P2O7 
ceramic was degraded in phosphate buffered saline (PBS) solution.  
 
Figure 8.17: Degradation profile of Ca2P2O7 ceramic of P:L 1.5 g/mL and sintered at 
1200°C in the presence of ALP over 24 days.  
 
8.2.4.2. Degradation in foetal bovine serum solution (serum) 
To carry out further degradation experiments, Ca2P2O7 ceramics were aged in serum 
since further increase in the concentration of ALP was found to have no effect 
(Figure 8.17). Rather than increase the concentration of ALP significantly serum 
which is cheaper and thought to contain enzymes with pyrophosphatase activity was 
used. Due to the increased compressive strength ceramics sintered at 1200°C with 
P:L 3.0 g/mL (Figure 8.10b) were used. The ceramic was degraded over 26 days in 
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serum and as a negative control brushite cement at the same P:L ratio was degraded 
in serum and PBS solution. Over a period of 26 days 38 wt% of the original brushite 
cement was degraded in serum and 14 wt% of the original brushite cement degraded 
in PBS solution (Figure 8.18). The increased degradation of brushite cement in 
serum than in PBS solution follows that previously reported by Grover et al. (Grover 
et al., 2003). Brushite is more soluble than HA in physiological condition, therefore 
apatite formation within brushite cement decreases the cement degradation (Theiss et 
al., 2005). Apatite formation within brushite cement is inhibited by serum therefore 
the brushite cement degrades at a normal rate (Grover et al., 2003). Only 3 wt% of 
the original sintered Ca2P2O7 ceramic degraded in serum (Figure 8.18). The slow 
degradation of Ca2P2O7 ceramic was surprising as the presence of proteins and 
enzymes such as pyrophosphatases were expected to enhance degradation.  
 
Figure 8.18: Degradation profile of brushite cement and Ca2P2O7 ceramic at P:L 3.0 
g/mL  and 1200°C in foetal bovine serum (serum) for 26 days at 37°C. 
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The SSA of brushite cement at 3.0 g/mL is 1.013 ± 0.122 m2/g whereas that of 
Ca2P2O7 ceramic at 1200°C and 3.0 g/mL is 0.318 ± 0.002 m
2/g. The porosity of the 
brushite cement is 21 ± 1% while that of the Ca2P2O7 ceramic is 30 ± 2% illustrating 
the significant effect SSA has on the rate of materials degradation in comparison to 
porosity.  The sintering temperature and P:L ratio of Ca2P2O7 ceramic was reduced to 
400°C from 1200°C and to 2.5 g/mL from 3.0 g/mL respectively. These changes 
produced a significant increase in SSA from 0.318 ± 0.002 m2/g to 8.658 ± 0.847 
m2/g whereas the porosity increased only slightly from 30 ± 2% to 32 ± 2% a change 
that was statistically insignificant. 21 wt% of the Ca2P2O7 ceramic (P:L = 2.5 g/mL) 
sintered at 400°C degraded in serum while 50 wt% degraded in PBS solution over 28 
days (Figure 8.19).  
 
Figure 8.19: Degradation of Ca2P2O7 ceramic sintered at 400°C with a P:L of 2.5 
g/mL in serum and PBS solution. 
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At P:L ratio of 2.5 g/mL the microstructure of Ca2P2O7 ceramic sintered at 400°C 
shows that the particles are fused together but the particles are visible and the large 
pore structure would enable the degradation to proceed easily (Figure 8.20a). The 
degradation was slowest when the P:L ratio was increased to 3.0 g/mL and the 
sintering temperature was increased to 1200°C. The microstructure of the ceramic 
shows that the neck formed during sintering are tightly fused and the pores are 
reduced making it very difficult for small particles to be released from the ceramic 
matrix (Figure 8.20b).  
 
Figure 8.20: Microstructure of a) sintered Ca2P2O7 ceramic (P:L = 2.5 g/mL, 400°C) 
and b) sintered Ca2P2O7 ceramic (P:L = 3.0 g/mL, 1200°C). 
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8.3. DISCUSSION 
8.3.1. Ceramic characterisation 
Brushite cement was heat treated to temperatures ≥ 400°C to form Ca2P2O7 ceramic. 
The formation of Ca2P2O7 occurred in two stages (i) the dehydration of brushite to 
form monetite and (ii) the condensation of monetite to form Ca2P2O7 (equations 
8.10b and 8.10c). The dehydration of brushite to form monetite occurs at 
temperatures ≥ 55°C (Grover et al., 2005; Safronova et al., 2007). The XRD and 
DTA analysis showed that this reaction takes place at about 100°C and goes to 
completion at 200°C (Figures 8.2 and 8.4). Assuming the cement setting reaction 
was in accordance with equation 8.7a using an acid concentration of 3.5M the matrix 
should consist of 92 wt% brushite and 8 wt% unreacted β-TCP.  Based on this the 
theoretical weight loss following heating to 200°C should be 19 wt%. 
                                    ... (8.10a) 
                           ... (8.10b) 
The observed weight loss using the data from the DTA analysis was about 12 wt%, 
the inconsistency between these two figures could be due to the cement setting 
reaction not going to completion.  At 200 – 500°C all the monetite present was 
converted to γ-Ca2P2O7 by a condensation reaction as illustrated in equation 8.10c. 
This conversion to γ-Ca2P2O7 was confirmed by XRD, DTA and TGA results 
showing a weight loss of 6.3% between 200 – 400°C, this is in line with theoretical 
weight loss calculated to be 6%. Further phase changes occur within the ceramic at 
550 – 1100°C converting γ-Ca2P2O7 to β-Ca2P2O7. The phase change from β-
Ca2P2O7 to α-Ca2P2O7 occurs at 1200°C as confirmed by XRD (Figure 8.3) and 
Rietveld plot (Figure 8.14). These phase changes which occur when brushite is 
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heated in air is in line with that observed by Safronova et al. (Safronova et al., 2007). 
At temperatures above 1200°C a glass phase was formed within the ceramic which 
caused the material to melt and thus lose its shape (Gbureck et al., 2008).  
                       … (8.10c) 
There are three stages of sintering: initial, intermediate and final stage. Solid state 
sintering progresses along these stages as the sintering temperature is increased. The 
initial phase of sintering is associated with growth and formation of contact points 
(necks) between the particles of the compact cement/ceramic. The particles of 
Ca2P2O7 ceramic were shown to contact and coalesce between 400 – 700°C (Figure 
8.6b and 8.6c). As the sintering temperature is increased further the sintering enters 
the intermediate stage whereby the necks formed merge and shrink resulting in the 
formation of interconnected pores along the particle junctions. The microstructure of 
the ceramic sintered at 1000°C showed the sintering to be at the intermediate stage 
(Figure 8.6d). The final stage of sintering which occurs at 1200°C involves pore 
closure and further crystal densification (Figure 8.6e).  
 
As discussed above the increase in sintering temperature results in the densification 
of the crystals and increased pore closure within the ceramic matrix therefore 
volumetric shrinkage is increased (Figure 8.11a and 8.12). The conversion of 
brushite to monetite and then Ca2P2O7 were the only chemical reactions that occurred 
within the ceramic therefore so there was little mass loss as the sintering temperature 
was increased from 400 – 1200°C (Figure 8.11b). TGA analysis confirmed that there 
was little change in the weight of the ceramic 400°C (Figure 8.4). The SSA of 
Ca2P2O7 at P:L ratio of 1.5 g/mL reduced with increasing sintering temperature. This 
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is due to larger particle size which as explained above occurs through crystal growth. 
The compressive strength increased from 2.5 ± 0.9 MPa to 7.5 ± 2.0 MPa over 400°C 
to 1200°C due to the reduction in pore sizes i.e. ceramic densification as the sintering 
temperature is increased (Figure 8.7).  
 
For uniformly shaped and sized crystals the pore spacing is uniform therefore it is 
uniformly eliminated as the sintering temperature is increased (Figure 8.21a). For 
irregularly shaped and sized crystals the pore spacing would vary so that it is not 
uniformly eliminated with increase in sintering temperature (Figure 8.21b).  
 
Figure 8.21: Schematic diagram showing the pore spaces between a) uniform crystals 
of the ceramic and b) crystals of different shape and size within the ceramic.  
 
The uniformity of crystal shape and size also ensures that ceramic densification is 
increased with increased sintering time i.e. compressive strength should increase 
with increasing sintering time. Since Ca2P2O7 ceramic consists of crystals with 
irregular shape and size (Figure 8.5) the pore spaces are not uniformly reduced 
therefore compressive strength did not increase with increase in sintering time (Table 
8.1). The porosity of the post sintered Ca2P2O7 ceramic did not reduce with increase 
in sintering time (Table 8.1). This is due to the competing effect of neck formation 
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and growth (pore formation/closure) which is affected by sintering temperature and 
crystal densification which is affected by sintering time.  
 
Interestingly, although increasing sintering temperature from 400ºC to 1000ºC 
caused an increase in the mean compressive strength of the post-sintered ceramic; 
there was not a corresponding reduction in porosity (Figure 8.8 and 8.10). This is 
surprising since it is established that compressive strength is inversely proportional to 
porosity (equation 8.5). For ceramics with P:L ratio of 2.0 g/mL  the increase in 
porosity when the sintering temperature was increased from 400°C to 700°C was 
statistical significant (Figure 8.8). The increase in porosity is due to the growth of 
„neck‟ formed between the crystals of the ceramic creating larger pores. Further 
increase in sintering temperature resulted in further densification resulting in the 
reduction of porosity. For ceramics at P:L ratio of 2.5 and 3.0 g/mL any change in 
porosity between 400°C and 700°C was of no statistical significant (Figure 8.10). For 
all the ceramics at P:L 2.0, 2.5 and 3.0 g/mL the compressive strength increased with 
sintering temperature up to 1000°C (Figure 8.8 and 8.10). The reduction in 
compressive strength of Ca2P2O7 ceramic sintered at 1200°C (Figure 8.8 and 8.10) 
could be the result of microcracks which were shown to be present within the 
ceramic matrix (Figures 8.9).   
 
As P:L ratio is increased the amount of crystals present within the cement matrix 
increases therefore the pore spaces are reduced. This ensures that the pore closure 
within individual crystals is more uniform as the sintering temperature increases, 
therefore porosity is gradually reduced as sintering temperature is increased (Figure 
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8.12). The increase in the number of particles present within the ceramic matrix also 
ensures that as the crystals grow the volumetric shrinkage of the ceramic is reduced 
(Figure 8.15). As the P:L ratio of brushite cement is increased the β-TCP content 
within the cement is increased which means the brushite content reduces (Table 8.3). 
Therefore the corresponding Ca2P2O7 content of the ceramic is reduced and the 
compressive strength of the ceramic reduced (Table 8.3) (Grover et al., 2003). The 
corresponding decrease in the amount of brushite present within the cement means 
that the water which is evaporated through condensation reactions (equation 8.2 and 
8.3) is reduced. Therefore mass loss from the Ca2P2O7 ceramic is reduced (Figure 
8.15). Using equation 8.1, as H3PO4 acid concentration is increased the amount of 
brushite crystals present within the cement is increased (Table 8.3). This means that 
the amount of water evaporated from the brushite cement post sintering is increased 
from 9% (1.5 M H3PO4 acid) to 21% (4.5 M H3PO4 acid), therefore mass loss is 
increased (Figure 8.13a). The increase in brushite crystals means that the crystals 
become larger when sintered and the pores present are decreased leading to increase 
in the volumetric shrinkage of the ceramic.    
 
8.3.2. Ceramic degradation  
As noted with CPPD crystals, Ca2P2O7 ceramic degradation was enhanced in the 
presence of ALP (Figure 8.16). The Ca2P2O7 ceramic was structurally unstable over 
16 days therefore smaller ceramic particles were easily released into solution and 
degraded into Ca2+ and P2O7
4- ion. The P2O7
4- ion is then hydrolysed by ALP thereby 
driving Ca2P2O7 ceramic degradation further. Once the P:L ratio was increased from 
1.25 – 1.5 g/mL the ceramic matrix became structurally stable in solution and the 
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effect of ALP was not realised (Figure 8.17). The structural stability of the ceramic at 
P:L of 1.5 g/mL ensured that smaller particles are not easily released into solution. 
Increasing the ALP concentration 8 fold did not enhance ceramic degradation 
confirming the assumption that ceramic degradation just as crystal dissolution did not 
take place through surface cleaving by ALP enzyme. By increasing the P:L ratio 
from 1.25 g/mL to 1.5 g/mL (sintering temperature was kept constant at 1200°C) the 
SSA was reduced from 0.347 m2/g to 0.319 m2/g (obtained from a single 
experiment). This shows that as the SSA in increased the mass of ceramic which 
degrades in ALP and control Tris HCl solution increases.  
 
Brushite cement was found to degrade faster in serum than in PBS solution (Figure 
8.18). This is due to serum inhibiting apatite formation within brushite cement as 
reported by Grover et al. (Grover et al., 2003). The mass percentage of Ca2P2O7 
ceramic (3 wt%) which degraded in serum was much lower than that of brushite 
cement (38 wt%) in the same solution and at the same P:L ratio. The porosity of the 
brushite cement (21 ± 1%) is lower than that of the calcium pyrophosphate ceramic 
(30 ± 2%) which was sintered at 1200°C. The SSA of brushite cement was measured 
as 1.013 ± 0.122 m2/g but once it was sintered at 1200°C to form Ca2P2O7 the SSA 
was reduced significantly to 0.318 ± 0.002 m2/g. The increased porosity in the 
sintered ceramic did not result in an increase in degradation, therefore the 
degradation rate of the cement and ceramic is affected by the SSA and not porosity 
(Barralet et al., 2002).  
Figure 8.7 shows that at P:L = 1.5 g/mL the increase in sintering temperature results 
in the reduction of SSA of Ca2P2O7 ceramic. Increasing the P:L ratio of the ceramic 
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from 1.25 g/mL to 1.5 g/mL resulted in the decrease in SSA (stated above). The 
decrease in sintering temperature from 1200 – 400°C and the reduction in P:L from 
3.0 – 2.5 g/mL resulted in an increase in  SSA of the Ca2P2O7 ceramic from 0.318 ± 
0.002 m2/g to 8.658 ± 0.847 m3/g. The increase in SSA produced a corresponding 
increase in the mass of Ca2P2O7 ceramic which degraded in serum from 3 wt% to 21 
wt% of the original (Figure 8.19). Surprisingly Ca2P2O7 ceramic degradation was not 
enhanced in serum even though it is expected to contain active phosphatase and 
pyrophosphatase enzyme. Figure 8.19 shows that 50 wt% of the original Ca2P2O7 
ceramic degraded in PBS solution as compared with 21 wt% in serum. It is suspected 
that the presence of calcium and orthophosphate ion in serum is responsible for 
significantly reducing the rate of ceramic degradation as compared with the PBS 
solution. Besides the SSA, increased ceramic degradation at lower sintering 
temperature and P:L ratio can be attributed to their microstructure (Figure 8.20). The 
microstructure of brushite cement shows the presence of crystals which are easily 
removed from the cement matrix leading to fragmentation (Figure 8.20a). The 
particles of Ca2P2O7 ceramics are tightly held together by strong primary bonds and 
the crystals are tightly fused (Figure 8.20).  As the sintering temperature is increased 
the crystals grow larger and it is therefore more difficult for ceramic fragmentation to 
occur.  
 
Finally the degradation of Ca2P2O7 ceramic in serum is thought to occur by: (1) the 
release of smaller particles from the ceramic matrix into solution and (2) the 
hydrolysis of the small particles into its component ions and (3) enzyme mediated 
degradation of the component ion.  
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8.4. CONCLUSIONS 
Ca2P2O7 ceramic was successfully synthesised by the thermal treatment of brushite 
cement at temperatures ≥ 400°C. The formation of Ca2P2O7 ceramic was confirmed 
using XRD, TGA and DTA analysis. Generally the compressive strength of the 
sintered ceramic increased with increased sintering temperature up to 1000°C. The 
presence of microcracks within the ceramic structure that was sintered at 1200°C was 
responsible for the decrease in the compressive strength. Although expected, the 
porosity of Ca2P2O7 ceramic did not reduce with increase in compressive strength 
and sintering temperature. This is due to the competing effect of ceramic 
densification and density changes associated with phase change. The variations in 
P:L was found to have an effect on the mass loss, volumetric shrinkage and 
compressive strength of the ceramic. Ca2P2O7 ceramic at P:L of 1.25 g/mL degraded 
faster in ALP solution than the control. Increasing the P:L ratio resulted in a more 
structurally stable ceramic, therefore pyrophosphate ion was released into the ageing 
solution at low concentration and ALP could not enhance the ceramic degradation. 
The increase in ALP concentration did not produce a corresponding increase in the 
mass of sintered ceramic which degraded in ageing solution. Therefore Ca2P2O7 
ceramic was aged in serum solution which is expected to contain phosphatase and 
pyrophosphatase enzymes. The control experiment involved degrading brushite 
cement in serum and PBS solution. The brushite cement degraded faster than the 
sintered Ca2P2O7 ceramic and it also degraded faster in serum than in PBS solution. 
The increased degradation of brushite in serum than PBS solution is the result of 
serum inhibiting the formation of apatite within the brushite cement. Brushite cement 
has a larger SSA than Ca2P2O7 ceramic and its crystals are easily removed from the 
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cement matrix result in the fragmentation of the cement. When the sintering 
temperature was reduced from 1200°C to 400°C and the P:L ratio was reduced from 
3.0 g/mL to 2.5 g/mL the SSA of the resulting Ca2P2O7 ceramic increased 
significantly. The increase in SSA was reflected in the reduction in particle size as 
observed using SEM. The change in cement composition and process variable 
resulted in an increase in the mass of Ca2P2O7 ceramic which degraded in serum 
solution. The Ca2P2O7 ceramic degradation was faster in PBS solution than in serum 
due to the likelihood that calcium and orthophosphate ion present in serum inhibited 
the Ca2P2O7 ceramic degradation.   
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9. FABRICATION OF CALCIUM PYROPHOSPHATE CERAMIC 
USING STEREOLITHOGRAPHY 
In this thesis it has been established that CPPD crystal dissolution may be accelerated 
in the presence of ALP and it has also been demonstrated that this can be scaled up 
so that sintered Ca2P2O7 ceramic exhibit the same degradation profile. Sintered 
ceramics are difficult to shape as required but this can be made possible by using 
various rapid prototyping processes. Rapid prototyping also enables the production 
of reproducible ceramic materials. Some rapid prototyping processes have been 
discussed below.  
 
Selective laser sintering (SLS) 
A thin layer of powder is spread on a flat surface using a cylindrical roller. A high 
precision carbon dioxide (CO2) beam scans the powder bed and selectively sinters 
the powder to fuse certain areas as defined by the geometry of the computer aided 
design (CAD) model. The areas of the powder which are not sintered by the laser 
beam are used for support to build subsequent layers. A piston or inkjet printer head 
is used to spread a new layer of powder which is then fused with the previous one 
layer by the laser beam. The process is repeated until the desired material is built. 
SLS can bind powders directly without the aid of binders (Tay et al., 2003).   
 
Three dimensional printing (3D printing) 
3D printing uses the technology of an ink jet printer (Gbureck et al., 2007; Safari et 
al., 2001). A roller or mechanical, acoustic, ultrasonic vibration is used to roll and 
level dry powder into a thin layer. The inkjet printer then sprays a binder onto the 
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powder in selected area depending on the material geometry designed using CAD. 
Once that layer dries a new powder layer is laid down and the process is repeated 
until the desired shape is realised.  3D printing is a flexible process which employs 
the use of various powders and binders in a single fabrication process to build a 
material of various geometries.  
 
Laminated object manufacturing 
Laminated object manufacturing was developed in 1985 to build components with 
layers of paper or plastic (Tay et al., 2003). The sheet feedstock is cut to a defined 
structure using a laser before it is sprayed with an adhesive solvent. Another layer is 
placed upon the previous one before pressing with a heated roller and thereby 
activating the adhesive. 
 
Fusion deposition modelling  
The deposition of fused ceramics was developed at Rutgers University (Agarwala et 
al., 1996) using the fusion deposition modelling technique. A material feedstock 
(combination of polymer and ceramic) are heated close to the melting point inside a 
heated liquefier head before being extruded through the nozzle of a small orifice 
(Leong et al., 2003). The motion of the liquefier is computer controlled (x-and y- 
direction). Once the material has been extruded it solidifies and welds to the previous 
layer. Controlling the direction of material deposition ensures that the pore structure 
and interconnectivity can also be controlled. 
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Stereolithography 
Stereolithography was the first solid freeform fabrication technique to be developed 
(Hull, 1996) and has since been modified to produce ceramic materials (Griffith and 
Halloran, 1996). Stereolithography is a process by which 3D biomaterials can be 
produced in a layer by layer method. The material which is to be produced using 
stereolithography is designed using CAD. Figure 9.1 is a schematic diagram of the 
operation of a typical stereolithography apparatus.  
 
 
Figure 9.1: Schematic diagram showing the operation of a typical stereolithography 
apparatus.  
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The photocurable polymer resin (or polymer/ceramic composite) deposited on a bath 
plate is exposed to ultraviolet (UV) light (beam) is controlled in x- and y- direction 
(Tay et al., 2003). The liquid polymer is polymerised (cured) selectively depending 
on the geometry designed on the CAD program. After the initial layer is cured the 
elevator raises the sample so that another polymer layer is cured as shown in figure 
9.1.  
 
Once the materials fabrication is completed unreacted resin is washed off and the 
material is post cured. The polymer binder is „burnt off‟ through sintering to leave 
the ceramic material. Although various rapid prototyping processes are used for 
producing 3D materials, stereolithography was used in this thesis to produce bespoke 
Ca2P2O7 implants. By using stereolithography it is easy to control the microstructural 
properties of ceramic materials such as porosity and pore connectivity. The operating 
conditions for the industrial Perfactory3® XGA Desktop (envisionTEC, Germany) 
stereolithography machine were also investigated. The ceramic loading of the 
polymer/ceramic suspension was also investigated to ensure that the powder is 
present in sufficient amount so that the ceramic matrix after sintering is structurally 
stable materials. Therefore the compressive strength of the sintered ceramic would 
increase with ceramic loading. The polymer used should be sufficiently viscous in 
order that is also important that β-Ca2P2O7 powder is uniformly distributed within the 
composite material. 
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9.1. MATERIALS AND METHODS 
9.1.1. Preliminary investigation 
Initial experiments involved curing calcium pyrophosphate ceramic and polymer 
suspension using a light engine which used an LED as its light source before 
transferring the formulation onto the industrial Perfactory3® XGA Desktop 
(envisionTEC, Germany) stereolithography machine. The polymer cured using the 
light engine was a mixture of 70 wt% 1, 6-Hexanediodiacrylate (HDDA; Sigma 
Aldrich, Dorset) and 30 wt% N-methyl-2-pyrolidone (pyrolidon, Sigma Aldrich, 
Dorset). β-Calcium pyrophosphate powder (β-Ca2P2O7; Sigma Aldrich, Dorset) was 
added to the polymer mixture at a loading of 40 wt%. To this ceramic suspension 
Triton XL 100 (Sigma Aldrich, Dorset) a dispersant was added at 4 wt% of the 
ceramic. The dispersant ensures that the ceramic does not settle or coagulate within 
the polymer. The suspension was then mixed on a magnetic stirrer for 2-3 days to 
ensure that large ceramic particles were dispersed within the polymer mixture. α-
benzyl-α-(dimethylamino)-4-morpholinobutyrophenon (Sigma Aldrich, Dorset) a 
photoinitiator was added at 4 wt% of the ceramic content. A thin layer of the ceramic 
suspension was placed on a glass plate in the light engine with a 0.5 cm2 aperture 
exposing it to the LED light source (ENFIS LTD, Swansea). The LED power output 
is up to 38 W and the wavelength is between 365 – 870 nm. The single layer was 
cured before being placed in the light box for 10 seconds to cure any unreacted 
polymer. The cured ceramic material was then cleaned with propan-2-ol (Fisher 
Scientific, UK) to remove any remaining unreacted polymer.  
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Although the ceramic suspension of HDDA, pyrolidon and β-Ca2P2O7 ceramic was 
shown to cure on the light engine it was not possible to build a ceramic monolith on 
the Perfactory3® XGA Desktop. Various polymers were mixed with β-Ca2P2O7 
powder and precipitated brushite crystals (precipitation method was described in 
chapter 7) and the viscosity of the resulting suspensions were measured. The 
viscosities of the suspensions were measured at a shear rate of 0.01 s-1 with 40 mm 
plate geometry on AR-Rheometer (TA Instruments, UK). The polymer mixture 
investigated are: 1) HDDA and trimethylolpropane triacrylate (TMPTA, Sigma 
Aldrich, Dorset), 2) HDDA and pyrolidon and 3) dipentaerythritol penta-/hexa-
acrylate (DPA; Sigma Aldrich, Dorset) and 1, 6-Hexanediol ethoxylate diacrylate 
(HDeDA; Sigma Aldrich, Dorset). The particle size of the precipitated brushite 
crystals and β-Ca2P2O7 ceramic powder purchased from Sigma Aldrich were 
measured using a Mastersizer (Malvern Instruments, UK). The sintered Ca2P2O7 
ceramic was not used in these experiments as it was not possible to grind it into very 
fine powder which would be properly suspended within the polymer matrix.  
 
9.1.2. Formation of Ca2P2O7 monolith using stereolithography 
The new polymer mixture consisted of 70 wt% of DPA and 30 wt% HDeDA. β-
Ca2P2O7 powder was added gradually to the polymer mix at 40 wt% before mixing 
for 2 - 3 day depending on the dispersion of the ceramic. The photoinitiator was 
added at 3 wt% of the polymer and a dye, orange orasul (Sigma Aldrich, Dorset) was 
also added at 0.05 wt% of the ceramic content. The dye is a photo inhibitor that 
ensures the ceramic suspension is cured at a controlled rate by preventing 
spontaneous polymerisation. Prior to successfully fabricating Ca2P2O7 monolith on 
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the Perfactory3® XGA Desktop the viscosity of the ceramic suspension at various 
ceramic loading was measured. After 2.5 h experimental time nine Ca2P2O7 ceramic 
cylinders with an average height of 8 mm and diameter of 4 mm were produced.  
 
9.1.3. Material characterisation 
The ceramic polymer composite was then characterised using simultaneous thermal 
analysis (STA 1500, Stanton Redcroft). This equipment enables the change in mass 
and heat flow within the ceramic to be monitored with increasing temperature (25 – 
1200°C). The STA was operating at a flow rate of 50 mL/min and at a heating rate of 
20°C/min. The crystalline composition of the sintered Ca2P2O7 monolith was 
monitored and confirmed using XRD. The X-ray diffraction was carried out as 
described in section 8.1.2 using a step size of 0.015° and a step time of 0.25 s.  
9.1.3.1. Effect of sintering temperature on ceramic density and 
microstructure 
After burning off the polymer binder the ceramic is left in the furnace for further 
densification. As the sintering temperature is increased the change in density of the 
remaining ceramic matrix is measured using a helium pycnometer (Micromeritics, 
Bedfordshire). The microstructure of the ceramic/polymer composite and the sintered 
ceramic is observed using SEM. It was not possible to obtain geometrical 
measurement of the sintered ceramic due to the structural instability of the resulting 
matrix.   
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9.2. RESULTS  
It is important that the polymer used in binding β-Ca2P2O7 powder or brushite 
crystals cured once exposed to UV light. Therefore initial investigation involved 
testing various photocurable polymers which would suspend the powder and cure 
once exposed to the LED light source (Figure 9.2).   
 
Figure 9.2: Initial investigation into the fabrication of Ca2P2O7 ceramic by curing 
polymer/ceramic suspension on a light engine.  
 
Since it took 2.5 h to produce nine cylindrical ceramic/polymer composites (Figure 
9.4a), the viscosity of the polymer is also very important; the polymer should be 
sufficiently viscous to enable suspension of the ceramic solid component while the 
material is fabricated on the stereolithography machine. The mixture of HDDA and 
TMPTA was used as the polymer which when mixed with brushite crystals the 
viscosity was 207 Pas which fell drastically to 0.4 Pas when β-Ca2P2O7 powder was 
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used. The particle size of β-Ca2P2O7 powder is twice as large as that of precipitated 
brushite crystals (Table 9.1); this is thought to have contributed significantly to the 
reduction in viscosity.   
Table 9.1: Effect of polymer and particle size on the viscosity of ceramic suspension. 
Material 
type 
Particle Size 
(μm) 
Viscosity of polymer and 
cement/ceramic suspension (Pas) 
HDDA + 
TMPTA 
HDDA + 
Pyrolidon 
HDeDA + 
DPA 
Brushite 79.90 ± 1.04 207.2 35,640.0 42,800.0 
β-Ca2P2O7 170.42 ± 41.03 0.418 1.404 9.383 
 
The larger the particle size of the powder component the more difficult it is to be 
suspended within the polymer. The large particles of the β-Ca2P2O7 powder settled to 
the bottom of the suspension during the fabrication process. By mixing the 
ceramic/polymer suspension vigorously some of the larger particles are broken down 
into smaller particles which are easily suspended within the polymer. It was difficult 
to fabricate brushite materials using the Desktop because of the extremely high 
viscosity of the brushite/polymer suspension. In comparison, the extremely low 
viscosity of the HDDA and pyrolidon mixture made it difficult to fabricate the β-
Ca2P2O7 using the desktop. The polymer mixture was changed but this did not 
produce a successful fabrication process until a dye was added.  
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The addition of a dye and photoinitiator to the HDeDA, DPA and β-Ca2P2O7 mixture 
resulted in a decrease in viscosity from 9.38 Pas to 1.47 Pas as shown in figure 9.3. 
The viscosity of the ceramic suspension at 40 wt% calcium pyrophosphate was 
measured at shear rates in the range of 0.01 – 100 s-1.   
 
Figure 9.3: Viscosity of β-Ca2P2O7 and polymer suspension as a function of shear 
rate at 40 wt% ceramic loading. 
 
The movement of the elevator over the ceramic suspension (Figure 9.1) can have an 
effect on the viscosity of the suspension therefore it was of great importance that 
there was no sudden change in the viscosity of the suspension with changes in shear 
rate (Figure 9.3). The formulation consisting of β-Ca2P2O7 ceramic, HDeDA and 
DPA polymer was successfully fabricated on the stereolithography machine as is 
shown in figure 9.4a. Each layer that makes up the ceramic cylinder shown in figure 
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9.4a is 25 μm thick. Once sintered the orange dye was decomposed at high 
temperature, along with the polymer binding the ceramic (Figure 9.4b).  
 
Figure 9.4: Photograph of a) cured 40 wt% calcium pyrophosphate ceramic 
suspension and b) the ceramic and polymer composite material after sintering at 
800°C for 3 h.  
 
Figure 9.4b shows that at 40 wt% β-Ca2P2O7 ceramic loading the ceramic matrix did 
not retain it cylindrical shape. The thermogravimetric analysis shows that the 
polymer decomposition began at about 315°C and continues to about 600°C (Figure 
9.5a). There was no phase change within the Ca2P2O7 ceramic as the sintering 
temperature was increased (Figure 9.5b).  The increase in heat flow within the 
ceramic is associated with the decomposition of HDeDA, DPA, photoinitiator and 
the dye as shown in figure 9.5a. The β-Ca2P2O7 powder added to the polymer 
mixture was found to contain β-TCP as well as β-Ca2P2O7 (Figure 9.5b). 
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Figure 9.5: a) Effect of temperature on the heat flow and mass changes of the cured 
40 wt% Ca2P2O7 ceramic and b) effect of sintering temperature on the chemical 
composition of fabricated Ca2P2O7 ceramic.  
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There was no chemical reaction between the ceramic powder and the polymer as 
there was no change in the crystalline composition of β-Ca2P2O7 after sintering. It 
was not possible to see the crystals with defined shape and size β-Ca2P2O7 within the 
composite material (Figure 9.6a). As the sintering temperature was increased from 
410°C to 1200°C β-Ca2P2O7 crystals became densified and the particle size increased 
(Figure 9.6).  
 
 
Figure 9.6: SEM micrograph of: a) cured Ca2P2O7 ceramic, b) cured ceramic sintered 
at 410°C to remove the polymer binder, c) sintered at 1000°C for 3 h  and d) sintered 
at 1200°C for 8 h.  
 
 
 
163 
 
The density of the sintered ceramic increased with sintering temperature. In this case, 
the significant increase in density of the ceramic with temperature can be attributed 
to the decomposition of the relatively low density (specify) polymeric phase. Figure 
9.7 provides further evidence that the polymer was fully decomposed by 600°C as 
shown in figure 9.5a. 
 
Figure 9.7: Effect of sintering temperature on the density of the fabricated Ca2P2O7 
ceramic.  
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9.3. DISCUSSION 
Stereolithography is a rapid prototyping process whereby three dimensional materials 
are produced layer by layer when a photocurable polymer is exposed to UV light. 
The particle size of ceramic material suspended within the polymer was found to 
have an effect on the viscosity of the ceramic suspension (Table 9.1). The viscosity 
of all the brushite suspension studied was found to be greater than that of the 
Ca2P2O7 suspension (Table 9.1). It has been reported that the viscosity of a ceramic 
suspension be below 5 Pas for its successful fabrication using stereolithography 
(Porter, Pilliar, & Grynpas 2001). The viscosity of all the brushite suspension was 
significantly higher than 5 Pas and therefore it was not possible to fabricate 
monoliths from it. The viscosity of the Ca2P2O7 suspension was lower than 5 Pas 
except were the ceramic was suspended in HDeDA and DPA polymer. It was not 
possible to fabricate composite materials from the mixture of HDeDA, DPA and 
Ca2P2O7 until a photo inhibitor (dye) was added (Figure 9.4a). Prior to composite 
fabrication on the Desktop various polymer mixtures were tested one of which was 
HDDA and pyrolidon. This polymer with the addition of β-Ca2P2O7 powder was 
cured using the light engine (Figure 9.2). As the HDDA and pyrolidon polymer 
mixture was not sufficiently viscous to suspend a higher ceramic loading it was not 
used on the Desktop.  
 
Despite preparing sintered Ca2P2O7 ceramic (chapter 8) this was not used in this 
investigation as the particles of the ground ceramic were not small enough to be 
suspended within the polymer. The ceramic suspension was expected to contain 28 
wt% Ca2P2O7 ceramic but from the TGA graph 24 wt% of the ceramic was detected 
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when the polymer was decomposed at 550°C (Figure 9.5a). The Ca2P2O7 ceramic 
was not uniformly distributed throughout the polymer binder which could be the 
reason why there was a difference in the actual and expected weight of the remaining 
ceramic. β-TCP was found to be contained within the β-Ca2P2O7 powder purchased 
from Sigma Aldrich (Dorset, UK). The cured monolith has to be sintered at 
temperatures greater than 410°C for the polymer binder to be removed (Figure 9.5a). 
Sintering temperature was also shown to have no effect on phase change within the 
Ca2P2O7 ceramic as shown in figure 9.5b. As sintering temperature is increased the 
crystallites from which the ceramic was composed become larger as is shown in 
figure 9.6. As discovered using TGA analysis the burning off of the polymer began 
at about 410°C and finished at about 600°C. Therefore the true density increased 
from 1.5 gcm-3 for the composite material to 3.1 gcm-3 when the polymer was burnt 
off completely at 600°C. Subsequent heating of the remaining ceramic material 
produced slight increases in the true density of the material (Figure 9.7). The 
difficulty in using stereolithography is the relatively low ceramic loading which 
means that the sintered material is structurally unstable and the compressive strength 
cannot be measured. Further experiment is needed to investigate polymers and 
various operating conditions which would enable higher ceramic loading and 
subsequently more structurally stable materials.    
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9.4. CONCLUSION 
Ca2P2O7 composite discs were successfully produced on a light engine exposed to an 
LED light source. The polymer used was then changed and a photo inhibitor added to 
avoid uncontrolled polymerisation before fabricating composite materials on the 
Desktop. The viscosity of the polymer/brushite suspension was very high due to its 
smaller particle size in comparison with that of β-Ca2P2O7 powder. The extremely 
high viscosity prevented the fabrication of brushite composite materials on the 
stereolithography instrument. The polymer used in the production of Ca2P2O7 
composite did not affect the crystalline composition of the material. TGA analysis 
showed that the polymer binder was burnt off at temperature between 410 – 600°C. 
XRD pattern showed that the powder added to the polymer mixture was a 
combination of β-Ca2P2O7 and β-TCP and remained unchanged with increasing 
sintering temperature. 
 
The crystallites of the composite were further densified as the polymer was 
completely burnt off with increased sintering temperature. This followed the trend 
observed in ceramic materials as shown in chapter 8. The material which remained 
after sintering was structurally unstable due to low ceramic loading. This also 
prevents compressive testing and geometrical testing of the ceramic matrix.   
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10. RESEARCH FINDINGS, CHALLENGES, CLINICAL 
IMPLICATIONS AND ALTERNATIVE APPROACHES. 
Worldwide around 2.2 million bone graft procedures are carried out in the repair of 
bone defect in orthopaedics and dentistry (Lewandrowski et al., 2000). Bone tissue 
taken from the patients themselves (autograft) is still the gold standard in the repair 
of bone defect as it provides the optimum osteoconductive, osteoinductive and 
osteogenic properties required (Giannoudis et al., 2005).  Post operative pain, 
increased operating time and cost are some of the disadvantages associated with the 
autograft procedure (Ilan and Ladd, 2002). When a large amount of tissue is required 
and cannot be obtained from the patient, tissue is taken from another individual 
(allograft tissue) to be used. Allograft tissue is osteoconductive but it has lost most of 
its osteoinductive properties (Giannoudis et al., 2005). There is also potential for 
infection and disease transmission with allograft tissue (Buck et al., 1989). To 
overcome these problems synthetic materials have been developed as an alternative 
to the biological bone graft (autograft and allograft). An ideal synthetic bone graft 
should be osteoconductive, osteoinductive, bioactive and bioresorbable (Giannoudis 
et al., 2005).  
 
Calcium phosphates cements are synthetic materials with a wide range of 
applications in the field of orthopaedics and dentistry due to their bioactive and 
osteoconductive properties, non-toxicity and chemical similarity to the mineral 
component of mammalian bones and teeth (Dorozhkin, 2010; Ginebra et al., 1997; 
Bohner, 2000).  TCP has a stoichiometry similar to amorphous bone precursors, 
whereas HA has a stoichiometry similar to bone mineral (Giannoudis et al., 2005). 
168 
 
The low stability of HA in physiological conditions is a limiting factor in its use as 
an implant. If the implant remains in situ for a long period of time there is likelihood 
of mechanical failure requiring the patient to return for surgery to replace the failed 
implant. For materials which degrade too fast it will be impossible for the implant to 
provide sufficient support to the new tissue formed. It is desirable to have a material 
that is resorbed over time leaving space for the formation of new tissue. The rate of 
bone turnover varies with the age, health and sex of the patient (Havill, 2004). 
Therefore it is difficult to link the rate of bone formation to the resorption of the bone 
implant. To overcome this problem a bioresponsive material should be used as the 
bone replacement. A bioresponsive material is one which will degrade in response to 
the presence of a biological stimulus which in the case of bone formation and 
mineralisation is ALP. It is therefore possible that each patient will produce ALP 
which will then regulate the degradation of the implant.  
 
The aim of the thesis was to formulate and produce a calcium pyrophosphate 
material which would degrade faster in the presence of ALP thereby developing a 
novel bioresponsive bone replacement. Xu et al. (Xu et al., 1991b) found that CPPD 
crystals which have the same dimensions as that found in the joints of patients 
suffering from pseudogout dissolved faster in the presence of ALP. ALP is also 
thought to perform an important role in bone mineralisation by removing P2O7
4- ion 
(a known inhibitor to bone mineralisation) (Anderson et al., 2004). ALP hydrolyses 
P2O7
4- ion to form PO4
3- ion which can then be used in the precipitation of apatite 
crystals which make up the inorganic component of bone (Thouverey et al., 2009). 
Therefore the research in this thesis began by confirming that CPPD crystals 
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dissolved faster in the presence of ALP. The results also showed that CPPD crystal 
dissolution was not achieved by a stereoselective process. The CPPD crystals 
dissolved in solution to produce Ca2+ and P2O7
4- ion before the P2O7
4- ion was 
hydrolysed by ALP to form PO4
3- ion. 
 
Once the interaction between the P2O7
4- ion and the ALP enzyme has been 
established, bulk calcium pyrophosphate ceramic was produced by sintering brushite 
cement at temperatures ≥ 400°C. The composition of the brushite cement was varied 
between 1.25 – 3.0 g/mL, once sintered for 5 h at temperatures between 400 – 
1200°C the compressive strengths of the ceramic was between 2.5 – 11.6 MPa which 
is within the range of that of cancellous bone (0.5 – 50 MPa, Table 2.1). The porosity 
of Ca2P2O7 ceramic (P:L = 1.25 g/mL) sintered at 1200°C was 32% while its 
compressive strength was 6.7 ± 0.8 MPa. This ceramic degraded faster in ALP (48 
wt%) solution over 16 days but the bulk ceramic was structurally unstable. From this 
result Ca2P2O7 ceramic at P:L 1.25 g/mL and 1200°C would probably not provide 
sufficient support for the new bone tissue formed. Once the P:L ratio was increased 
to 3.0 g/mL the compressive strength increased to 11.1 ± 1.8 MPa and the porosity 
decreased to 30%. Due to the cost of ALP enzyme it was impossible to continue the 
degradation experiment using ALP therefore the ceramic was degraded in serum 
solution. Serum is expected to contain proteins and enzymes with pyrophosphatase 
activity.   
 
Ca2P2O7 ceramic at P:L 3.0 g/mL and 1200°C was structurally stable throughout the 
degradation period but only 3 wt% degraded in serum over 26 days as compared to 
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38 wt% of brushite cement at the same P:L ratio which degraded in serum (Figure 
8.18). The SSA of the ceramic was found to be strongly linked to the degradation of 
the ceramic (Barralet et al., 2002). The sintering temperature and P:L ratio were 
reduced to 400°C and 2.5 g/mL respectively. The compressive strength of this 
ceramic was 9.5 ± 1.2 MPa and the porosity was 23%. The SSA increased from 
0.318 ± 0.002 m2/g (3.0 g/mL and 1200°C) to 8.658 ± 0.847 m2/g (2.5 g/mL and 
400°C). The mass of ceramic which degraded in serum increased to 20 wt% and it 
was structurally stable throughout the duration of the experiment (Figure 8.19). This 
confirms the link between SSA and ceramic degradation. Although no in vivo 
experiments were carried out in this thesis, the Ca2P2O7 ceramic is expected to be 
suitable for use in vivo due to suitability of similar materials (Lin et al., 1995b; Sun 
et al., 2002). The limitation of sintering is that it is difficult to produce an implant 
which can fit irregular shaped bone defects. Although there has been development in 
the design of mouldable cements the difficulty in tailoring implant degradation to 
bone formation still exists (Frayssinet et al., 1998). To overcome this problem the 
final part of this thesis investigates the use of stereolithography to fabricate Ca2P2O7 
ceramic which can be designed to fit any size defect.  
 
It is possible to obtain an X-ray of a bone defect requiring bone implant, design the 
implant using a computer aided design programme before fabricating on the 
stereolithography machine. Preliminary investigations carried out in this thesis 
showed that it was possible to fabricate a Ca2P2O7 and polymer composite material. 
Once the material is sintered between 410 – 600°C the polymer is burnt off leaving 
the Ca2P2O7 ceramic. Only 24 wt% of the ceramic remained once the polymer was 
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burnt off even though the composite mixture was loaded at 40 wt% of the polymer. 
The low ceramic content led to the production of ceramic materials which were not 
structurally stable leading to loss of the shape of the implant designed. This problem 
of loss of ceramic structure does not overcome the limitations associated with 
material sintering. The main challenge in this part of the research was the difficulty 
in increasing the ceramic content of the material. It is therefore necessary to further 
research polymers which would enable the incorporation of larger amounts of 
ceramic powder and experimental conditions which would also enable higher 
ceramic content. An alternative approach to using stereolithography would be to 
investigate a process by which the ceramic powder can be used to make the implant 
without requiring a polymer binder. Therefore the material would not be sintered, 
thereby retaining the shape of the bone defect.   
 
To conclude the bulk calcium pyrophosphate ceramics produced in this thesis had 
compressive strength between 2.5 ± 0.7 MPa to 11.6 ± 2.7 MPa which is within the 
range of compressive strength recorded for cancellous bone (Table 2.1). Therefore 
from these compressive data alone it is possible for the ceramics in their present form 
to be used as replacement for cancellous bone. The ceramics at P:L 1.25 g/mL were 
shown to degrade faster in ALP solution which is also promising development in the 
development of a bioresponsive material. Although the ceramic was structurally 
unstable at 1.25 g/mL, perhaps it could be used in the replacement of bone defects in 
low load bearing areas.  
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11. CONCLUSIONS 
ALP mediated degradation of calcium pyrophosphate dihydrate crystals   
Phase pure CPPD and brushite crystals were successfully precipitated and 
characterised using XRD, FTIR and SEM analysis. The precipitated CPPD crystals 
degraded faster in the presence of ALP but the dissolution of brushite crystal was not 
affected by the presence of ALP. ALP enzyme was found to have high affinity for 
pyrophosphate ion which results in a large increase in the concentration of 
orthophosphate ion. The solution becomes saturated with orthophosphate ion which 
is reprecipitated as apatite onto CPPD crystals inhibiting further CPPD crystal 
dissolution. Therefore by increasing the volume of aliquot removed from solution the 
concentration of orthophosphate ion is reduced and CPPD crystal dissolution 
increased. The use of visking tube to separate CPPD crystals from ALP solution 
showed that the dissolution occurred in two steps: 1) hydrolysis of the crystals in Tris 
HCl solution and 2) enzymatic degradation of pyrophosphate ion.  
 
Synthesis and dissolution of calcium pyrophosphate ceramic 
Ca2P2O7 ceramics were successfully produced by sintering brushite cement at 
temperatures greater than or equal to 400°C. The mechanical strength of Ca2P2O7 
ceramic was found to increase with increasing powder liquid ratio i.e. increase in the 
β-TCP content of the ceramic. Generally as sintering temperature is increased the 
compressive strength was increased but the porosity did not reduce. This is due to the 
competition between the densification and phase change within the ceramic which 
means that the trend expected was not realised. As the sintering temperature was 
increased the SSA of the ceramic reduced and this was found to have an effect on the 
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degradation rate of Ca2P2O7 ceramic. As the P:L ratio and sintering temperature is 
reduced the ceramic degradation increased.  
 
Fabrication of calcium pyrophosphate ceramic using stereolithography 
Stereolithography was used to successfully produce uniformly formed calcium 
pyrophosphate ceramic. The layer by layer technology was used to produce a 
cylindrical matrix with cement loading of up to 50 wt%. It is difficult to achieve 
uniformly shaped materials at higher ceramic loading (60 – 90 wt %) due to the high 
viscosity of the ceramic suspension. Using TGA analysis the acrylate binder which is 
used to hold calcium pyrophosphate powder in place is removed at temperatures 
between 340 - 540°C. The acrylate binder was found to have no chemical effect on 
the composition of calcium pyrophosphate as observed on the XRD pattern. This 
shows that it is possible to fabricate calcium pyrophosphate ceramic of various 
shapes and size which can be used to fill any size bone defect.   
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12. FUTURE WORK 
This thesis has described the method by which CPPD crystals dissolve in the 
presence of ALP. The sintering of brushite cement to form Ca2P2O7 ceramic and its 
degradation in ALP containing solution was also investigated. It is difficult to build a 
mould of varying shapes and sizes from which brushite cement is cast therefore 
stereolithography a layer by layer technology was investigated. This process uses a 
computer aided design program therefore Ca2P2O7 ceramic of various shapes and size 
can be built. The mechanism of CPPD crystal dissolution, optimisation of sintered 
Ca2P2O7 ceramic and the mechanism of degradation can be further investigated. 
Stereolithography process also has to be optimised to increase the ceramic loading of 
the ceramic/polymer suspension. The following are recommendations for future 
work on the CPPD dissolution and the optimisation of ceramic manufacturing 
processes.  
 
ALP mediated degradation of calcium pyrophosphate dihydrate crystals 
Using a phosphate assay CPPD crystals were shown to dissolve faster in ALP 
solution. There are limitations with this procedure as the reprecipitation of 
orthophosphate ion as apatite crystals might distort the result. Therefore the rate of 
CPPD dissolution and the mechanism of dissolution might not be accurate. To avoid 
this discrepancy it is more accurate to measure the calcium ion in solution, a calcium 
electrode was used in this thesis, however, the results were not sufficiently 
reproducible or reliable to be used.  Future work should use inductively coupled 
mass spectroscopy to evaluate calcium ion concentration with time. 
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Effect of process conditions and cement composition on ceramic property and 
degradation 
Ca2P2O7 ceramic was successfully produced by sintering brushite cement at 
temperatures ≥ 400°C. The compressive strength of the human cancellous bone is 
within 1.9 – 7.1 MPa this corresponds to the ultimate compressive strength measured 
for the sintered Ca2P2O7 ceramic. The effect of sintering temperature on the mass 
loss and volumetric shrinkage of the sintered ceramic must be explored further in 
other to determine the shape of the final ceramic. The link between sintering 
temperature and ceramic porosity and compressive strength of porosity and pore 
connectivity is important in the degradation of the material, growth of bone tissue 
and flow of nutrient into the tissue for nourishment. Further systematic 
experimentation needs to be undertaken to investigate these relationships.  
 
Fabrication of calcium pyrophosphate ceramic using stereolithography 
Calcium pyrophosphate ceramics were successfully manufactured using 
stereolithography. The material produced was sintered to remove the polymer binder 
leaving the Ca2P2O7 ceramic. It is important to investigate different polymer mixture 
which ensures the suspension of the Ca2P2O7 powder over the duration of the 
manufacturing process. It was not possible to increase the ceramic loading of the 
ceramic/polymer suspension beyond 50 wt%. At such low ceramic loading the 
resulting ceramic is not structurally stable. Efforts have been made to increase the 
ceramic loading but it has been unsuccessful therefore subsequent processes have to 
be investigated to increase the ceramic loading.   
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14. APPENDIX 
Part of the research carried out on ceramic fabrication and characterisation (chapter 
8) was successfully published in a peer reviewed journal. If you would like to read 
the article it can be found at http://www.trailab.net/Liam%20-%20Papers/28.pdf. 
• Bolarinwa A.O., Wright A.J., Gbureck U., Purnell P., Bold M. and Grover 
L.M. "Cement casting of calcium pyrophosphate based bioceramics". 
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